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Abstract 
Tendon injury is one of the most common forms of musculoskeletal injuries that could 
occur in both human and equine patients. However, the conventional therapies have 
been unsuccessful when addressing the clinical need for the treatment of tendon injury. 
Therefore, the urgent need for more effective therapeutic strategies has set researchers 
along the route of exploring the causes underlying tendon injuries. In the past few 
decades, advances have been made in the understanding of tendon injury and its repair. 
Standing on the foundation of such discoveries, novel therapeutic approaches including 
gene therapy have been applied to the treatment of tendon injury. 
It is established that tendon tissue repaired via the natural healing process after injury 
has a weakened mechanical property compared to the healthy tendon due to the scar 
tissue and adhesion formed during the repair process. Type III collagen and several 
cytokines including transforming growth factor-beta is reported to be closely associated 
with the formation of scar tissue. Consequently, it is hypothesised that through the 
suppression of the COL3α1 gene, which is responsible for the production of type III 
collagen, the formation of scar tissue could be reduced to restore the mechanical 
property in the repaired tendon. 
RNA interference is a reliable way to suppress the expression of a target gene using 
specific siRNA. However, the use of siRNA has several limitations including 
extracellular degradation by enzymes in tissue fluid, intracellular degradation by 
lysosomes and difficulties penetrating the cell membrane. Therefore, an efficient and 
safe siRNA delivery system is required, and the cationic polymer-based delivery system 
is a strong candidate. Cationic polymer poly (dimethylaminoethyl acrylate) (PDMAEA) 
is a biodegradable synthetic polymer that showed great potential as a delivery vector. 
This prompted the development of a new siRNA delivery system based on four-armed 
PDMAEA. It is hypothesized that the cationic four-armed PDMAEA polymer can 
effectively bind to negatively charged siRNA to form a nano-sized polyplex. It is also 
hypothesized that a four-armed PDMAEA could be more efficient than counter-part 
linear polymers in terms of binding to siRNA and the cytotoxicity profile. Cationic 
polymer PDMAEA was selected as a delivery vector for its good buffering capability, 
siRNA condensation efficiency and biodegradable property. 
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The work presented in this thesis describes the synthesis of a library of PDMAEA 
polymers of different molecular weights and architectures via RAFT polymerisation. 
The synthesized polymers were characterized by 1H-NMR, 13C-NMR, GPC and 
potentiometric titration to confirm the desired molecular weight, architecture and pKa 
value. Firstly, a dsDNA with low base pair number was chosen as a model molecule to 
optimise the experimental conditions. Afterwards, the formation of the 
PDMAEA/dsDNA and PDMAEA/siRNA polyplexes were confirmed by agarose gel 
electrophoresis, and the solution properties, in particular the hydrodynamic diameter 
and zeta-potential, were confirmed using DLS. Later, the polymers and their polyplexes 
were tested on mouse 3T3 fibroblast cells and adult horse tenocytes to determine their 
cytotoxicity profiles. Finally, the optimised therapeutic siRNA-PDMAEA polyplex was 
applied to adult horse tenocytes stimulated with TGF-β1 to observe the transfection and 
silencing effect of the COL3α1 gene in induced in vitro conditions. The expression level 
of the COL3α1 gene was determined by qPCR and type III collagen protein expression 
was monitored by immunocytochemistry. The results showed that the developed 
cationic PDMAEA was effective in delivering therapeutic siRNA in a clinically relevant 
in vitro condition and achieved controlled suppression of type III collagen expression. 
The developed delivery system could potentially be used to reduce scar tissue formation 
in many other tissues.  
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1. Chapter 1 Introduction 
1.1. Tendon and Tendon Injury 
1.1.1. Tendon Function and Mechanical Properties 
Tendons are strong connective tissues which connect bones and muscles. Their primary 
function is to transmit active forces generated by muscles1,2. Besides, another important 
function of tendon tissue is to store elastic energy during motion3. For instance, the 
tendons and ligaments of the foot and leg store up to 50% of the energy required for 
walking and running. The energy stored can be released over a short period of time with 
high efficiency3. Tendon tissue contains large amounts of water, ~60% average in 
different types of tendon. The remaining dry weight is predominantly provided by 
collagen, which occupies up to 85% of the total dry weight and is in the form of fibres 
aligned longitudinally4.  
Tendons display elastic behaviours similar to elastomeric materials. The stress/strain 
relationship in tendon tissue is nonlinear and shown in figure 1.1.  
 
Figure 1.1 Stress/strain curve of tendon tissue. In low strain, low stiffness was observed. As the 
strain increases, tendon tissue showed an approximately linear elastic deformation. 
 
Low stiffness was observed when the initial load was applied on tendon tissue, and that 
is because tendon collagen fibres, bearing zero loads, are not linear but rather in a 
crimped shape. The initial loading stretches the collagen fibres and removes the crimped 
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shape, turning collagen fibres into straight and stretched structures. The subsequent load 
applied to tendon tissue results in an approximately linear elastic deformation. If the 
load continues to increase to exceed the physical limits, damage to these fibres 
themselves or to the cross-links between fibres were observed. Excessive loads might 
cause injuries, including micro-, macro-, or complete rupture of tendon tissue. Pain and 
inflammatory response can be observed before the ultimate tensile strain limit is 
reached. Therefore, pain and inflammatory response are often considered as responses 
of severe tendon injury1. 
The function of tendon tissue is fulfilled by its multilayer, highly complex structure, as 
well as the protein-based extracellular matrix composition. In this chapter, the following 
topic will be introduced and discussed: 
1) The anatomy and biochemical composition of tendon tissue. 
2) What tendon injury is and the characteristics of injured tendon tissue. The healing 
process of tendon tissue after injury and its changes on a molecular level. 
3) Current treatment for tendon injury and its limitation.  
4) Potential novel therapeutic approaches for the treatment and improved healing of 
tendon injury. 
1.1.2. Tendon Anatomy and Biochemical Composition 
Tendon tissue has a highly complicated and multi-layered structure. Tendon tissue 
consists of tenocytes and tendon extracellular matrix (ECM), which are composed 
mainly of collagen, as well as other non-collagen proteins5. Tenocytes are considered to 
be the primary cellular composition of the tendon tissue, and it is an elongated 
specialised fibroblast6. Other smaller cell populations found in tendon tissue include 
adipose-derived stem cells and muscle cells7. Tenocytes are essential for tendon 
formation and natural repair due to their ability to produce proteins, especially in the 
collagen protein family. Tenocytes produce collagen as well as other proteins that are 
essential for the construction of the tendon extracellular matrix6. The produced collagen 
protein is a vital component of tendon ECM, occupying 60-85% of the dry weight of the 
tissue8. Figure 1.2 demonstrates the structure of tendon tissue9. Collagens and other 
proteins align in a different style to form complex linear, helical and branched 
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molecules that further interact with each other to form fibrils10, these fibrils merging 
into a collagen fibre that further consolidates into the primary fibre bundle. The outside 
of the primary fibre bundle is surrounded by a thin layer of connective tissue called 
endotenon. Endotenon contains the vascular system, nerve system and immune 
component that are vital for tendon tissue11. The primary fibre bundles align with each 
other, forming the secondary fibre bundle, known as fascicle. Fascicles unite into 
tertiary fibre bundle and further into the tertiary fibre bundle, eventually became tendon 
fibre which has a layer of connective tissue called epitenon on the outside12. 
  
Figure 1.2 The multilayer hierarchical structure of tendon. Figure adapted from Sharma et al. 9. 
 
Tendon function is determined by the structure and cellular composition. Figure 1.3 
shows the cellular and acellular composition of tendon tissue. The composition of 
tendon tissue includes collagen, elastin, glycosaminoglycan (GAG), proteoglycans and 
other structural proteins2. 
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Figure 1.3 Cellular and acellular components of tendon tissue. Figure adapted from Lamos et al.10 
 
Collagen is the primary content of tendon tissue (about 60-85%% of the dry weight) and 
provides multiple functions including transmitting force, load bearing, maintaining the 
complete structure of the tendon tissue and the prevention of possible mechanical 
failures8,13,14. All collagens are proteins whose basic units consist of either homo- or 
heterotrimeric assemblies formed by three sets of polypeptide chains that wind around 
each other, known as tropocollagen (figure 1.4). Homotrimerically assembled collagen 
molecules, such as type III collagen, are formed by three α chains while 
heterotrimerically assembled collagen molecules, such as type I collagen, is formed by 
two α1 chains and one α2 chain. The polypeptide chains that form into triple helix are 
approximately 1000 amino acids long and are comprised of triplets with a repeating 
sequence of Gly-Xaa-Yaa, where Xaa and Yaa frequently represent (2S)-proline (Pro, 
28%) and (2S,4R)-4-hydroxyproline (Hyp, 38%), respectively15. In animals, individual 
tropocollagen assemble in a complex, hierarchical manner that ultimately leads to the 
macroscopic fibres and networks observed in tissue and basement membranes. The 
proline and 4(R)Hyp residue played a vital role in the correct conformation and stability 
of the tropocollagen as they are related to the formation of inter-strand hydrogen bonds.  
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Figure 1.4 A schematic demonstration of the collagen triple helix. (A) a crystal structure of a 
collagen triple helix formed from (ProHypGly)4–(ProHypAla)–(ProHypGly)16.  (B) Ball-and-stick 
image of a segment of collagen triple helix and the ladder of inter-strand hydrogen bonds. The 
figure is adapted from Shoulders et al.17 
 
The importance of collagen as a scaffold for animals is determined by various of 
essential characteristics, including thermal stability18, mechanical strength, and the 
ability to engage in specific interactions with other biomolecules. These properties are 
derived from the fundamental structural unit of collagen, the triple helix, and it has been 
established that the inter-strand hydrogen bonds, Prolines isomers and the hydroxylation 
of Pro residues play vital roles in stabilising the tropocollagen structure17. The amide-
amide hydrogen bond is the most abundant hydrogen bond within the triple helix 
structure (figure 1.4 B) and it’s of great importance for collagen triple-helix stability. In 
the strands of human collagen, about 22% of all residues are either Pro or Hyp, which 
pre-organises the strands in a PPII conformation, thereby reducing the entropic cost for 
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collagen folding19. Furthermore, the Pro isomers also have certain effects on the triple-
helix folding and stability. For example, Pro forms tertiary amides within a peptide or 
protein, which have a significant population of both the trans and the cis isomers (figure 
1.5). However, all peptide bonds in collagen are trans, which suggests that all the cis 
peptide bonds must be isomerised to trans before a strand can fold into a triple helix17. 
Replacing a Gly-Pro amide bond with an alkene isostere that is trans-locked would also 
results in a destabilised triple helix20. 
 
Figure 1.5 A schematic demonstration of Pro cis–trans isomerisation. The figure is adapted from 
Shoulders et al. 17 
 
The stabilisation effect provided by 4(R)Hyp residue in the Yaa position was explained 
by two different theories. The first theory suggested that the hydroxyl groups in 
4(R)Hyp would form water bridges through hydrogen bound between backbone groups. 
Berman et al. illustrated in their study that the hydroxyl groups of Hyp were involved in 
the formation of water bridges with amide groups from Glycine and other carbonyl 
groups both inter- and intrachain21. The second theory explained that the hydroxyl 
group has an inductive effect which alters the ring puckering of the pyrrolidine ring and 
thus, changes the cis/trans conformation ratio in the peptide chain. A closer inspection 
of the collagen peptides structures by X-ray crystallography revealed a preference of γ-
endo pucker (down puckering) of the pyrrolidine ring in the Xaa position and γ-exo 
pucker (up puckering) of the pyrrolidine ring in the Yaa position22,23. Further studies 
verified that (2S,4R)-4-hydroxyproline residue favour the γ-exo pucker while its 4S 
isoform favour the γ-endo pucker24. Because of the energy difference between the cis 
and trans conformation is greatly reduced with γ-endo pucker, peptides with 4S-
Hydroxyproline in Yaa position would have a higher population of the cis conformation 
compared to those with 4R-Hydroxyproline25. These findings may have explained the 
stabilising effect of 4(R)Hyp in the Yaa position. More recently, a study by Raines et al. 
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provided evidence to support that Hyp hydroxyl groups act primarily through stereo-
electrostatic effects in the stabilisation of collagen triple helix26. The combination of 
Van der Waals force between proline rings in adjacent peptide chains, the hydrogen 
bonding network that links the hydroxyl groups and the carbonyl groups and the stereo-
electrostatic effects, resulted in an optimally assembled tropocollagen and enabled 
collagen fibrils to provide tensile strength to tissues to fulfil its function. 
Type I collagen takes up to 90% of the total dry weight of all collagens and is 
considered the most abundant collagen in the human body27,28. It is found in in over 
90% of the organic matrix and has a huge impact on the biomechanical properties and 
functional integrity of biological tissues. The fundamental unit of type I collagen is a 
heterotrimerically assembled molecule, typically by two α1 chains and one α2 chain, 
forming into a triple helical structure29. The biosynthesis of type I collagen molecule is 
a process containing multiple post-translational modification reactions to ensure the 
correct conformation and interchain cross-link formation that provided the protein with 
necessary chemical and biological characteristics. Naturally, type I collagen is 
synthesised by fibroblasts and tenocytes as a soluble procollagen chain intracellularly30. 
The synthesis of type I collagen α chains in human tissues are controlled by the 
COL1A1 (for α1) and COL1A2 (for α2), located on the long arm of chromosome 17 and 
chromosome 7, respectively31. After transcription, the polypeptides undergo post-
translational modification, such as the hydroxylation of proline and lysine, under the 
catalytic action of different hydroxylase enzymes. This step is vital for the assembly of 
the collagen triple helix, the hydroxyl groups from hydroxyproline and hydroxylysine 
being key to the stabilisation of tropocollagen32. The healthy tendon tissues are 
predominantly comprised of type I collagen, and it is considered to be the major 
component that provides tendon tissue with tensile strength and stiffness to function 
properly.  
Other collagen types, such as type III collagen and type V collagen, also play a vital role 
in tendon tissue. Type III collagen accounts for only a small amount of all collagen 
types in the healthy tendon. In healthy tendon, Type III collagens are mostly found in 
endotenon and epitenon layers33. However, in tendon injury or in tendinopathy, type III 
collagens are found not only in endotenon and epitenon but all over the tendon matrix12. 
Changes in gene expression also indicated that the production of type III collagen had 
been up-regulated in  injured tendon tissue and tissue with tendinopathy34. The increase 
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in type III collagen expression level suggested a possible increase in the production and 
secretion of type III collagen, which could be involved in the healing and repair process 
of tendon tissue. In some cases, especially injured tendon tissue, collagen types III 
could associate with collagen types I to form a heterotypic fibril, which has a smaller 
diameter than regular fibril bundles35. Another vital member in the collagen family is 
type V collagen, which is less abundant in tendon but plays a key role in collagen fibril 
assembly. Typically, type V collagen is found at the centre of a collagen fibril bundle 
and is responsible for collagen growth and expansion36. Similar to type III collagen, an 
increase in collagen type V has been observed in injured tendon as well. In tendon tissue 
suffering from tendinopathy, collagen types V can also associate with type I collagen 
and form heterotypic fibril, which also weakens the tendon strength by reducing the 
tendon fibril diameter37. Other types of collagens such as XII and XIV are found 
essential to tendon matrix formation as well. These collagens would aid and supplement 
collagen I bundles’ ability to glide over each other during the force transition process. 
When a force is applied, these molecules can decrease the interactions between fibres to 
avoid potential damage to tendon tissue38,39.  
1.1.3. Tendon Injuries and Tendon Healing 
There is an unmet clinical need in the treatment of tendon injury for both human and 
equine patients. It is estimated that about €140 billion is spent on healthcare related to 
tendon injury worldwide per year and increasing40. As it affects the population of a wide 
range, it is estimated that about 25% of the adult population would suffer from tendon 
related condition41. Though numerous therapeutic strategies have been developed, data 
indicated that few of them had achieved recovery that is comparable with pre-injury 
states42.  
 Tendon injury and its causes 
Tendon injury includes acute tendon injuries, like ruptures or tears, chronic tendon 
disorder or pain and acute tendon pain with inflammation, which are termed tendon 
rupture, tendinopathy and tendinitis respectively43,44.  
Tendinopathy is the primary tendon disorder caused by overuse or degeneration and the 
patient would experience chronic pain in a clinical situation45. Tendinopathy is caused 
by intrinsic and extrinsic factors with interactions between each other46. Intrinsic factors 
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including age, gender, anatomical variants, body weight and systemic disorder could 
have an effect on the tendon. It is reported that biomechanical failure and alignment 
faults within tendon tissue are the major reason for sport-related Achilles tendon 
disorder47. It is considered that excessive loading during vigorous physical activity is 
responsible for degeneration pathologically48. In some cases, the cause of tendinopathy 
is a result of both intrinsic and extrinsic effects. Under the influence of intrinsic factors, 
such as age and genetic disorder, the tendon is more prone to injury under excessive 
load and repetitive pressure49. The nature repair of tendon tissue is vital, for, without 
enough time for the tendon to repair the damage and generated neo-tissue, the trauma 
would accumulate and eventually leads to more severe injury or rupture50. Evidence 
showed that sedentary working/living habit, recreational sports and a propensity for 
obesity might be held responsible for the increasing incidence rate of tendinopathy51. 
Genes have recently been found related to tendinopathy, due to the lack of a specific 
gene related to the production of collagen V and tenascin C, some patients might have a 
more significant potential of being affected by tendinopathy52,53. 
Tendon rupture is described as an acute injury caused mainly under external load, 
though intrinsic factors also play an indirect role. For example, most of the tendon 
rupture happens in the fifth decade of a person’s life. Therefore age is considered to be 
one of the intrinsic factors related to tendon rupture. However, Achilles and 
Supraspinatus rupture are mostly found in the younger population which indicates 
rupture is also associated with the activity level of the population. Tendon rupture tends 
to occur in the Achilles tendon and Anterior Cruciate Ligament (ACL). But in other 
tendon tissue like the Rotator cuff and Patellar tendon, cases of tendon rupture can also 
happen54,55. In most of the ruptured tendon, degeneration is found, and as Arner et al. 
reported, degeneration was observed in all of their seventy-four patients with an 
Achilles tendon rupture56. Tendon degeneration leads to a reduction in tensile strength, 
which can significantly reduce the force tendon tissue can sustain. Studies done by 
Tallon et al. showed that in the ruptured tendon, a higher level of degeneration was 
observed than that in chronic pain tendon57. Currently, tendon rupture is generally 
treated with surgical options. Patients receiving surgical treatment will still suffer from 
long and painful recovery58. In the past decades, a significant amount of effort has been 
made to better understand the molecular pathology, aetiology and the mechanism of 
tendon matrix remodelling, which can be used as the guideline for the research of new 
therapeutic treatment for tendinopathy and tendon rupture51,59,60. 
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 The natural healing process of tendon tissue 
The normal steady-state conditions of tendon tissue are maintained by a combination of 
cell and matrix turnover. Results from methods to measure tendon turnover indicated 
half-life values from two months to over a hundred years, which suggested tendons 
have very low turn over and thought to have limited their healing potential61,62,63. 
Recently, a study was conducted to examine tendon turnover in human volunteers of 
different ages64. Their findings suggested that collagen synthesis occurs primarily 
during age 0-17, and there is no significant tendon tissue turnover at later stages. 
Though tendons have low turnover, they are highly sensitive to mechanical stimulation 
and injury. Tenocytes activity increases during exercise, as well as collagen production 
and cell proliferation65,66. This suggests that tenocytes can respond to changes in 
physical activity, and is an active participant in the maintenance of tendon tissue. 
Similar to exercise stimulation, tendon tissue can also respond to damage and injuries 
and initiates a natural healing process which is critical in tendon repair. The tendon 
healing process consists of three phases (figure 1.6).  
 
Figure 1.6 The tendon healing process in human and a summary of cellular and matrix changes in 
tendon repair.  
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In the initial inflammatory phase, commonly referred to as the first 24-72 hours after 
injury, erythrocytes and inflammatory cells such as neutrophils, monocytes and 
macrophages enter the site of the injury67. Angiogenic factors are released to initiate the 
formation of a new vascular network, for vascular response is vital to avoid the 
diminution of blood supply at the site of injury68. Other changes including increased 
release of cytokines, stimulation of tenocyte proliferation and involvement of more 
inflammatory cells, all in favour of tendon tissue repair and generation of new fibrous 
tissue69. With the immigration and generation of more tenocyte, the type III collagen 
synthesis is also initiated 70.  
The second phase is called the proliferation phase or repair phase where the tenocyte 
continues to proliferate, synthesis of type III collagen peaks and lasts for a few weeks. 
Production of other proteins proteoglycans and glycosaminoglycans is maintained at a 
high level as well. The synthesised type III collagen, proteoglycans and 
glycosaminoglycans, which are the main components of tendon ECM, are arranged in a 
random pattern70. 
The third phase referred to as remodelling phase, can be divided into two stages: the 
consolidation stage and maturation stage. During this phase, proteins and tendon ECM 
are resized and reshaped71. In the consolidation stage, tenocyte metabolism remains at a 
high level while tenocytes and collagen start to align along the direction of stress. Also, 
a higher level of type I collagen is synthesized and aligned with tenocytes. This stage 
would last from six to eight weeks and the maturation stage then follows72. In the 
maturation stage, newly synthesized fibrous tissue gradually remodels to scar tissue in a 
period of over a year.  
A variety of cytokines play vital roles in the healing process of tendon tissue. At the 
start of the repair, inflammatory cytokines such as interleukin are produced by 
inflammatory cells. Later in the proliferation phase, a good number of cytokines 
including basic fibroblast growth factor (bFGF), Bone morphogenetic protein (BMP), 
insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF) and transforming growth factor beta (TGF-β) all 
contribute to the repair of tendon tissue. The changes in the tendon healing process have 
been summarised in figure 1.6. 
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It is suggested that the combination of the extrinsic and intrinsic cellular mechanisms is 
behind the tendon healing process68,73. The intrinsic route involves the proliferation of 
epitenon and endotenon tenocytes typically. These intrinsic tenocytes contribute to the 
tendon repair by secretion of a large amount of protein, especially collagen, to 
reconstruct tendon ECM74. The extrinsic route is that fibroblasts and inflammatory cells 
from blood vessels and circulation attach to the injury site and provide cytokines and 
secreted proteins75. However, the extrinsic route does contribute to the repair of 
damaged tendon tissue; it also results in the formation of adhesion, and a large amount 
of disorganised tissue referred to as scar tissue.  
In most of the patients, the post-injury tendon usually does not fully regain the 
mechanical properties. In figure 1.7 is demonstrated a comparison of the post-injury 
tendon with the healthy tendon. The left side of the figure shows the anatomy 
characteristics of the healthy tendon tissue. It is shown that collagen fibres are tightly 
bundled and aligned, supported with organised vascular systems in the connective tissue 
around tendon tissue. On the right side of the figure is demonstrated the tendon after 
injury. Thinner and disorganised collagen fibres are surrounded by an excessive number 
of proteoglycans (shown in yellow and blue)76. The post-injury tendon tissue is found to 
have a higher level of type III collagen than type I, which is believed to be related to the 
formation of scar tissue. As the major component of scar tissue is type III collagen 
which is thinner and weaker than type I collagen, it has a reduced mechanical property 
and therefore, would cause the reduction of the tensile strength of tendon tissue77.  
 
Figure 1.7 A schematic illustration of normal tendon anatomy (left) compared to healed tendon 
after injury(right). Figure adapted from Scott et al.76 
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Due to the formation of scar tissue and disorganised collagen fibre, healed tendon tissue 
is found to be weaker compared with the healthy tendon77. The weakened mechanical 
property may expose the repaired tendon to a higher risk of re-injury77. 
 Changes in the molecular level of tendon tissue 
The molecular changes in damaged tendon tissue can serve as a guideline for 
researchers to better understand the mechanism of tendinopathy and tendon natural 
healing. Tendon matrix is a highly complicated structure and consists of multiple 
different components. In tendon matrix, the primary composition includes collagen 
proteins, proteoglycan and glycoprotein. Cytokines like a variety of growth factors and 
enzymes that affect the hydrolysis of the tendon matrix are also found to be regulated in 
damaged tendon tissue59. The research conducted by Riley et al. showed the changes in 
molecular composition in injured tendon tissue51. As shown in table 1.1, there is a 
significant increase in collagen type I and III gene expression, especially type III 
collagen, in tendon matrix. 
Table 1.1 Changes of structural molecules, Enzymes, Cytokines and signalling factors expression 
level in tendinopathy matrix. The table is adapted from Riley et al. 51 
In matrix Cytokines and signalling 
factors 
Enzymes 
Collagen type I ↑ TGF-β ↑ MMP1,2,9,19,23,25 ↑ 
Collagen type III ↑ IGF-I ↑ TIMP1,3 ↑ 
Fibronectin ↑ VEGF ↑ MMP3,7,10,12,27 ↓ 
Tenascin C ↑ PGE2 → TIMP2,3,4 ↓ 
Aggrecan ↑ BMP ↑   
Biglycan ↑ Glutamate ↑   
Versican → Substance P ↑   
Decorin → NMDAR ↑   
Pentosidine ↓ TGF-βR1 ↓   
Dematin sulphate ↓ PDGFR ↑   
Also, an increased amount of type III collagen was found in tendinopathy tendon 
matrix78. Collagen is one of the most important proteins that comprise of the tendon; 
changes in collagen level after tendinopathy may indicate a possible therapeutic target 
for tendon treatment. The level of glycosaminoglycan, tenascin C, aggrecan, biglycan, 
chondroitin sulphate proteoglycans is increased in tendon matrix which is consistent 
with a healing process78. Changes in the level of a family of enzymes called matrix 
metalloproteinases (MMPs) also draws attention. The matrix metalloproteinases 
(MMPs) are a family of enzymes responsible for the degradation of the tendon matrix in 
both healthy and diseased tendon. There are 23 types of MMPs in human and four 
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naturally occurring inhibitors known as tissue inhibitors of matrix metalloproteinase 
(TIMPs)51. In ruptured tendon, expression of MMP1, MMP9, MMP19, MMP25 and 
TIMP1 is increased, and expression of MMP3, MMP7, TIMP2, TIMP3 and TIMP4 is 
decreased. In chronic pain tendon, reduced the level of MMP3, MMP10 and TIMP3 was 
observed along with the increased expression of MMP2351. 
One of the most critical kinds of molecule in tendon regeneration are growth factors. 
Growth factors are released from platelets, polymorph nuclear leukocytes and 
macrophages. They transmit a specific signal or message to cells79. Growth factor binds 
to the specific receptor on the membrane of cells and then activates a series of 
biochemical reactions that result in collagen synthesis, fibroblast proliferation and 
overall tendon matrix remodelling 9,59,80,81. 
1.1.4. Current Treatment and Novel Strategy 
 Current Treatments 
Currently, several conventional therapies have been applied to the healing process of 
tendon tissue. Different treatments are applied to different levels of injuries. For minor 
injuries, movement management and physical therapy can be used to control the 
damage and prevent further deterioration of injuries. For patients who experience pain 
and swelling, non-steroidal anti-inflammatory drugs (NSAIDs) are given for pain 
management in a clinical situation. It is reported that the overuse of NSAIDs and 
steroids might increase the chance of tendon injury, but this lacks sufficient supporting 
evidence82. For those who suffer from chronic or severe pain, or even a ruptured tendon, 
a surgical option may be applied83. A summary of current treatments and new therapies 
in development is shown in table 1.2. 
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Table 1.2 A summary of current treatment for tendinopathy. Table adapted from G. Riley51. Note 
that this table summarises therapy for tendon chronic pain only. Now therapy for tendon rupture 
and tears is limited to a surgical operation. 
Treatment Putative target or mode of action 
Rest or modification of 
activity 
Removal of precipitating factors and prevention of reinjury 
Orthotics Removal of precipitating factors and prevention of reinjury 
Cryotherapy Reduction of acute inflammation and decrease in cell metabolism 
Heat treatment Stimulation of cell activity and to increase blood flow 
Physiotherapy  Stimulation of cell activity and to increase blood flow 
Electrical stimulation Reduction of pain perception, stimulation of blood flow and increase in 
cell activity 
Laser treatment (pulsed or 
continuous 
Possible analgesic effects and unspecified (unknown) effects on cell 
activity 
Pulsed electromagnetic 
fields 
Possible analgesic effects and unspecified (unknown) effects on cell 
activity 
Ultrasound shock wave Thermal effects on tissue, stimulation of cell activity and increased blood 
flow 
NSAIDs Reduction of inflammation through inhibition of prostaglandin synthesis 
It’s shown that most of the treatments for tendinopathy now is physical modality-based, 
which includes ultrasound shock wave, pulsed magnetic fields therapy and laser 
therapy. For minor injuries, the physical modulated therapies show a positive outcome 
in managing the symptoms79. A controlled amount of exercises can be beneficial as 
well. Exercise is vital in both prevention and treatment of tendinopathy, but a report 
showed that in clinical trials there was little evidence supporting this is beneficial for 
the patient. Apart from physical exercise, medication has been applied as well. The use 
of NSAIDs in clinical treatment for tendinopathy has been employed for several years, 
and it was proved helpful for reducing the pain and inflammation. However, NSAIDs 
can only be used as a short-term pain and inflammation management approach. For 
some cases, when medication and movement management proved to be little help, a 
surgical operation is applied. However, patients treated in this way have to endure a 
very painful postoperative recovery and have a high chance of re-rupture rate51. In 
conclusion, the current conventional treatments are not sufficient for treating 
tendinopathy and tendon rupture (particularly to enhance the tendon regeneration). 
Scientists are looking for an alternative approach for curing this condition, and several 
new therapeutic approaches come into sight. 
 Advanced Treatment Strategies for Tendon Injury 
Conventional treatments for tendinopathy might not be sufficient for the proper healing 
of tendon tissue. Alternative approaches for the treatment of tendinopathy are urgently 
needed. In the past decade, significant developments have been made in the 
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understanding of tendon and tendinopathy, and new therapeutic strategies have been 
developed. Some of the strategies involve the use of growth factors and morphogenetic 
proteins (PDGF, TGF-β, FGF, and IGF-1). Other approaches include the use of gene 
therapy and gene delivery. 
 Growth factors in healing tendon 
Varieties of growth factors were found related to tendon healing and regenerating 
processes, including insulin-like growth factors (IGFs), platelet-derived growth factors 
and their receptors (PDGFs and PDGFRs), transforming growth factors (TGFs), 
Fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGFs). 
Different growth factors play different roles in tendon matrix healing and remodelling84.  
However, there are limitations to some of these treatments including the high cost of 
manufacture, lack of an efficient delivery system and difficulty in purifying the product. 
These problems have limited the application of growth factors and morphogenetic 
proteins as the treatments for tendinopathy. However, it is possible to produce 
endogenous growth factors and morphogenetic proteins and develop a therapeutic 
strategy accordingly. Gene therapy, as a potential therapeutic strategy for tendon injury, 
might achieve up-regulation production of these further improve the healing of tendon 
tissue. 
1.2. Gene Therapy for Tendon Injury 
1.2.1. Introduction of Gene Therapy 
The term “gene therapy” was first reported by Clyde E. Keeler in 1947, where it was 
described as “the correction of gene-based deviations in plants and animals”85. 
Subsequently, the concept has been extended to include the isolation or design, 
synthesis and introduction of genes into defective cells, tissue or organs86,87. 
The first attempt of exogenous gene delivery into human recipients was performed by 
Stanfield Rogers in 1970, who administrated the native Shope rabbit papillomavirus to 
three German siblings with a purpose of treating arginase deficiency88,89. Though no 
satisfactory result was achieved in this trial, it is considered as the first anticipation of 
the potential of viral carriers.  
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In July 1980, another human trial led by Martin Cline attempted to treat β-thalassemia. 
The bone marrow cells from patients were extracted and translated with plasmids 
encoding the β-globin gene and the herpes simplex virus thymidine kinase (HSVtk) 
gene before being transplanted back into the patients. Unfortunately, this study ended 
with neither good nor harmful results but was criticised for ethical reasons90.  
Another decade later, in the early 1990s, Rosenberg led a trial to treat patients with 
advanced melanoma with lymphocytes marked with the Escherichia coli neomycin 
phosphotransferase gene using retroviral vectors. This is reported to be the first case of 
using a marker gene to observe the biodistribution of transgene cells 91. 
In the past decade, one historical event marked the beginning of a new era, for the first 
veterinary gene therapy vaccine, RABORAL V-RG which is a recombinant vaccinia 
virus in which the thymidine kinase gene has been replaced by the glycoprotein G of the 
rabies virus, was approved. This vaccine helped to reduce the rate of rabies in wildlife, 
pets and livestock and is suggested to be the predecessor of a series vaccines92.  
Though great advances in gene therapy have been achieved, discouraging news was 
announced in September 1999, when Jesse Gelsinger died in the gene therapy clinical 
trial for liver genetic disease ornithine transcarboxylase deficiency using adenoviral 
vector. Other patients enrolled in the trial were also affected with minor myalgias, fever 
and biochemical abnormalities93. It is suggested that the patients, including Jesse 
Gelsinger, suffered from vector toxicity. This is the first case of patient death in clinical 
trials and laid a shadow over the whole field of gene therapy93. 
The death of Jesse Gelsinger raised awareness towards the safety of gene therapy along 
with many other issues. It was realised that many obstacles must be overcome before 
gene therapy becomes practical for clinical application. Also, this incident led to the 
questioning of whether gene therapy could fulfil the expectation that was once 
promised. Undoubtedly, it was also realised that efficiency, safety and ethical issues 
were all important aspects of a delivery system. Although the research progress in gene 
therapy had been difficult and experienced several setbacks, there is no denying that the 
advances in the field of gene therapy and gene transfer offer an unprecedented 
possibility for the treatment of numerous diseases and may alleviate the suffering of a 
great many patients.  
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Nowadays, gene therapy refers to the cell delivery of a gene-expressing unit that can 
promote the transcription of RNA. The transgene unit normally contains a promoter, 
gene of interest and a polyadenylation signal. The therapeutic gene unit not only needs 
to cross the cell plasma membrane but also needs to penetrate the cytosol and find its 
way into the nucleus. Upon reaching the target cell genome, or in some cases the 
transgene unit is capable of replicate and express independently, the gene of interest is 
transcribed into RNA. The RNA either displays a therapeutic effect by itself or encodes 
a protein or peptide that itself is therapeutically active. In addition to gene therapy, 
Scherman et al. proposed the term “genetic pharmacology”, which refers to “the use of 
short synthetic oligonucleotides to manipulate gene expression” and principally includes 
the use of antisense RNA, anti-gene, or RNA-interfering strategies94. Genetic 
pharmacology involves the use of short single-strand oligonucleotides as a therapeutic 
agent, which is distinguished from a classic small chemical base therapeutic strategy. 
The oligonucleotide employ as the therapeutic agent is typical with a length of around 
20 base pair which is necessary to ensure the target specificity and capability of 
recognising the target through the Watson-Crick hydrogen bonds between base pairs. 
Genetic therapy involves the delivery of small oligonucleotide molecules as a 
therapeutic agent that target DNA or RNA strands, which differs from gene therapy and 
small molecule drug delivery, for later ones deliver a self-expressive DNA unit and 
small molecules targeting proteins, respectively. The distinction between gene therapy, 
genetic pharmacology and small molecule drug delivery is displayed in figure 1.8.  
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Figure 1.8 Gene therapy involves the use of a gene-expressing unit ( composed of a promoter, gene, 
and termination signal), while small molecule (chemical) drugs target proteins, short 
oligonucleotides used in genetic pharmacology generally target DNA and/or RNA.  
 
Though gene therapy and genetic pharmacology have been distinguished from each 
other by Scherman et al., it has been acknowledged that other authors employ the term 
“gene therapy” to all strategies implying the use of any oligonucleotide molecule94.  
Several advantageous properties render gene therapy indispensable for the treatment of 
a variety of disease. Based on the progressive understanding of genetic control over 
cellular activity and gene-disease activity relationship, also with the identification of the 
gene involved in disease development, gene therapy may provide exceptional 
opportunities to cure the currently untreatable conditions or considered as an exceeding 
alternative of the existing therapeutic strategies95. 
First of all, gene therapy is able to grant treatment to any diseases that are caused by the 
deficiency of gene or protein expression. For instance, this is the case for alpha-1 
antitrypsin deficiency which causes patients to suffer breathing difficulties due to the 
lack of alpha-1 antitrypsin, which is a protein serves as a protective agent for lung 
tissues. Another example is Duchenne muscular dystrophy, for which the vital 
expression of dystrophin protein in the muscle cytosol is missing96. 
Secondly, the delivery of protein may lead to variations in concentration. This can cause 
uncertainty in dosage in the target tissue and can induce toxicity when protein levels 
reach excessive concentrations. An example of such was observed in the treatment of 
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haemophilia where the administered protein, recombinant clotting factors, is lower than 
the therapeutic threshold due to its short half-life 97. On the other hand, gene therapy, 
unlike recombinant protein therapy, could provide a constant expression of missing 
protein when the delivered gene is controlled by a permanently activated promoter. In 
addition, gene delivery provides the advantage of long-term protein release and 
availability, reducing the need for multiple injections of exogenous factors. 
Another advantage of gene therapy comes from its specificity when the transgene unit is 
designed properly to obtain spatial control of its effect. Approaches including local 
delivery of therapeutic gene delivery unit or using a tissue or cell-specific vector, the 
expression of the desired protein could be restricted to a certain organ, tissue, even a 
specific cell type. Immune responses are frequently overserved in the delivery of 
missing protein in gene deficiency for it is considered to be exogenous by the host. By 
using gene therapy, one could avoid immune responses by restricting transgene 
expression to cell types with less antigen presence.  
To conclude, gene therapy is a powerful and promising therapeutic strategy with many 
advantages. It might be used 1) to treat gene deficiency disease by compensating of the 
missing protein 2) to enhance the expression of a protein factor or cytokine 3) to trigger 
an apoptosis gene in the treatment of cancer 4) to inhibit or suppress the expression of a 
given protein. There are many studies and research that can be listed as examples as the 
prove of gene therapy application.  
For instance, gene therapy can be applied in the treatment of Haemophilia A and B. 
Haemophilia A and B are congenital bleeding disorders caused by a deficiency of 
functional clotting factor, FVIII and FIX, respectively. Current therapy for haemophilia 
is largely dependent upon the delivery of protein substitution, generally recombinant or 
plasma-derived clotting factors FVII and FIX97. The short half-life of the clotting 
factors results in the demand of a relatively higher dosage to compensate the losses, and 
a higher frequency of infusion is also necessary. In some cases, patients produce 
antibodies that neutralise the injected clotting factors which reduces the efficiency of 
further therapy97. Gene therapy as a potential alternative treatment strategy might 
address the issues of conventional protein delivery. Studies on haemophilia animal 
models (mice and dogs) using adenoviral vectors that contains Factor VIII or FIX 
encoding gene has been reported, and the results confirm a robust clotting factor 
expression level with limited toxicity98,99. Similar pre-clinical studies have used 
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lentiviral vectors to achieve long-term FVIII expression100. Though proven efficient in 
pre-clinical studies, the administration of adenoviral vectors encoding FVIII in a phrase 
I clinical trial stimulated an inflammatory response and was ceased to stop97. These 
might have indicated the selection and use of appropriate delivery method should be 
considered before administration.  
Another example is the use of gene therapy in the case of Duchenne muscular dystrophy 
(DMD) therapy. DMD is a genetic disease caused by the lack of functional dystrophin 
protein, controlled by genes on the X chromosome, in skeletal muscles. The symptoms 
of DMD include the weakness of muscle, especially upper arm muscles and the muscles 
of the hips and thighs101. Until recently, the most advanced gene therapy for this disease 
being developed is the use of antisense oligonucleotides to mask certain RNA sequence 
motifs on the pre-messenger RNA, which is called exon-skipping, so that formation of 
the spliceosome on the target exon is inhibited and the target exon is excluded from the 
mature gene transcript101. The exon-skipping should be able to restore the read frame of 
the DMD gene and in fact, as Graham et al. and Arechacala et al. reported, it did restore 
the expression of dystrophin in cultured DMD patient cells and in DMD disease animal 
models102,103. On the basis of pre-clinical studies on the treatment of DMD, phase I 
clinical trial of the DMD exon skipping treatment has been undertaken. In phase I trial, 
levels of detectable dystrophin protein at 3-15% of normal levels were observed in 
patients four weeks after administration, and no adverse events were observed104. 
1.2.2. RNA Interference 
The RNA interference (RNAi), as one of many gene therapy approaches, has progressed 
significantly in recent years. The RNA interference (RNAi) is “a process of sequence-
specific posttranscriptional gene silencing induced by double-strand RNA (dsRNA)”105. 
This biological phenomenon was initially described in insects, plants and fungi106. 
However, only after the work of Fire and Mello in Caenorhabditis elegans was awarded 
for a Nobel-prize, it was suggested  that a potential post-transcriptional gene silencing 
effect, referred to as RNAi, exists105. Subsequent research on the use of synthetic RNA 
duplexes of 21 base pairs as RNAi triggers in mammalian cultured cells confirmed the 
possible utilisation of short double-stranded RNAs to mediate knockdown without 
activating cellular immune response (base pair of <30)107.  
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Recently, the U.S. Food and Drug Administration (U.S. FDA) and the European 
Medicines Agency both approved Patisiran, which is an intravenously administered 
RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR 
amyloidosis. Patisiran blocks the production of transthyretin by targeting and silencing 
the specific messenger RNA in the liver, reducing its accumulation in the  tissues in 
order to stop or slow down the progression of the disease. No doubt, the approval of 
Patisiran is a piece of strong evidence that proves the clinical value of RNAi and this 
incident would inspire researchers in the field related to RNAi worldwide. 
The mechanism of exogenous RNAi-mediated knockdown depends on the use of the 
guide strand RNA that is complementary to the target mRNA called RNAi Triggers, 
which includes small interfering RNA (siRNA), microRNA(miRNA) and small hairpin 
RNA (shRNA). A small hairpin RNA is a synthetic RNA molecule with a hairpin 
structure and can be used to silence target gene expression via RNA interference108. The 
expression of shRNA in target cells normally requires the use of an expression vector, 
such as a plasmid, with appropriate transmembrane RNA delivery. Expressed shRNA 
requires the further process by the ribonuclease Dicer into smaller mature dsRNAs 
before mediating the RISC dependent silence.  
MicroRNAs (miRNAs) are endogenous non-coding dsRNAs that regulate gene 
expression through a mechanism that involves the inhibition of translation and transcript 
degradation and are related to the regulation of many basic cellular programs 109. It is 
found that miRNA molecule could trigger RNAi-mediated gene silencing, though most 
of the endogenous miRNAs in mammals are not fully complementary to their mRNA 
target. The genome produced long dsRNAs were processed by enzymes Drosha and 
Pasha to generate ~70 nucleotides long loop structured molecules call pre-miRNA. The 
pre-miRNA molecules were then processed in the cytoplasm by enzyme Dicers to 
generate mature miRNAs which are around 22 nucleotides long110,111. The mature 
miRNAs contain one guide strand, which is responsible for the recognition of mRNA 
templates and assist target mRNA cleavage, and one passenger strand which are 
degraded by enzymes in the late stage of the silencing process. MicroRNAs are 
responsible for the regulation of multiple biological functions and plays a vital role in 
differentiation and biological developments. 
Small interfering RNA (siRNA) is a group of small dsRNA molecule of 20~25 base pair 
in length and are capable of triggering the RNAi-mediated silencing112. Like miRNA, 
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the siRNAs contain one guide stand that is responsible for the recognition of mRNA 
templates and assists target mRNA cleavage and one passenger strand. In mammalian 
cells, most siRNAs are normally exogenous. The siRNAs are produced during the early 
stage of the RNAi process when larger exogenous dsRNA molecules are sliced by the 
Dicer into smaller fragments. Synthetic siRNAs were also used to trigger RNAi-
mediated gene silencing with RNA delivery systems113. 
RNAi processes start with the introduction of exogenous dsRNA such as shRNA into 
the target cell, followed by the encounter of dsDNA with RNAse ribonuclease Dicer 
(demonstrated in figure 1.9). The Dicer is normally composed of one N-terminal 
helicase domain, one dsRNA-binding domain, one RNA binding Piwi/Argonaute/Zwille 
(PAZ) domain and two tandem RNase III domains114. The dsRNA sequence was 
processed into siRNAs and microRNAs(miRNA) of around 20-25 base pair. Note that 
exogenous siRNA sequences introduced into target cell do not require the process of 
Dicers112,115,116. These smaller dsRNAs were involved in the formation of an RNA-
induced silencing complex (RISC). RISC is a ribonucleoprotein complex composed of 
Argonaute proteins (Ago), dsRNA template and complementary target mRNAs. The 
Ago protein family plays an important role in the process of RNAi due to the presence 
of the PAZ domain and Piwi domain in its structure117. The PAZ domain of Ago protein 
can engage siRNA or miRNA, and the Piwi domain adopts an RNase H-like structure 
that is related to the cleavage of the guide strand. The siRNA or miRNA is unwound by 
RNA helicase to form a guide strand (antisense) and a passenger strand (sense). The 
guide strand directs the cleavage of target mRNA while the passenger strand is degraded 
during RISC activation118. The target mRNA is cleaved at its phosphodiester bond 
which is positioned between nucleotides 10 and 11, resulting in a decrease of expression 
of the target gene119. 
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Figure 1.9 Mechanisms of RNA interference. Double-stranded RNA (dsRNA) molecule first binds to 
a Dicer protein, which cleaves it into small interfering RNAs (siRNAs). These siRNAs bind to the 
RNA-Induced Silencing Complex (RISC), which separates the siRNAs into two strands. The 
passenger strand is degraded while the guide strand serves as a template, which guides RISC to 
complementary RNA targets.  
Delivery of RNA molecules showed great potential both as an experimental tool and a 
therapeutic application. RNAi can create repression of a specific gene and one can 
observe the gene-specific deficiency effect and study the role of certain genes in the 
development of the disease. With the advanced understanding of the role genes play in 
diseases development, novel treatment approaches could be developed. For example, 
Urban-Klein et al. reported a significant reduction of tumour growth in the animal 
model treated with HER-2 receptor specific siRNA- Polyethylenimine polyplexes 120. It 
is clear that RNAi and delivery of RNA molecules will continue to contribute to the 
understanding and treating of many diseases. 
1.2.3. Obstacles to Overcome in Gene therapy 
Though gene therapy shows unprecedented potential in the treatment of many diseases, 
many scientific obstacles must be overcome before it is clinically practical for therapy. 
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 Vector Toxicity and Immune Response 
The case of Jesse Gelsinger’s tragic death is an example of an adverse effect in gene 
therapy that was caused by vector toxicity. The post-mortal autopsy showed that 
substantial amounts of the viral vector had accumulated in the spleen, lymph nodes and 
bone marrow and subsequently triggered a severe inflammatory response that led to 
intravascular coagulation, acute respiratory disorders and multiorgan dysfunction 121. 
Other patients administrated with similar dosages showed tolerance against the 
adenoviral vector, or at least showed less severe adverse effects compared to Jesse 
Gelsinger.  
Viruses, whether wild type or specifically engineered with therapeutic genetic 
information, have a high chance of triggering the immune defence system of the human 
body. All viral vectors showed degrees of immunogenicity, while Adenovirus vectors 
showed the most among all, and overcoming the immunogenicity of viral vectors. The 
capsid of the viral vector could induce the virus-neutralizing antibody responses as well 
as the cytokine-mediated inflammatory responses. Also, the transgene product 
expressed by the transduced cells could trigger the cytotoxic T-lymphocyte 
response122,123.Another factor that affects the toxicity is the vector dosage. Studies have 
shown evidence that the inflammatory response measured by immunohistochemistry 
have increased linearly in response to increased viral vector dose124. 
To address this issue, various strategies have been developed. Elimination of the 
original viral genome from the vectors can reduce the cytokine response, though capsid-
mediated inflammatory response was still detected99,125. Studies focused on the dose-
escalation pointed out that the relationship of viral vectors and an immune response is 
characterised by a threshold theory: when administrated vectors exceeded a threshold 
limit, the cellular toxicity increases dramatically and induces severe cellular injury126. 
Other approaches include the use of a less toxic vector system such as lentivirus vector 
or Adeno-associated virus vectors. The development of non-viral vector as an 
alternative for viral vectors has advanced greatly in the recent decade, and compared to 
viral vectors, non-viral vectors showed much lower toxicity and immunogenicity at the 
cost of transfection efficiency127. 
Besides vector-caused immune response and toxicity, the oligonucleotides themselves 
could be considered as exogenous pathogens and trigger immune response through the 
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activation of Toll-like receptors (TLRs). Toll-like receptors are a family of protein 
receptors expressed in mammalian immune cells. Members of the TLR family are 
involved in recognition of pathogen-associated molecules, including flagella and 
exogenous nucleic acids. The siRNA triggered an innate immune response are mostly 
by the activation of TRL7 and TRL8128. Not all the siRNAs could trigger the activation 
of TLR7 and TLR8 since the recognition of RNA molecules are sequence-dependent. It 
is suggested that RNA sequences rich in uridine-guanosine (UG) and adenosine- uridine 
(AU) could be more immunostimulatory129,130,131. However, RNA sequence is not the 
only cause of immune response, for it is reported that RNAs lack of GU and UA rich 
sequences are also immune active131. The structure and length of RNA molecules could 
also determine its immunogenicity. Though both double strands and single strands RNA 
could trigger immune activity, it is suggested that in some cases the single strands acts 
as a stronger stimulator than double strands131. It is also reported that some RNA 
molecules, though rich in uridine, guanosine and adenosine, are poor stimulators of 
immune response due to their length (<20 bp)128. These findings may have provided a 
guideline for design and selection of RNA molecules and the use of siRNA that are of 
short, double-strand molecules lacks GU- or AU- rich regions may provide silencing 
activity with low immunogenicity.  
 Insertional Mutagenesis 
In 2000, Cavazzana-Calvo and his colleagues reported a successful establishment of a 
functional immune system in three children patient suffering from human severe 
combined immunodeficiency (SCID)-XI disease. Haematopoietic stem cells were 
transduced with murine leukaemia virus (MLV) with a gene that encodes the γ-c chain 
cytokine receptor and transplanted back into the patients132. The γ-c chain cytokine 
receptor plays a vital role in cytokine signals recognition pathways, and without it, 
lymphocytes cannot mature into functional T cells and natural-killer cells133. Based on 
this study, more patients received treatment for SCID-XI and achieved satisfactory 
results. However, two of the patients were later found to have developed a leukaemic 
disorder. It is because the retrovirus genome had inserted in the LIM domain only 2 
(LMO2) oncogene during the transduction of stem cells. The insertional mutation 
activated the expression of LMO2 gene and caused the transduced cells to derive into 
cancerous T cells134.  
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 Vector Specificity and Off-target Effect  
Wild-type viruses are limited in the ability to infect certain organs and tissues due to the 
route of transmission, but the engineered or recombinant viral vectors are not. For 
instance, adenoviruses and AAVs do not normally infect cells in the central nervous 
system, but once injected into the brain, both vectors showed high transfection 
efficiency into neurones. This could be considered as both benefit and liability: from 
one perspective, viral vectors showed less restriction in transfection; from another 
perspective, this could also lead to undesired cellular uptake by non-target cells in 
organs and tissues in systematic administration. Even in local administration, there is a 
risk of leakage and dissemination to other tissues and organs. 
Another obstacle is the off-target effect in gene therapy, especially in RNAi-mediated 
gene silence. The first recognition of the siRNA off-target effect was observed in 2003 
by Jackson et al.135. While using several different siRNAs to target the same gene, 
different siRNAs treated groups showed unique results in microarray expression 
profiling. The off-target transcripts were analysed and strikingly, some of the transcript 
shares only 8 nucleotides(nt) of complementarity of the siRNA sequence. This is due to 
the partial sequence complementarity between the 3’ untranslated region (3’ UTR) of 
the off-target mRNA and the 5’ of the small RNA molecule guide strand seed region. 
The seed region refers to the positions 1~8 at the 5’ end of the sequence in the guide 
strand of small RNA interference molecules, and it plays a vital role in target 
recognition 136. Since microRNA are mainly endogenous encoded non-coding RNAs 
that regulate hundreds of mRNA expression, the off-target effect is more commonly 
overserved in miRNA mediated silencing. However, since siRNA and miRNA share the 
silencing mechanism, the off-target effect in siRNA mediated silencing should not be 
neglected.  
 Barriers in intracellular delivery 
The cellular membrane preserves human genomic information and protects it from 
damage and contamination137, yet it also created barriers for the delivery of DNA and 
RNA molecules. For the delivery of antisense oligonucleotides (such as siRNA and 
miRNA) and ribozymes is intended to reach cytoplasm where the therapeutic molecular 
mRNA is located138. And for the delivery of plasmid DNA, antigene oligonucleotide 
and therapeutic gene sequence, it requires entry into nuclear before it could be 
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therapeutically active139. Several inherent factors including charge, size and stability of 
nucleic acids molecules present possible barriers to its intracellular delivery. The 
electrostatic repulsion between the negatively charged cell membrane and the negatively 
charged nucleic acids (due to the phosphate backbone) is the primary cause of 
inefficient cellular association. The delivery of large DNA molecules such as plasmid 
DNA is found more difficult compared with smaller molecules such as siRNA. Besides, 
the nucleic acids have low stability in vivo and can be rapidly degraded by hydrolytic 
nucleases. Those molecules that do obtain intracellular access are still susceptible to 
degradation. Upon internalisation, DNA and RNA molecules are up-taken by endosomal 
vesicles where they can be degraded. The acidic environment of endosome promotes the 
hydrolysis and activates the lysosomal enzymes that can degrade DNA and RNA 
molecules. The barriers in the delivery process are demonstrated in figure 1.10. 
 
Figure 1.10 The barriers in siRNA/DNA delivery using cationic carriers from the administration 
site to the target site. The figure is adapted from Luo et al.140 
 
Therefore, suitable and efficient methods of DNA and RNA intracellular delivery is one 
of the key steps in successful gene therapy. Current nucleic acid delivery methods can 
be classified into three categories: Electrical methods, Mechanical methods and Vector-
based methods.  
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Examples of mechanical methods include microinjection and particle bombardment. 
High transfer efficiency is achieved in microinjection at the cost of time since the gene 
is precisely injected into one target cell at a time141. Particle bombardment, or more 
commonly referred to as “gene gun” is to use a device powered either by pressure to 
shoot a payload composed of a heavy metal particle with genetic materials into the 
target cell or tissue. Though it is a direct and highly efficient method of delivery DNA 
and RNA, it is suggested to be uncontrollable, for the payload is introduced randomly 
into the target cells. Electroporation is an example of electrical methods used in gene 
delivery. It uses high voltage electrical current to increase the permeability of the target 
cell membrane and further facilitate the gene transfer. Though highly effective, reported 
to be ten times more effective than chemical-stimulated permeabilisation, it is 
accompanied by high cell mortality. It is well established that electrical methods and 
mechanical methods have achieved high transfer efficiency. However, it is also 
considered to be invasive and complicated for clinical situation 141. 
The use of a vector-based delivery system has received great many attention in the past 
few decades, and the field of vector-based delivery system has advanced dramatically. 
Various of vector-based delivery systems have been developed and studied to address 
the need for a safe, efficient and affordable intracellular delivery method in gene 
delivery. In the past few decades, various vectors, both viral and non-viral, were 
developed and studied for the transfecting ability, toxicity, biocompatibility and other 
characters142. However, there has been a heated debate on the use of the viral and non-
viral delivery system, for both possess advantages and disadvantages that would provide 
the application with different challenges.  
1.3. Viral and Non-Viral Delivery Systems 
1.3.1. Viral Delivery Systems 
It is difficult to directly use the genetic material as a therapeutic molecule without an 
efficient delivery system because naked DNA and RNA molecules cannot gain access 
into the cytoplasm. Therefore, to develop a safe and efficient delivery system that relies 
on the use of carriers (normally called vectors) to transport genetic material into target 
cells has become a primary objective for the utilisation of gene therapy. Since the early 
stage in the development of gene therapy technology, viruses have been widely used as 
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a carrier vector for gene transfer. Modification of virus vector included the removal of 
part of its original genome to prevent replication and added the sequence of a 
therapeutic gene to be expressed. Commonly used recombinant viruses include 
adenovirus, adeno-associated virus (AVV), retrovirus and lentivirus.  
 Adenovirus Vectors 
Adenoviruses are medium-sized, nonenveloped double-stranded DNA viruses with an 
icosahedral nucleocapsid and can infect a variety of vertebrate hosts. Adenoviruses used 
as delivery vectors are human adenoviruses that isolated from multiple sources 
including adenoids and conjunctiva of patients with upper respiratory disease or the 
faeces of infants with diarrhoea143. There are more than 50 different adenovirus 
serotypes divided into subgroups A through E. In gene therapy, the most commonly 
used ones are serotypes 2 and 5 of the subgroup C, for the viral structure and biology is 
well studied, and the production of recombined subgroup C adenoviruses are therefore 
more convenient 144. 
The structure of adenoviruses consists of an icosahedral protein capsid and one double-
stranded DNA molecule that contains the viral genetic information. The icosahedral 
capsid is approximately 70 - 100 nm in diameter and is composed of 240 hexon 
capsomeres, and each capsomere is comprised of six hexon subunit which is formed by 
three copies of the 105kD hexon protein. The icosahedral structure has 20 faces and 12 
vertices. Each vertex is formed by five units of penton base protein and three units of 
fibre protein and are adjacent to five hexon capsomeres. The fibre protein points 
outwards and interacts with a high-affinity receptor on the target cell membrane. Capsid 
protein IX, IIIa and VI are also found in adenoviruses structure, and their function is to 
interact with hexon capsomeres to stabilize the capsid structure. Inside the capsid 
situates the adenovirus genome which is a dsDNA molecule around 36,000 base pair145. 
The dsDNA molecule is surrounded by capsid core protein VII, and at the 5’ end of each 
DNA strand, a terminal protein is attached. The 3D structure and the schematic structure 
of the adenovirus is demonstrated in figure 1.11. 
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Figure 1.11 The 3D structure(right) and the schematic structure(left) of the adenovirus. 
 
The internalisation of adenoviruses starts with the recognition of the fibre protein on the 
virus capsid by the coxsackievirus and adenovirus receptors (CARs) (figure 1.12)143. 
The RGD sequences in the penton base protein interact with cell surface integrins αVβ3 
or αVβ5 (for serotype 3 and 5 respectively). The adenovirus enters the cell through 
clathrin-mediated endocytosis and is rapidly released into cytoplasm after entering 
endosomes. The viruses in the cytoplasm proceeded quickly to the nucleus and were 
later transported onto microtubules. The virus capsid docks on the nuclear pore complex 
(NPC) and then the NPC dissociates the DNA from the capsid and imports the viral 
DNA into nucleus membrane146. Though it is considered that hexon on the viral capsid 
plays a major role in the NPC-mediated DNA transport into the nucleus, there might be 
other unidentified factors involved in this process147. 
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Figure 1.12 Internalisation of adenoviruses from the outside plasma membrane into the nucleus. 
 
Adenoviruses have been widely used in gene therapy since the early stages in the gene 
therapy development, and nowadays adenoviruses-based vectors have been applied in 
the treatment of many diseases including cancer and genetic deficiency. 
 Adenovirus-associated virus Vectors 
Adenovirus-associated virus (AAV) is a small, DNA-containing virus that originally 
obtained in the laboratory preparation of adenovirus and is not related to the cause of 
any known diseases. It was later recognized as a different from adenovirus. The 
replication of AAVs are largely relying on the help of adenoviruses, but other viruses 
such as herpesvirus were also found to function as a helper for AAV replication, though 
much less efficient. AAV has a non-enveloped icosahedral symmetric structure and is 
about 20 nm in diameter. The capsid of AAV is composed of three types of the capsid 
protein, VP1, VP2 and VP3 with a ratio of 1:1:8. Inside the capsid contains a linear 
single-stranded DNA genome with a molecular weight of 1,500kDa. Each capsid is 
composed of 60 protein subunits and all the amino acid residues, except residues from 
VP1, could be detected on the structure. The capsid surface has a distinctive topology 
where three peak-like structures in each threefold icosahedral axis (figure 1.13). Each 
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peak is intergraded with two interacting protein subunits. The peak structure appears to 
be related to receptor binding interactions with heparin sulphate148.  
 
Figure 1.13 The structure of AAV determined by x-ray crystallography. Figure adapted from Xie et 
al.148 
 
There are 11 serotypes of AAV reported, and it is found that different serotypes of AAV 
are different in the ability to transfect cells and organs. Also, the route of administration 
and the capsid sequence of the AAV also contributed to its transfection ability.  
For the majority of the AVV vectors, the internalisation of AVV into cells is mediated by 
endocytosis. Upon AVV surface protein binding to the heparin receptor, AVV is 
internalised by clathrin-mediated endocytosis149,150. For different serotypes of AVV 
vector, clathrin-independent uptake was also found 151. 
Studies using fluorescently labelled AAV2 vector particles revealed that endocytosis 
could be mediated through αVβ5 integrin/Rep dependent pathways151. After entering 
the cytoplasm membrane, the AAVs were delivery to endosomes. The escape of vectors 
from endosomes was suggested to be mediated by a latent phospholipase activity 
resident in the N terminus of VP1152. The escaped AAVs travel rapidly towards the 
nuclear and with the assistance of a helper virus, normally adenovirus of herpesvirus, 
they gain entry into the nucleus. Although the nuclear entry and uncoating of AVV 
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remain partially understood, it is suggested that it does not involve the use of the 
nuclear pore complex153. It is also concluded that in the absence of helper virus, there is 
a reduction in the transportation of vector genome into the nucleus of the target cell153. 
AAV vectors have been developed into a delivery system for the treatment of many 
diseases including haemophilia B, muscular dystrophies and central nervous system 
diseases154. 
 Retroviral Vectors 
Retroviruses are lipid-enveloped, single-stranded RNA viruses with approximate 
diameters of 100~200 nm. There are seven genera (Alpha, Beta, Gamma, Delta, 
Epsilon, Lentivirus and Spumavirus) in the Retroviridae family and that include many 
viruses widely related to a variety of diseases including cancers and acquired immune 
deficiency syndrome155. Unlike other viruses with DNA genome, the genetic 
information of retroviruses is encrypted in the viral RNA genome and is reverse 
transcribed into a double-stranded DNA by reverse transcriptase upon uptake. The 
reverse transcribed DNA are subsequently delivered to the nucleus and is inserted into 
the host genome by the integrase protein. The virus genome inserted into the host 
genome, which is referred to as provirus, is expressed by the host cell protein synthesis 
machinery to produce viral proteins essential for the assembly of new viruses. The 
newly assembled immature virus particle is composed of a viral membrane, envelope 
protein (Env), Group antigen protein (Gag) that serves as major structural proteins, 
DNA polymerase (Pol) that serves as the replication enzymes, and the retroviral 
genome156. Later in the maturation of viral particles, the Gag protein is cleaved by viral 
proteinase into capsid protein, matrix protein and nucleocapsid protein157. The matrix 
protein is found to bind to the inner part of the viral membrane, while the capsid protein 
assembles into capsid that surrounds the nucleocapsid protein-RNA complex and 
enzymes critical for viral replication158.  
Within mature retroviruses, the capsids are found to be of different shapes and sizes. 
Lentiviruses and HIV-1 capsids are mainly cone-shaped, while Rous sarcoma virus 
(RSV) and murine leukaemia viruses (MLV) capsids are found to be polyhedral or 
spherical-like155,159,160. Compared to icosahedral viruses, such as adenoviruses, the 
protein organisation of retroviruses capsids follows the principle of fullerene 
arrangement, which means 12 pentamers form into a hexagonal capsid 161. In a 
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spherical-like retroviruses capsid, the 12 pentamers are distributed randomly, while 
cylindrical capsids have six pentamers at each end of the cylindrical tube. It is suggested 
that the immature retroviral particle contains 1000~5000 units of Gag proteins. 
However, during the maturation process, only a small portion was essentially converted 
to capsid proteins for the formation of the virus core162. Considering the various shapes 
and sizes of retrovirus capsid, it might be necessary to have an excess amount of Gag 
protein to ensure the proper maturation of the retroviruses163. 
The intracellular transportation of retroviruses starts with the receptor recognition on the 
cell surface, allowing fusion with the cell membrane or activates endocytosis (figure 
1.14). Different retroviruses may differ in internalisation pathways. For example, the 
cellular entry of mouse mammary tumour virus relies on a low pH-dependent viral 
fusion reaction with the target cell membrane164, while ecotropic murine leukaemia 
viruses (MLV) is internalised through macropinocytosis pathway165. One unique feature 
of retroviruses is their ability to reverse transcribe the single-stranded RNAs into DNA 
and deliver the integration-competent DNA into the nucleus. After retroviruses gain 
entry into the cytoplasm, the viral RNA is reverse transcribed into linear double-
stranded DNA by reverse transcriptase (RT). The primer binding site of the retroviral 
RNA is one of the most important motifs for it is critical for the initiation of reverse 
transcription. A cell derived tRNA serves as the primers and binds to the binding site 
before RT-polymerase, and the polypurine tract (PPT) mediates the synthesis of the 
second DNA strand166. The product of the reverse transcription is associated with 
various cellular proteins and some viral proteins (includes approximately 100 different 
proteins) to form a complicated structure termed the transcription preinitiation complex 
(PIC). Intracellular transportation of the PIC is delivered by the microtubes, and it is a 
host cellular protein-dependent process167. However, not all retroviruses can actively 
cross the nuclear membranes. For instance, all viral PICs from the Gammaretrovirus 
genus cannot actively enter the nuclear membrane, possibly due to a linker molecule 
being missing in the nuclear transport machinery. The breakdown of the nuclear 
membrane during mitosis provided an opportunity for the PIC to enter the nucleus. 
Some other retroviruses, like lentiviruses, are able to actively enter nuclear membranes 
and therefore are capable of transducing resting cells. Having encountered the host 
genome, the viral DNA integrates into the host genome. The integration of the viral 
DNA into the host genome occurs without major interference of the original cellular 
sequences and does not form transgene concatemers. The viral DNA was transcribed 
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into viral mRNA and then is exported to the cytoplasm where mRNA is translated into 
Gag, Env and Pol, which are used as components for the assembly of new retroviruses  
 
Figure 1.14 Retroviral internalisation and viral gene expression as shown for a simple 
gammaretrovirus example164. 
 
The therapeutic use of retroviruses as delivery agents has focused on gammaretroviral 
vectors. Key applications of gammaretroviral vectors include the expression of 
oncogenes in cancer therapy and the genetic engineering of T-lymphocytes and 
Hematopoietic stem cells 168,169. 
 Advantages and Limitations of Viral Vectors 
The use of viruses as gene delivery vectors exploit their natural ability to enter target 
cells and express the genetic information they carry. This provides viral vectors with 
high transfection rate and rapid transcription of the foreign gene inserted in the viral 
genome. Besides the high transfection efficiency, each type of viral vectors has its own 
characteristic advantages compared with other viral vectors. For instance, adenoviruses 
have a large gene capacity for foreign gene and low cell specificity, which makes it 
possible for adenoviral vectors to infect any cell type. Or in the case of lentivirus 
vectors, it can infect resting cells and with a relatively large gene capacity, unlike many 
other retroviral vectors that can only transfect dividing cells.  
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However, each type of viral vector has its own limitations as well. Adenovirus vector, 
though efficient with large gene capacity, has high immunogenicity and high vector 
toxicity, and combined with its low target cell specificity, it provides hindrance in the 
systematic administration of such vector. The adeno-associated virus vector is relatively 
safer since it is not related to the cause of any known disease, but it has a relatively 
smaller gene capability (can carry gene up to a length 5.8K base pair, only 15% of 
adenovirus vector capability) and has a rather complicated production process which 
indirectly increases the cost and difficulty for its application. For most of the retrovirus-
based vectors, the lack of ability to transfect resting cells limits its application in 
targeting certain tissues. The advantages and limitations of each viral vector have been 
listed in table 1.3. 
Table 1.3 This table show the advantages and disadvantages of several well-studied viral gene 
delivery systems. Table adapted from Bolt et al. 170 
The advances in the field of viral gene therapy have led to the production of 
commercially available gene therapy products in the market. The first viral-based gene 
therapy product was Gendicine, a cancer gene therapy approved in China in 2003 that 
delivers the tumour suppressor gene p53 using an engineered adenovirus. More recently, 
the United States Food and Drug Administration (FDA) approved an adeno-associated 
virus (AAV) gene therapy called Voretigene Neparvovec from Spark Therapeutics for 
the treatment of a rare inherited retinal disease. Nonetheless, even the approval of viral-
based gene delivery products could not eradicate the shadow once shed by the clinical 
trial that caused the tragic death of Jesse Gelsinger as well as immune responses 
observed in other patients95. The debate over the safety of the viral vector application 
has lasted over several decades and continues to this day. Those who believe there could 
be an alternative vector that provides good gene transfection efficiency with low 
toxicity and immunogenicity turn their attention to search for substitutes.  
Viral Vector Advantages  Limitations Ref 
Adenoviruses 
vectors 
 Large transgene capacity (up 
to 38 kb) 
 low target specificity 
 Tend to yield natural and acute 
immune responses 
 Short-term gene expression 
171,172 
Adeno-
associated 
vectors 
 Comparatively higher safety  Complicated production process 
 Limited gene capacity (up to 4.8 kb) 
173,174 
Retroviral 
vectors 
 Medium gene capacity (up to 
8 kb) 
 Low efficiency in vivo 
 High immunogenicity 
 Can only transduce dividing cells  
 Possible random gene insertion 
175,176 
Lentivirus 
vectors 
 Able to infect both dividing 
and resting cells  
 Medium gene capacity (up to 
8 kb) 
 Difficult to design and produce 
 High immunogenicity 
 
177,178 
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1.3.2. Non-viral Delivery Systems 
Non-viral Delivery vector systems provide alternative forms of delivery for gene 
therapy and have been studied in the past decades. The non-viral delivery approach 
involves the use of physical or chemical methods to achieve the delivery of nucleic 
materials. Physical methods are mainly based on physical stimulation such as using 
electrical stimulation and sonic stimulation. The chemical method is based on the use of 
varieties of lipids, polymers, dendrimers or other natural materials combined with DNA 
or RNA materials to form nanoparticles or complexes127,142,179,180. Unlike viral vectors 
that are based on the natural ability to infect cells, non-viral vectors consistently exhibit 
reduced transfection efficiency due to the extra- and intracellular obstacles. However, 
non-viral vectors possess advantages including biocompatibility and potential for large-
scale production which makes these vectors attractive for gene therapy181. A significant 
amount of studies in the past decade has focused on the development and application of 
non-viral delivery vectors that can overcome the barriers in vitro and in vivo for gene 
delivery.  
 Lipid-based delivery systems 
Lipid-based delivery systems (LBDS) used cationic lipid to combine with nucleic 
materials, forming nanosized particles called lipoplex for the delivery of genetic 
material. LBDS was one of the earliest gene transfer strategies used to introduce foreign 
genetic material into target cells. In the past decades, various studies have demonstrated 
the capability of delivering external genetic material into target cells using lipid-based 
vectors 182-184. Early work suggested the mechanism for the lipid-based delivery system 
is related to the direct plasma membrane fusion of lipoplex into target cells 185, yet other 
studies revealed that the intracellular uptake of lipid-based vectors is primarily through 
endocytosis 186. After cellular entry, the lipoplexes destabilise the endosomal membrane 
and initiate a flip-flop reorganisation of phospholipids. These phospholipids play a 
major role in the release of genetic materials into cytoplasm by interaction with the 
cationic lipid in the lipoplexes 187. The cationic lipids used as delivery vectors normally 
contain three major structural domains: a cationic headgroup, a hydrophobic tail, and a 
linker domain that connects the other two. The density and nature of the cationic 
headgroup affect the transfection related ability and the length and type of the 
hydrophobic tail can affect the transfection efficiency of a given lipid as well188. With 
 40 
 
proper manipulation and modification on the headgroup and tail-group, the chemical 
and physical properties of the cationic lipid can be adjusted to suit the purpose of the 
delivery189. 
Cationic lipid vectors for gene delivery are widely used in gene delivery thanks to their 
ability to condense anionic nucleic acids. Cationic lipid-based gene delivery system has 
been applied to the treatment of many diseases. For example, cationic lipid-based gene 
delivery system has been used in the field of cancer treatment. Tabernero et al. 
performed an RNAi therapy targeting VEGF and kinesin spindle protein in cancer 
patients using cationic lipid-siRNA complexes mediated treatment190. Applications in 
other fields such as therapy in liver diseases were also reported191,192. LBDS have many 
advantages as a gene delivery system including high cargo capability, good 
biocompatibility and versatility. Another advantage of LBDS is the formulation can be 
modified in a variety of ways to fulfil the requirements for different patient and different 
diseases193-195.  
 Dendrimers 
Dendrimers are polymer compounds consisting of a central core structure with highly 
branched arms of symmetric pattern around it. The unique molecular structure provided 
dendrimers with distinctive properties (an example was shown in figure 1.15). 
Dendrimers are synthesised through a gradual stepwise approach which means, in 
general, that they have a well-defined size and structure with a relatively low 
polydispersity index. The high density of terminal groups provided dendrimers with 
multiple attachment sites and the potential for customized modification. With these 
critical properties, dendrimers have gained much attention and made them particularly 
interesting for gene delivery vectors. Dendrimers can interact with various types of 
nucleic acids, such as plasmid DNA or oligonucleotides, to form complexes that protect 
the nucleic acid from degradation196. It is suggested that the interaction between 
dendrimer and the nucleic acid is sequence non-specific and based on electrostatic 
interactions197. 
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Figure 1.15 An example of a PAMAM dendrimer molecule structure 198. 
 
In 1993, Haensler et al. reported the first use of Polyamidoamine (PAMAM) dendrimers 
as transfection agents 199. For the past decade, the use of dendrimers as a gene delivery 
vector has developed rapidly and has been applied to the treatment of many diseases. 
Maruyama-Tabata et al. intravitreally injected lipid lysine dendrimer complexes and 
inhibited neo-vascularisation of the choroidea by down-regulation of VEGF200. Sato et 
al. demonstrated that intratumoral injection of dendrimer-plasmid complexes that 
encode tissue inhibitor of the metalloproteinase-2 gene (TIMP2 gene) would inhibit the 
growth of tumours 201. Undoubtedly, dendrimer-based delivery systems have 
demonstrated considerable potential as tools for the further development of genetic 
therapies. 
 Polymer-based delivery systems 
The polymer-based delivery system is to use nano-scale particles or micelles that are 
composed of a polymer and a specific loading material (genetic materials, small 
molecule drugs or peptides) to deliver its content to a specific tissue or organ202.  
Early stage studies in polymer gene delivery system focused on the use of poly-l-lysine 
and polyethylenimine (PEI). It is well established that polylysine is the first cationic 
polymer used as a gene delivery vector203. On its own, polylysine is not an efficient 
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gene transfer agent. Even with the aid of chloroquine, suggested to be capable of 
helping delivered nucleic acids escape from their vesicles and avoid lysosomal 
degradation 204, polylysine-DNA complexes showed moderate transfection efficiency. 
The polylysine based vectors were proved to be valuable in early research studies, but 
its low transfection efficiency limited the application in the clinical situation. 
Polyethylenimine (PEI) is considered to be one of the most effective cationic polymer-
based gene delivery vectors studied up to date, has been widely studied and used since 
1995205. PEI can efficiently mediate gene delivery without any additional 
endosomolytic agent. Moreover, PEI has successfully mediated in vivo gene delivery to 
multiple organs including kidney and lungs206. However, though efficient and in vivo 
active, the further application of PEI as gene delivery vector is hindered by its relatively 
high toxicity.  
With improved understanding of the obstacles in extra- and intracellular gene delivery 
and further knowledge of the key steps that affect the gene transfer efficiency, polymers 
were designed to address specific barriers, such as biocompatibility and endosomal 
escape. It is suggested that endosomal escape is a key step in gene delivery, and certain 
synthetic acid-responsive polymers have been produced to enhance its transgene 
efficiency, which is inspired by specific peptides viruses developed in their capsid to 
enable protonation and become fusogenic with endosomal membrane207. An example is 
provided by Tirrell et al. that synthesised polyethylacrylic acid that can cause membrane 
disruption at low pHs208. Another approach to enhance polymer delivery vector 
performance is to increase the biocompatibility. Cationic polymers like PEI showed 
significant transfection efficiency but also high toxicity. It is now known that the ability 
of protonation under acidic environment might be the key to efficient endosomal 
escape. It is suggested that a biocompatible material could be chemically modified to 
have a buffering capacity at physiological and lysosomal pH. In one study, a 
homopolymer of histidine and gluconic acid was prepared and combined with DNA and 
transferrin-polylysine conjugates to form polyplexes. The histidine contains imidazole 
groups that has the desired protonation properties (pKa ~6) and the gluconic acid 
increased the aqueous solubility of the homopolymers209. The complex showed good 
efficiency compared to control groups, and furthermore, the complex showed low 
toxicity at gene delivery concentrations209. Undoubtedly, polymer-based gene delivery 
systems showed promising potential as delivery vectors in gene therapy. 
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Furthermore, many novel polymers with unique architectures, including star polymers, 
comb polymers and many others can be generated using block copolymers (figure 1.16). 
These novel designs may provide the polymers with significantly different solution 
behaviours as well as from their ability to self-assemble. By coordinating the 
architecture and composition of polymers, materials with a diverse range of attributes 
can be generated and utilised in various applications210. 
 
Figure 1.16 Examples of various polymer architectures that can be achieved. (a) linear; (b) graft; 
(c) brush or comb; (d) ring; (e) star AnBn; (f) star-block (AB)n; (g) AB2 star. Figure is adapted 
from Gregory et al. 210. 
 
For example, Ma et al. synthesised a novel star‐shaped porphyrin‐poly(L‐lysine) 
dendrons polymer. Due to its amphiphilic property, the obtained polymer has a low 
critical micelle concentration in an aqueous solution and can load a moderate amount of 
doxorubicin. Moreover, the doxorubicin‐loaded polymer shows a higher cytotoxicity 
under the light stimulation compared to polymer or DOX alone, which suggests that the 
star‐shaped porphyrin‐poly(L‐lysine) dendrons polymer has a potential application in 
combined photodynamic therapy and chemotherapy211. 
1.4. Cationic Polymer-based Gene Delivery System 
Cationic polymers are polymers bearing positive charges or polymers synthesised with 
cationic moieties in their backbone and/or in their side chains. The cationic moieties 
include primary, secondary, tertiary and quaternary amines, as well as other positively 
charged groups like amidines. The cationic polymers can electrostatically condense to 
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genetic materials into particles termed polyplex. The size of the polyplexes ranges from 
tens to several hundreds nanometers in diameter212. Thanks to the flexibility of polymer 
chemistries, it might be possible to provide cationic polymers with multiple functions 
required for efficient gene delivery while maintaining good biocompatibility. The goal 
of using a cationic polymer delivery system, or any other delivery system, is to address 
the problems in gene delivery. This section will discuss how cationic polymer delivery 
vectors can be applied to address problems in gene delivery including gene packaging 
and protection, trans-membrane activity, and endosomal escape. Examples of well-
studied cationic polymers will also be described. 
1.4.1. Gene Therapy Complexation 
One problem in gene delivery is the delicacy of genetic materials. Unprotected DNA or 
RNA is degraded by corresponding enzymes within a short period of time. An efficient 
delivery system can neutralise the negatively charged nucleic acid to prevent charge 
repulsion against the cellular membrane. Also, the condensation of polymers with 
nucleic acids could efficiently prevent extra- and intracellular degradation by nucleases. 
Three major packaging strategies have been developed to achieve polymer-gene 
condensation: electrostatic interaction, encapsulation, and adsorption. The majority of 
the cationic polymers exploited the anionic nature of DNA and RNA to achieve 
successful condensation via electrostatic interaction, while encapsulation (figure 1.17) 
and adsorption are more commonly seen in the case of neutral and biodegradable 
polymers such as poly(lactide-co-glycolide).  
 
Figure 1.17 Polyplexes formation via electrostatic interaction between cationic polymers and 
nucleic acids. 
The amine- and amino- groups in the cationic polymer can be protonated at neutral pH 
and below, enabling the electrostatically driven assembly of cationic polymers and 
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nucleic acids. Several forces are involved in the condensation of cationic polymers with 
nucleic acids, including bending, mixing entropy, coulombic force213. Bending and 
mixing free energies resists the condensation process, while the coulombic force, at 
least under certain conditions, is in favour of the condensation. According to Bloomfield 
et al, the bending free energy of a DNA molecule can be described as follows213: 
∆𝐺𝑏𝑒𝑛𝑑𝑖𝑛𝑔 = 𝑅𝑇𝑎𝐿 2𝑅𝑐
2⁄  
Where L is the length of the DNA with persistence length a. The radius of the bent part 
is Rc . The mixing free energy is described by Post et al.214 as: 
∆𝐺𝑚𝑖𝑥𝑖𝑛𝑔 = 𝑅𝑇𝐿 𝑎⁄  
Nucleic acids condensed negative charges and generate powerful repulsion energy 
between condensed and uncondensed DNA. The free energy of the electrostatic 
repulsion is summarized based on Oosawa’s work215 by Bloomfield213:  
∆𝐺𝑟𝑒𝑝𝑢𝑙 =
𝑛𝑘𝐵𝑇
2𝜉𝑧2
2 ln
𝑉𝑢𝑛𝑐𝑜𝑛𝑑𝑒𝑛𝑠𝑒𝑑
𝑉𝑐𝑜𝑛𝑑𝑒𝑛𝑠𝑒𝑑
 
where then is the total number of phosphate charges, z2 is the valence of condensing 
cationic. The V is the volume of the condensed and uncondensed molecules assumed to 
be a sphere.  
One possible attraction force is the induced dipole interaction between the fluctuating 
ion atmosphere and its free energy is given by Marquet et al.216: 
∆𝐺𝑓𝑙𝑢𝑐 =
3𝐿𝑘𝐵𝑇
𝑋
(𝜃2𝑧2
2𝜉)2
(1 + 𝜃2𝑧2
2𝜉)2
 
Where X is the distance of interhelix centres in the condensed DNA. 
The addition of four free energy equations, combined with experimental data collected 
by Bloomfield et al., provided a total free energy ΔGtotal of -0.11 to -0.24 kJ/mole bp 
with cations of charge +3 or greater, suggesting by that the cation-DNA condensation 
process is entropically driven self-assembly213. The resulting polyplexes are typically 
spherical, micellar, or toroidal structures with size ranging from about 20 to several 
hundred nanometers217,218. The nitrogen to phosphate ratio (N: P ratio), also referred to 
as charge ratio, is used to describe the ratio between the polymer and nucleic acids used 
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during the polyplexes formation. The N: P ratio can significantly affect the formation of 
stable polyplexes, and different N: P ratios are required for different cationic polymers 
for stable nucleic acids condensation. High N: P ratio presents larger groups positive-
charge moieties that increases the polyplexes stability due to a stronger electrostatic 
charge, though a strong stronger electrostatic charge that favours the polyplexes stability 
may lead to difficulties of nucleic acid release in the later stage of gene delivery219. 
Therefore, the design and synthesis of cationic polymers should balance binding 
strength to ensure nucleic acid packaging and protection with the capability of the 
endosomal escape of nucleic acids into its target site.  
1.4.2. The Internalisation of Cationic Polyplexes 
Another obstacle in cationic polymer-based gene delivery is the plasma membrane. To 
gain cellular access, passive diffusion is typically not applicable to polyplexes due to 
size limitation by the membrane pores and low partition efficiency into lipid bilayers. 
Many intracellular delivery approaches have exploited the natural cell endocytosis 
process, which cells use to transport external macromolecules from the extracellular 
space into the cytoplasm. Many known pathways of endocytosis, including clathrin-
dependent endocytosis, caveolae-mediated endocytosis, phagocytosis, macropinocytosis 
and clathrin- and caveolae-independent endocytosis, offered a diverse and regulated 
mechanism of cellular entry.  
 Clathrin-dependent Endocytosis 
Clathrin-mediated endocytosis, also called clathrin-dependent endocytosis, is one of the 
major routes and is well-characterised in most mammalian cell lines220,221.  The key 
component in this endocytosis route, clathrin protein, is composed of a heavy chain 
(~190 kDa) and a light chain (~25 kDa). Clathrin protein can form different lattices 
including hexagonal lattices and cage-like lattices composed of hexagons and/or 
pentagons222. Other proteins, such as AP-2 protein, dynamin and Eps15, and over 50 
other cytosolic proteins, are involved in the clathrin-mediated endocytosis process223. 
The endocytosis process is initiated by the interaction of extracellular “cargo” 
molecules with the cell membrane (figure 1.18). The first step is to assemble clathrin-
coated pits on the cellular membrane, which is composed of clathrin and many other 
proteins (figure 1.18). The clathrin-adaptor proteins, such as the heterotetrameric 
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adaptor protein AP2 complex, first bind to the lipids site where the external “cargo” 
molecule is located in the plasma membrane. Then the scaffold proteins, such as 
clathrin, interact with clathrin adaptors and cluster to form the coat components224. The 
clathrin-coated pit in contact with the external “cargo” molecules on the plasma 
membrane initiates the endocytosis process225. After clathrin-coated pit assembly, a 
group of actin molecules would polymerise at the endocytic site, forming the actin 
module. The actin module includes critical regulatory components such as the proteins 
of the Wiskott–Aldrich syndrome protein family, which play vital roles in the activation 
of dynamin, and the actin filaments226. The actin module is also of vital importance for 
the invagination and scission of the endocytosis vesicle. The actin filament 
polymerisation provided force for the bending of the plasma membrane and results in 
the formation of the endocytosis vesicle. 
 
Figure 1.18 The clathrin-dependent endocytosis process. The figure is a modified reprint from Roux 
et al. 227 
 
Following the formation of the endocytosis vesicle, the scission of the invagination neck 
is mediated by a large GTPase dynamin. Dynamins assemble at the neck of the clathrin-
coated pit into a helical collar. With the aid of other proteins including endophilin and 
amphiphysin, dynamin constricts the neck to allow fission of the endocytosis vesicle 
228,229. The protein-coated endocytosis vesicle was released into the cytoplasm where the 
disassembly of the protein coat take place. Two mechanisms have been suggested in the 
disassembly of the coat: HSC70 (heat shock protein 70kDa) chaperone-mediated 
clathrin lattice degradation and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) 
dephosphorylation230,231. The disassembly of the coat releases the endocytosis vesicle 
and enables further fusing with early endosome to initiate the intracellular transportation 
of its “cargo” molecules. The endocytosed “cargo” is sorted in early endosomes and 
further routed different destinations. The “cargo” molecule could be transported to late 
endosomes and lysosomes, or delivered to the secretory sorting station trans-Golgi 
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network (TGN) and was directed to different subcellular destinations, or to endosomal 
recycling carriers that bring the molecule back to the plasma membrane232. 
 Caveolae-Mediated Endocytosis 
Caveolae are small vesicles (50–60 nm in diameter) defined as invaginations of the cell 
membrane that is lined by caveolin-1. Caveolae system is the hydrophobic membrane 
microdomains that rich in cholesterol and sphingolipids 233-235. The internalisation 
mechanism involved varies in different cases; for instance, the internalisation of simian 
vacuolating virus 40 (SV40) is initiated upon virus binding to the cell surface and 
activates a tyrosine kinase-based signalling cascade that disrupts the local actin 
cytoskeleton and employs dynamin to the site of binding (figure 1.19)236. In another 
case, albumin triggers caveolae endocytosis through the binding to its receptor, gp60 
(glycoprotein 60kDa). Most of the internalisation of caveolar ligands is a signal-
mediated process that requires the presence of caveolin-1, for example, the interaction 
between caveolin-1 and gp60 is essential for albumin uptake237. Though some other 
caveolae ligand can mediate internalisation without caveolin-1, such as autocrine 
motility factor (AMF), a signalling factor which regulates cell motility, is internalized 
via a dynamin-dependent pathway in caveolin-1 deficient cells238. 
 
Figure 1.19 Caveolae-dependent endocytosis. The figure is adapted from Nabi et al. 239 
 
The “cargo” bound on the plasma membrane invaginates and forms caveosome that is 
delivered to early endosome for sorting. Depending on the content, caveosomes were 
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further transported to different destinations. For example, caveosomes that contain 
SV40 and caveolin-1 is delivered to the smooth endoplasmic reticulum (ER) without 
traversing the Golgi, while caveosomes that contain cholera toxin (CTX) is transported 
directly to Golgi240. CTX and SV40 could alternatively be transported to a common 
caveosome first before further segregated for delivery to Golgi and smooth ER, 
respectively. Cell treated with microtubule depolymerizing agent, nocodazole, could 
disrupt the delivery of SV40 and CTX delivery to Golgi and ER, but does not affect the 
delivery of AMF which is directly delivered to the smooth ER via a distinct pathway, 
suggesting the intracellular transportation of caveosomes is via microtubules 241. 
 Other pathways of Endocytosis 
There are other means of endocytosis pathways including macropinocytosis, and 
phagocytosis. Macropinocytosis is induced by tho-family GTPase triggered the actin-
driven process of membrane protrusion242. The large endocytic vesicles, referred to as 
macropinosomes, contain large amounts of extracellular medium and is an efficient 
route for the non-selective endocytosis of macromolecules243. Phagocytosis is 
conducted mainly by macrophages, monocytes and neutrophils. The endocytosis 
process of macropinocytosis and phagocytosis is shown in figure 1.20. 
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Figure 1.20 The phagocytosis and micropinocytosis process. 
 
In mammalian cells, phagocytosis is a major way to clear large pathogens such as 
bacteria, dead cells, fat deposits and large debris from apoptotic bodies244,245. Yet this 
pathway could be used for the uptake of exogenous molecules under special conditions 
by specific cell types. The phagocytosis requires interaction between the ligand of 
exogenous molecules and certain cell membrane receptors such as the fibronectin 
receptor and the immunoglobulin-like receptor (Fc receptors)245.  
 Role of glycosaminoglycans (GAGs) in polyplex internalisation 
Glycosaminoglycans are long unbranched biopolymers with repeating disaccharide 
units consisting of two hexose derivatives. These hexose derivatives are typically 
galactosamine or glucosamine and have either a carboxylate or sulphate group attached 
to one or both of the hexose derivatives which makes them negatively charged. For 
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example, the most common disaccharide unit in Heparin is composed of a 2-O-
sulphated iduronic acid and 6-O-sulphated, N-sulphated glucosamine (figure 1.21)246 
 
Figure 1.21 Structure of Heparin, an example of glycosaminoglycan. The disaccharide units are 
composed of 2-O-sulphated iduronic acid and 6-O-sulphated.  
 
There are several types of GAGs and the amount within cells vary depending on the cell 
type. Since GAGs are highly negatively charged, its interaction between positively 
charged polyplexes has a great effect upon the uptake and transfection efficiency of 
polyplexes. GAGs, as typical polyanionic molecules, can compete with nucleic acids 
and dissociate polyplexes. Some studies did show that high concentrations of GAGs in 
extracellular space and on the cell membrane could reduce or even completely inhibit 
the transfection efficiency247,248. However, in some cases, the existence of sulphate 
GAGs on the cell membrane would improve gene delivery efficiency. Hornof et al. 
reported improved uptake and transfection efficiency of PEI-polyplexes coated with low 
molecular weight hyaluronan249. Since the type and number of GAGs are cell type-
dependent, this indicates that the relationship between polyplexes and GAGs can vary 
with different polymers on different cell lines and would have an impact on gene 
delivery efficiency and its therapeutic effect.  
 The internalisation of cationic polymer polyplexes 
A series of studies have been conducted to determine the internalisation pathways of 
cationic polymer based polyplexes. Midoux et al. have summarised the result of   
several studies in different cell lines with different cationic polymers (table 1.4)250. 
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Table 1.4 Cationic polyplexes internalisation pathways summarised by Midoux et al. (t) indicates 
that the transfection efficiency is reduced by inhibitors of the related pathway. 
Polymers Cells Clathrin- 
dependent 
Caveolae- 
dependent 
Clathrin- 
independent 
Other 
bPEI A549/HeLa + +(t) - - 
COS-7/HUH-7 +(t) + - - 
lPEI A549/HeLa + +(t) - - 
COS-7/HUH-7 +(t) - - - 
Endothelial +(t) - - - 
pDMAEMA COS-7 + +(t) - - 
chitosan HEK293T /COS-7 cell +(t) - - - 
CHO - + - - 
Results indicated that the internalisation of cationic polyplexes, especially for polymers 
rich in amine groups such as PEI and PDMAEA, is via both clathrin-dependent 
endocytosis and caveolae-mediated endocytosis251. Other studies also indicated that 
clathrin-mediated endocytosis and caveolae-mediated endocytosis are the major routes 
of cellular uptake of polyplexes, with some cases where the clathrin-independent 
pathway is responsible for the uptake of polyplexes252-254.  
1.4.3. The Release of Nucleic Acids into the Cytoplasm 
After cellular entry, subsequent intracellular transportation includes several routes, such 
as delivery to intracellular organelles (Golgi apparatus, endoplasmic reticulum), 
recycled back to the cell membrane, or sorted to acidic degradative vesicles 244. The 
intracellular routing depends on the internalisation pathway, though some suggested the 
polymer type and formulation conditions may have an impact252,255. Cationic polymer 
based polyplexes are mainly internalised via clathrin-dependent endocytosis and 
caveolae-dependent endocytosis, which means they can be delivered to endosomal 
vesicles and shuttled through the endo-lysosomal pathway. Therapeutic nucleic acids 
condensed within the polyplexes, including DNA or siRNA, will need to be released 
into cytoplasm before they can be further processed and become active. Therefore, the 
release from the endosomal vesicles is critical to avoid degradation within the 
lysosomes by nucleases. Though most of the cationic polymers have different chemical 
structure, they share one feature that enables the efficient transfection, that is the ability 
to protonate at physiological pH. The majorities of the cationic polymers have amine- or 
amino functional groups in their structure which provide them with a good buffering 
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capability and enable protonation. The buffering capability is used to describe the ability 
to resist changes in pH due to the addition of an acid or base, and for cationic polymers, 
this is often used to describe the percentage of amine groups becoming deprotonated in 
an acidic environment 256. The endosomal escape of cationic polymer-based polyplexes 
are tightly associated with their protonation ability and is suggested to occur via “proton 
sponge effect” pathways257.  
 Mechanism of proton sponge effect 
The “proton sponge effect” was first mentioned by Boussif in 1995 when describing the 
PEI-polyplexes internalisation behaviour205. The up-taken polyplexes were transported 
via the endo-lysosomal route and would go through a series of pH change from 7.4 to 
6.0 in the endosome, then to 5.0 in the lysosome. Cationic polyplexes shuttled to 
endosomes would interact with protons residing inside endosomes, resulting in a high 
local concentration of positive charge due to protonation and consumption of H+ within 
the endosomes (figure 1.22). To maintain the pH within endosomes, the endosomal 
ATPase would actively “pump” protons into endosomes258. Besides, the influx of 
protons is coupled with the influx of chloride anions to keep the electrostatic balance 
within the endosome. As a result of the presence of cationic polymers and the 
continuous accumulation of protons and chloride anions, the osmotic balance changes 
and leads to swelling of the endosome. Meanwhile, the protonation of cationic polymers 
would expand its polymeric network due to electrostatic repulsion between 
polyplexes259. Under the joint force of these two phenomena, the life expectancy of the 
endosome is greatly reduced and eventually leads to endosomal rupture and the release 
of cationic polyplexes into the cytoplasm205.  
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Figure 1.22 The endosome escapes of cationic polyplexes via a proton-sponge effect pathway. 
 
1.4.4. Examples of cationic polymers used in gene delivery 
In the past few decades, many polymers have been synthesized and studied. The 
cationic polymeric drew attention for their high transfection efficacy and varieties of 
modifications available. Table 1.5 below shows some of the monomers used in the 
synthesis of cationic polymers widely used nowadays as delivery vectors. 
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Table 1.5 Commonly used cationic and neutral monomer. 
Structure  Name  
 
DMAEMA 2-dimethylaminoethyl methacrylate 
 
DMAPMA N-(3-(dimethylamino) propyl)methacrylamide 
 
DMAEA 2-dimethylaminoethyl acrylate 
 
DEAEMA 2-(diethylamino)ethyl methacrylate 
 
APMA 3-aminopropylmethacrylamide 
 
AEMA 2-aminoethyl methacrylamide   
 
HPMA 3-hydroxypropyl methacrylamide 
 
HEMA 2-hydroxyethyl methacrylate 
 
BMA butyl methacrylate 
 
PEI(linear) polyethylenimine 
 
PEI(branched) polyethylenimine 
Polyethylenimine (PEI) is one of the first-generation cationic polymers and considered 
to be the most widely studied260. It contains large amounts of repeated amine groups 
with two alkyl group between each amine group as a spacer. Two different architectures 
of PEI are typically seen: Linear PEI and branched PEI. Linear PEI consists of a 
repeated unit of a secondary amine, and every third atom is amino nitrogen that can be 
protonated, while the branched PEI has a much more complicated architecture and 
contains all primary, secondary and tertiary amine groups 261. Linear and branched PEI 
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(lPEI&bPEI)  both showed good transgene efficiency for gene delivery, thanks to their 
amine-rich structure and high buffering capability262. The first successful 
polyethylenimine-mediated oligonucleotide transfer was conducted by Boussif et al. in 
1995205. Subsequent studies not only focused on the use of PEI alone as gene delivery 
vector but also involved PEI in the design of block copolymers, which are polymers 
comprise two or more homopolymer subunits linked by covalent bonds. Twaites et al. 
reported the synthesis and application of PEI copolymers with poly- (N-
isopropylacrylamide) side chains in the transfection of mouse C3H muscle myoblasts263. 
Besides, the relationship between molecular weight and transfection efficiency of PEI 
has also been studied. Godbey et al. showed that the transfecting efficacy increases as 
the molecular weight of lPEI changes from 600 Da to 70000 Da264. However, high 
molecular weight polymers also result in significantly higher cytotoxicity. The toxicity 
of PEI is explained by the combination of acute disruption of cellular membranes and 
damaging cellular components 265. The free PEIs had interacted with negatively charged 
cell membrane proteins and had been caused by aggregation and adherence on the cell 
surface, which had resulted in significant necrosis266. The up-taken PEIs were 
intercellularly routed to endosomes and lysosomes, and during the endosomal escape 
process via the proton sponge mechanism, it would have caused endosomal and 
lysosomal rupture, resulting in the inhibition of normal cellular process 267. It is also 
suggested that when systematically administrated, the free PEIs would interact with 
negatively charged serum proteins and red blood cells, resulting in the formation of 
precipitants and clusters 266. 
Another monomer DMAPMA, which is called N- (3-(dimethylamino)propyl) 
methacrylamide, is a monomer with a tertiary amine. These polymers work as a 
“proton-sponge” which makes them easier to condense with DNA or other genetic 
material. However, due to its toxicity, Armes et al. decide to synthesise a copolymer 
using DMAPMA and HPMA268. HPMA is an example of a non-ionic moiety 
extensively used for gene delivery applications to form a stealth layer to cationic vectors 
in order to avoid clearance from the macrophages142.  
Another pair of cationic polymers, Poly (dimethylaminoethyl methacrylate) 
(PDMAEMA) and Poly (dimethylaminoethyl acrylate) (PDMAEA) have drawn 
attention in the past decade269-272. PDMAEMA showed great potential as gene delivery 
vector with lower toxicity205,273. PDMAEMA is also a water-soluble cationic polymer 
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and has groups of tertiary amines that can partially protonate in solution and create an 
internal cationic charge205. However, while in vitro and ex vivo studies showed 
successful gene transfer, some of the in vivo experiments failed to reach expectations. 
Storm et al. reported that when transfecting OVCAR-3 cells with these polymers, the in 
vivo transfection efficiency was significantly decreased compared to in vitro and ex vivo 
groups274. Also, there is concern about the cytotoxicity of the PDMAEMA vector when 
used as gene delivery system potentially due to disruption of vital organelles such as 
endosomes and lysosomes, even though it’s much less toxic than PEI counterparts274. 
Published works suggest that the transfecting efficacy and the toxicity are directly 
related to the molecular weight of the PDMAEMA142, therefore, the balance between 
transfecting efficacy and the toxicity can be modulated by finding an optimal  molecular 
weight of the PDMAEMA. There are other strategies to reduce the cytotoxicity of the 
polymer without reducing the transfecting efficacy. By designing copolymers, other 
more hydrophilic molecules or biodegradable molecules, such as HPMA or 
Polyethylene glycol (PEG), can be conjugated to the PDMAEMA which reduces the 
toxicity. The presence of PEG in copolymers can improve the solubility of the 
polyplexes due to its hydrophilic nature and further extend the circulation time in blood. 
Armes et al. synthesized a PDMAEMA-PEG block copolymer, and the results show that 
such modification can increase the hydrophilicity of the polymer–DNA of the 
copolymer polyplexes but reduced the cell membrane penetration ability275.  
Poly (dimethylaminoethyl acrylate), the acrylate version of PDMAEMA, is also a 
cationic polymer with great potential to be used as a gene delivery system. PDMAEA 
has various advantages including high cargo load capability, low immunogenicity and 
simplicity in the process of manufacture276. In addition, PDMAEA polymer was found 
to show some unique properties in aqueous solution. It is reported that PDMAEA would 
slowly degrade to poly (acrylic acid) (PAA) and dimethylaminoethanol (DMAE) in 
aqueous solution, due to a self-hydrolysis process 269. Like PDMAEMA, PDMAEA 
based copolymers were designed and synthesized to reduce its toxicity further and 
improve transfection efficiency. Monteiro et al. prepared a degradable diblock polymer 
based on PDMAEA, and it was able to be condensed with siRNA and achieve 
successful delivery into target cells277.  
Novel cationic polymers such as polycation or cationic polypeptide have been applied 
in gene delivery. Nasanit et al. reported the use of a polypeptide as a vector for the 
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delivery of pDNA and which more active at transfection than current systems such as 
PEI278. Another study by Soliman et al. demonstrated the preparation of 
multicomponent polymer-DNA polyplex279. The underlying logic was to create a 
polymer-based polyplex that mimics the behaviour of a virus. The viral-mimetic 
delivery vector is composed of two parts: 1) a reducible polycation core polymer that is 
able to condense with nucleic acids and be capable of endosomal escape, and 2) a 
“shield” hydrophilic polymer attached to the core polymer that contains targeting 
ligands and is designed to cleave in acidic environment such as in endosomes279. In this 
study, a series of reducible polycations were synthesised and condensed with luciferase 
encoding pDNA to form polyplexes before being attached with PEG “shield” polymers. 
The transfection efficiency of viral-mimic polyplexes containing targeting ligands were 
determine on human colon carcinoma cell line (HCT116) and human promyelocytic 
leukaemia (HL60). The data indicated that the polyplexes coated with “shield” polymers 
showed a lower transfection efficiency compared with the non-coated ones, while the 
coated-polyplexes with targeting ligands showed the same level of transfection 
efficiency compared with the non-coated ones. Besides, the results also suggested that 
most of the polycation polyplexes, both uncoated and shield polymer-ligand coated 
ones, showed higher transfection efficiency compared to PLL polyplexes and showed 
the same level of efficiency compared with PEI polyplexes in both cancer relevant cell-
lines279.  
In recent years, several branched polymers have been developed via in situ deactivation 
enhanced Atom-transfer radical-polymerisation (ATRP) and have shown a higher 
transfection capability280. Based on these findings, the efficacy of the polymer is found 
to be related to the molecule structure of the polymer. As a matter of fact, several 
researchers have reported that the structure (linear or branched, length and number of 
arms) is closely related to the transfecting efficacy of polymeric vectors 281. In these 
studies, they found that with increased branching, for a fixed molecular weight polymer, 
there is a trend of reduced toxicity. It’s shown that in order to reach a significant 
transfection a minimal molecular weight is necessary. Their research showed that a 
reasonable combination of branched structure and a suitable molecular weight would 
achieve low toxicity with high transfecting efficacy 282. Another study has suggested 
that the increased transfection efficiency of branched polymers compared to their linear 
counterparts is related to the self-assembly ability with nucleic acids. Polymers with a 
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higher degree of branching can condense with nucleic acids to form tighter and smaller 
polyplexes, which are easier to be internalised by cells283. 
Cationic polymers showed great potential as gene delivery vectors and might have 
provided an alternative approach of gene transfer without viruses. The production of 
cationic polymers is largely dependent on chemical polymerisation synthesis. 
1.5. Controlled/living Radical Polymerisation 
Most of the cationic polymers were obtained via chemical synthesis. The classic 
synthesis approach is represented by free radical polymerisation, which is a chain 
addition reaction in which monomers are added to free radicals and propagated into 
polymer chains. The free radicals can be created by various methods, such as the 
thermal decomposition or by the photolysis. The generated free radicals, which have 
unpaired electrons, are highly active and tend to “attack” the monomer molecules and 
initiate a polymerisation reaction. In carbon-carbon double bonds, one pair of electron 
forms a sigma bond and the other pair is held by pi bond which are less stable than a 
sigma bond. The free radical “attacks” one electron from a pi bond, resulting in the 
formation of a stable sigma bond with the carbon atom and one free electron, turning the 
whole molecule into a free radical. The newly generated free radical molecule continues 
to add to monomer molecules and propagate into polymer chains (figure 1.23)284. 
 
Figure 1.23. The thermal decomposition of AIBN and the free radical polymerisation of ethylene 
into polyethene. 
 
A free radical polymerisation is an approach of high value in the synthesis of polymers, 
both in the research and commercial scale. It provides an affordable and simple 
technique in the synthesis of polymers in large quantities285. Besides, the free radical 
polymerisation technique can be applied to a wide range of monomers, including 
methacrylates, styrenes, and acrylamides, under different conditions 286. Nonetheless, 
the free radical polymerisation has little control over the polymer structure and polymer 
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molecular weight distribution. This is explained by irreversible termination reactions 
throughout the reaction process287. 
In the past four decades, there has been a tremendous advance in the field of polymer 
synthesis due to the discovery and development of controlled free radical 
polymerisation techniques (CRP techniques)288. The advancement in the area of 
controlled polymerisation enabled the synthesis of desired macromolecules in a more 
convenient and efficient way. Moreover, CRP provides control over the molecular 
weights, molecular weight distribution (polydispersity, ᴆ) and well-defined functional 
end groups. In recent years, CRP techniques have been widely applied to the synthesis 
of a variety of polymers and copolymers289,290. Several unique CRP techniques have 
been discovered and applied in the field of research and manufacture. 
1.5.1. Different CRP Technique Applied in Polymer Synthesis 
 Nitroxide-mediated polymerisation 
One of the earliest CRP technique reported is stable free radical polymerisation (SFRP), 
published by Georges and his co-workers291,292 and the nitroxide-mediated 
polymerisation (NMP) is the most widely examined SFRP. The control in NMP is 
achieved with dynamic equilibration between dormant alkoxyamines and actively 
propagating radicals (figure 1.24) 293.  
 
Figure 1.24 Nitroxide-mediated polymerization: kd is the dissociation rate coefficient, ktr is the 
trapping rate coefficient, kp is the propagation rate coefficient and kt is the termination rate 
coefficient. Figure adapted from Etmimi et al. 294 
 
At high temperatures, the carbon-oxygen bond of the dormant alkoxyamines is cleaved 
into a nitroxide and a free radical. The free radical reacts with monomers and 
propagates into polymer chains. The propagated polymer chain with a free electron can 
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be terminated by a nitroxide into a dormant alkoxyamine, before it is cleaved again into 
a nitroxide and a new free radical. The NMP provided control over the molecular weight 
of the polymer, but there are limitations such as the requirement of a relatively high 
reaction temperature (~120 °C) and only a narrow range of monomers can be 
polymerised via such a technique 293. 
 Atom-transfer radical-polymerisation 
Atom transfer radical polymerisation (ATRP) is another CRP technique that relies on 
the use of an alkyl halide initiator. A transition metal complex, typically Cu species, is 
the key to an oxidation-reduction mechanism. The alkyl halide is transferred to the 
transition metal complex, generating a higher oxidation state of the metal and a free 
radical. The free radical interacts with monomers and propagates into polymer chains. 
The transition metal complex with the higher oxidation state can reversibly transfer the 
halogen to the polymer chain with the free electron, resulting in a dormant polymer 
chain and a lower oxidation state complex (figure 1.25)295. 
 
Figure 1.25 Mechanism of ATRP. An alkyl halide compound is transferred to the transition complex 
generating a higher oxidation state of the metal and a free radical (R·). The free radical is added to 
monomers to propagate into polymer chains (P). 
 
ATRP is reported to the most widely studied CRP technique and has been utilized in 
many applications. However, one disadvantage of this method is the metal catalyst can 
be considered as contamination, the removal of the toxic metal transition from the 
polymers may be critical for further application. 
 Reversible addition-fragmentation chain transfer polymerisation 
Reversible addition-fragmentation chain transfer (RAFT) polymerisation, another CRP 
technique that based on the use of thiocarbonylthio compounds as a chain transfer agent 
(CTA) received considerable attention in the past few years. Reversible addition-
fragmentation chain transfer (RAFT) polymerisation is, by IUPAC definition, one of 
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many controlled radical polymerisations in which “chain activation and chain 
deactivation involve a degenerative chain-transfer process which occurs by a two-step 
addition-fragmentation mechanism”. The control in RAFT polymerisation is achieved 
via the use of a degenerative chain transfer agent, which is the key to maintain a balance 
between addition, intermedia cleavage and propagation. First discovered by the 
Commonwealth Scientific and Industrial Research Organisation (CSIRO) of Australia in 
1998, RAFT polymerisation developed rapidly and now is one of the most crucial CRP 
techniques287,296. RAFT polymerisation has been used to synthesise a wide range of 
polymers with low polydispersity. Also, it has been applied in the synthesis of block 
copolymers as well as polymers with different architectures such as star-shaped, brush 
and comb 297,298. With the development of polymer-based drug delivery systems, the 
need for novel polymers that meet certain criteria as delivery vectors has increased 
dramatically. Since RAFT polymerisation technique is a versatile and convenient tool to 
produce well-defined polymers of various shapes and molecular weights, it has been 
used in the production of novel polymers that serve as drug and gene delivery vectors.  
1.5.2. The RAFT Polymerisation Mechanism 
With the recent development of CRP science, the RAFT polymerisation mechanism has 
been revealed by several studies299,300. As a brief description, RAFT polymerisation 
process can be divided into 4 phases, being initiation, pre-equilibrium, main equilibrium 
and termination, as demonstrated in Scheme 1.1 using dithioesters RAFT agent as an 
example. Firstly, to initiate the polymerisation, free radicals must be generated. Since 
RAFT polymerisation shares a similarity in some essential steps with a conventional 
free radical polymerisation, methods employed to generated free radicals in 
conventional free radical polymerisation can be applied. This is of great importance, for 
this means that the most commonly used initiators, such as 2,2-azobis(2-
methylpropionitrile) (AIBN) which can be applied in a wide range of temperature, is 
also applicable in RAFT polymerisations. The generated free radicals (1) would attack 
monomers and propagate to form macroradicals (2) which are mainly in the form of 
oligomeric molecules. The second phase is the pre-equilibrium phase, in which the 
generated macroradicals (2) add to the sulphur-carbon double bond of the RAFT agent, 
producing macroradicals-RAFT intermediate molecule (3). The produced 
macroradicals-RAFT intermediate molecule (3) undergoes β-scission, either going back 
to form the macroradicals (2) and the original RAFT agent or going forward to release a 
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leaving group radical (4) and a new dormant oligomer-RAFT (5) compound that serves 
as RAFT agent. When all the leaving groups from the initial RAFT agent have been 
released, the reaction enters the main equilibrium phase. In the main equilibrium, a 
propagated macroradicals living chain (6) would attack a RAFT agent-dormant chain 
(7) molecule, forming an intermediate molecule (8). The intermediate could go back to 
the living chain (6) and dormant-RAFT molecule (7), or it could move forward and 
replace the current dormant chain with a living chain to form a new dormant chain (10) 
and release the original dormant chain as a new radical chain (9). The recurring process 
established the equilibrium between dormant and living chains by which 
living/controlled characteristics are induced in the polymerisation. Towards the end of 
the polymerisation, as the monomers were consumed, radicals would be terminated 
through a bi-radical termination process and become dead species.  
 
Scheme 1.1 Schematic illustration of the initial stage, pre-equilibrium stage and main equilibrium 
stage of RFAT polymerisation process. P1·, Pm· and Pn· generally refers to free radical polymer 
chains generated during the reaction. Kad represents the addition rate coefficients, Kβ represents 
fragmentation rate coefficients. 
 
Kinetic parameters have been given to describe the individual reactions in both pre-
equilibrium and main equilibrium. The addition rate coefficients were referred to as Kad 
and fragmentation rate coefficients as Kβ. It is worth noticing that the Kad and Kβ values 
of the pre-equilibrium and main equilibrium are decided by different factors. In the 
asymmetric pre-equilibrium process, the coefficients are related to the chemical 
properties of the chain transfer agent and radicals employed while in the symmetric 
main equilibrium, it is related to the living and dormant chains.  
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1.5.3. RAFT Agents and its Compatibility with Monomers 
RAFT agents are the chain transfer reagents employed in the process of the reversible 
addition-fragmentation chain transfer polymerisation, and they play a vital role. The 
catalogue of RAFT agents covers a wide range of compounds including dithioesters, 
dithiocarbamates, trithiocarbonates and xanthates as shown in figure 1.26. All these 
compounds share the same C=S structure which plays a vital role in the process of 
RAFT polymerisation. 
 
Figure 1.26 Structures of different types of RAFT agents. 
 
Apart from the C=S structure, there are other structures that could affect the RAFT 
polymerisation process greatly. The important structures in these RAFT-agents are 
referred to as Z groups and R groups301,302. The Z groups control the reactivity of the 
RAFT agent as it determines the reactivity of the C=S bond with radicals. Also, the Z 
groups have a critical effect on the lifetime of the macroradicals-RAFT intermediate 
molecules formed during the RAFT polymerisation.  
As the Z groups govern the reactivity of the RAFT agents, the structure of R groups 
controls the ability to mediate the polymerisation in a controlled way. There are two key 
features for the R group. Firstly, the R group should be a good free radical   leaving 
group. Secondly, the leaving group radical then generated must be able to serve as an 
initiator and propagate. Also, the R group will have a profound effect on the kinetics in 
the pre-equilibrium step and overall control of the main equilibrium.  
With the proper combination of Z groups and R groups, some very effective RAFT 
agents can be produced. However, the efficiency is closely related to the monomer 
employed in the polymerisation reaction. An effective RAFT agent for one type of 
monomer may found to be inefficient for another. As there are a huge amount of RAFT 
agents available and the mechanism of how each kind of Z group and R group affect the 
overall property of a RAFT agent is highly complicated, and is not discussed here in this 
chapter. However, based on the CSIRO’s RAFT agent monomer matching guide, 
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Grajales et al. have summarized an abundant number of the commonly used RAFT 
agents and their compatibilities with some most commonly used monomer types as is 
demonstrated in table 1.6 and 1.7303.  
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Table 1.6 Commonly used RAFT agents and their compatibilities with monomers. 303 Where the 
number of + indicated the level of good compatibility with according monomers and – represent 
insufficient compatibility with such monomer. 
Structure Styrene Acrylate Acrylamide Meth- 
acrylate 
Meth- 
acrylamide 
Vinyl 
Ester 
Vinyl 
Amides 
 
++ + + +++ +++ - - 
 
+++ +++ +++ + + - - 
 
+++ +++ +++ + + - - 
 
+++ +++ +++ + + - - 
 
+++ +++ +++ + + - - 
 
++ ++ ++ +++ +++ - - 
 
++ ++ ++ +++ +++ - - 
 
+++ + - +++ +++ - - 
 
++ + + +++ +++ - - 
 
++ + - +++ +++ - - 
 
++ + + +++ +++ - - 
 
+++ +++ +++ - - - - 
 
- - - - - +++ +++ 
 
- - - - - +++ +++ 
 
- - - - - +++ +++ 
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Table 1.7 Corresponding chemical description of RAFT agents in table 1.6. 
Structure Chemical Name 
 
2-(Dodecylthiocarbonothioylthio)propionic acid 
 
2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid 
 
Methyl 2-(dodecylthiocarbonothioylthio)-2-methylpropionate 
 
2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid N-hydroxysuccinimide ester 
 
Poly(ethylene glycol) methyl ether 2-(dodecylthiocarbonothioylthio)-2-methylpropionate 
 
2-Phenyl-2-propyl benzodithioate 
 
1-(Methoxycarbonyl)ethyl benzodithioate 
 
2-Cyano-2-propyl 4-cyanobenzodithioate 
 
4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid 
 
2-Cyano-2-propyl benzodithioate 
 
Benzyl benzodithioate 
 
Cyanomethyl dodecyl trithiocarbonate 
 
Cyanomethyl methyl(phenyl)carbamodithioate 
 
Cyanomethyl diphenylcarbamodithioate 
 
Benzyl 1H-pyrrole-1-carbodithioate 
RAFT polymerisation is one of the living/controlled polymerisations that enables 
control over polymer architecture and molecular weight through the selection of 
appropriate chain transfer agents, also called RAFT agents. To synthesise polymers with 
desired molecular weight, architecture and low polydispersity, the RAFT polymerisation 
technique was employed in this study.  
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1.6. Gene therapy for Tendon injury 
In past decades, studies have focused on establishing gene delivery systems, both viral 
and non-viral, for healing and regeneration of tendon tissue. Some of their findings have 
been highlighted and summarised in table 1.8. 
Table 1.8 Use of gene transfection as an advanced delivery system for tendon healing and 
corresponding vectors 304 
Gene Vector Delivery system Animal/Human model Ref 
BMP-2, 
Smad8 
Liposome in vitro Rat, Achilles tendon 305 
BMP-14 Adenovirus In vivo/ in vitro Rat, Achilles tendon 170 
TGF-β1  PEI-modified 
PLGA 
Nanospheres 
In vivo & in vitro  Chicken, flexor tendon 306 
Gal HVJ*-liposomes In vivo/in vitro Rat, patellar tendon 307 
DCN, IL-10 
&TGF-β 
TransIT® -LT1 
(polymersome) 
In vitro Primary human tenocytes 308 
Fmod Histidylated 
liposomes & linear 
polyethylenimine 
In vitro/in vivo Rat, Achilles tendon 309,  
FAK & BMP-12 Adenovirus In vitro Chicken Achilles tendon 
 
310,311 
BMP-12,13 Adenovirus In vivo Rabbit semitendinosus, 
flexor, and patellar tendons 
9,312, 313 
bFGF Adeno-associated 
viral vectors 
In vitro Rat intra-synovial tendon 
tenocyte 
314 
TGF Adenovirus In vivo  Patellar tendon 315 
DCN Lentiviral vectors In vivo Rat patellar tendon 316 
For example, Delalande et al. reported the used of plasmid DNA (pDNA) encoding 
fibromodulin encapsulated in histidylated liposomes and histidylated liner 
polyethyleneimine polycomplexes on a rat Achilles tendon laceration model309. The 
results showed that, based on stiffness and histological analysis, treated tendons 
demonstrated an enhanced healing response that resulted in a tissue that was more 
phenotypically similar to healthy tendon than control groups309. Adenovirus vectors 
have been used for the delivery of exogenous FAK gene and BMP-12 gene into chicken 
tendon cells, resulting in a significant increase in expression of these genes when 
compared with controls, and in an enhanced healing of tendon tissue310,311. In another 
study, adenovirus promoting the expression of BMP-14 was transfected into the rat 
Achilles tendon laceration model. Histological and biomechanical effects were 
examined, and results showed that tendon treated with transfection exhibited 70% 
greater tensile strength and increased cellular proliferation of tenocytes when compared 
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with control groups at 2 weeks post-repair. No inflammatory response or production of 
undesired bone or cartilage was observed in this study170. Another example provided by 
Lu et al. is the transfection of rat patellar tendon cells with lentiviral-encoded shRNA to 
silence the expression of decorin specifically. Histological and biomechanical studies 
showed that downregulation of decorin to an appropriate level could promote the repair 
and regeneration of patellar tendon, and can result in a reduction in scar formation316.  
Moreover, downregulation of the intra-synthesis of TGF-b1 can be beneficial for the 
regeneration of tendon tissue. A PEI-modified poly (lactic-glycolic) acid (PLGA) 
nanosphere delivery system that can incorporate plasmids was shown to inhibit the 
expression of TGF-β1 specifically. The biodegradable PLGA nanospheres were first 
blended with polyethylenimine (PEI) solution to allow PEI adsorption to the surface of 
these nanospheres. Plasmid DNA can electrostatically bind to the cationic moieties of 
PEI on the surface of the PLGA nanoparticles. Results indicated the plasmid delivered 
into tenocytes can inhibit the expression of TGF-β1 with an lasting effect of more than 6 
weeks 306. In addition, Abbah et al. used plasmid DNAs encoding decorin and 
interleukin-10 to co-transfect human tenocytes with a commercially available cationic 
polymer transfection kit TransIT®-LT1 to suppress the expression of TGF-β and 
demonstrated positive results in vitro308. 
By identifying the target gene or target receptor, the specific delivery system can be 
designed. Studies have focused on exploring the potential gene targets for gene therapy 
in the treatment of tendon injury. Some of the commonly targeted genes have been 
summarised in table 1.9. 
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Table 1.9 Commonly targeted genes in tendon regeneration gene therapy 304. 
Gene Symbol Corresponding 
molecule 
Primary function Ref 
COL1α1 Collagen type I  Extracellular Matrix structural constituent synthesis; identical 
protein binding;  
34,82 
COL3α1 Collagen Type III Extracellular Matrix structural constituent synthesis; identical 
protein binding;  
51,82 
COL5α1 Collagen Type V Extracellular Matrix structural constituent synthesis; identical 
protein binding;  
37,53 
TNC Tenascin-C  Encodes an Extracellular Matrix protein; 10,59 
ACAN Aggrecan  Encodes an Extracellular Matrix protein; mutations in this 
gene may be involved in skeletal degeneration. 
10,51 
MMP Matrix Metallo- 
Proteinase 
Proteins of MMP family are involved in the hydrolysis of 
extracellular matrix in healthy tissue  
59 
TGFβ1 Transforming Growth 
Factor β1 
Encodes a member of the TGFβ family of cytokines.  317,318 
IGF-1/IGF-2 Insulin-like Growth 
Factor 
Encodes IGF-1/IGF-2, which is processed from a precursor, 
bound to a receptor, and then secreted. 
319 
PDGFA/PDGFB platelet-derived growth 
factor alpha/beta 
Encodes PDGFA/PDGFB 320 
ELN Elastin Encodes elastin, an extracellular matrix structural constituent 321 
FBN2 fibrillin 2 Encodes fibrillin 2 an extracellular matrix structural 
constituent 
321 
Scx  Scleraxis This gene encodes a protein is expressed during embryonic 
development of tendons and ligaments.   
322,323 
Tnmd Tenomodulin This gene is also a candidate gene for age-related macular 
degeneration, though a direct link has yet to be demonstrated 
323,324 
Fmod fibromodulin The encoded protein may play a role in the formation of 
extracellular matrix and also regulate TGF-beta level. 
325 
With an advanced understanding of the composition tendon tissue and knowledge of the 
functions tendon components during the healing process of tendon tissue, type III 
collagen has been identified as a critical molecule in scar tissue formation during the 
healing process of the tendon. The COL3α1 gene, which produces collagen III protein, 
is a potential target in gene therapy for tendon injury. By using specific small 
interference RNA, the expression of COL3α1 gene can be suppressed to reduce the 
production of type III collagen, further reducing the formation of scar tissue during 
tendon healing.  
However, an efficient gene delivery system is required. The cationic polymer-based 
delivery system is a preferred tool for the delivery of nucleic materials for its good 
biocompatibility, potential for chemical modification, easy manufacturing process and 
ability to condense with the nucleic acid.  
Poly (N,N′-dimethylaminoethyl acrylate) (PDMAEA), a biodegradable cationic 
polymer, is a strong candidate to be developed into a gene delivery system. PDMAEA is 
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consists of repeated units of DMAEA monomer that has a tertiary amine, which enables 
the quick protonation of PDMAEA under acidic environment. Protonated PDMAEA is 
condensed with nucleic materials to form polyplexes that serve as a gene delivery 
vector. Moreover, it is a biodegradable material that is perfectly suited for the in vivo 
delivery of small molecules. 
1.7. Thesis Aims and Objectives 
The overall aim of this thesis is to develop a PDMAEA based siRNA delivery system 
that can be locally injected into the site of injury to suppress the COL3α1 gene 
expression to achieve the improvement of tendon healing.  
The thesis was realised by following these four steps: The first objective was to 
synthesise a library of PDMAEA polymers of different molecular weights and 
architectures. The RAFT polymerisation technique was utilized to achieve controlled 
polymerisation with desired molecular weight and low polydispersity. It is reported that 
polymer molecular weight and architecture would affect its vital parameter as a delivery 
vector such as toxicity and transfection efficiency 326,327,328. The synthesized polymers 
were purified and characterised. These works are described and discussed in chapter 
three.  
The second objective was to formulate the PDMAEA polymer with dsDNA and siRNA 
to form polyplexes. The formulated polyplexes were characterised by agarose gel 
electrophoresis to confirm the successful formation. The polyplexes were also 
characterised by dynamic light scattering to obtain their hydrodynamic diameter and 
zeta-potential. These works are described and discussed in chapter four.  
The third objective was to determine the cytotoxicity of the synthesized PDMAEA 
polymers and according to polyplexes. The cytotoxicity of PDMAEA polymers and 
polyplexes were determined using cell proliferation assay and cell metabolic activity 
assay. Mouse 3T3 fibroblast cells and adult equine Achilles tenocytes were cultured as a 
model. These works were presented in chapter five.  
The fourth objective was to transfect equine tenocytes with siRNA-PDMAEA 
polyplexes and observe its silencing effect by qPCR. The type III collagen protein 
expression was determined by immunocytochemistry. This part of the thesis is described 
and discussed in chapter six.  
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All the general materials and methods involved were documented and presented in 
chapter two. 
The thesis is ended by a summary of the overall performance of PDMAEA polymer as a 
gene delivery vector based on the data presented, as well as a suggestion for further 
improvements of the system and possible future work.  
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2. Chapter 2 Material and Methods 
2.1. Introduction 
This chapter discusses the basic information regarding the materials and methods used 
in the study, including characterisation techniques and experimental conditions. The 
basic principles of techniques will also be introduced. 
2.2. Materials 
 General chemical reagents 
All general chemical reagents and solvents were purchased from Sigma-Aldrich UK and 
used as received. HPLC grade solvents used in chromatography were purchased from 
Fisher Scientific and degassed before use.  
 Dimethylaminoethyl acrylate 
 
Figure 2.1 Structure of Dimethylaminoethyl acrylate.  
 
Dimethylaminoethyl acrylate (DMAEA) is a carboxylic acid ester with a tertiary amino 
group towards the far end of the structure. DMAEA monomers are flammable, toxic and 
corrosive, and should be manipulated in a fume hood only. The DMAEA monomer used 
in this study is purchased from Sigma-Aldrich UK (98%), containing monomethyl ether 
hydroquinone as an inhibitor. Before use, the inhibitor was removed by passing 
DMAEA monomers through an aluminium oxide column. 
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 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid 
 
Figure 2.2 Structure of 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid.  
 
2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid (DDMAT) is a chain transfer 
agent used in reversible addition-fragmentation chain transfer polymerisation (RAFT 
polymerisation). It is a yellow powder. The DDMAT used in this study is purchased 
from Sigma-Aldrich UK (98% HPLC) and used as received. 
 Pentaerythritol tetrakis[2-(dodecylthiocarbonothioylthio)-2-methylpropionate] 
 
Figure 2.3 Structure of Pentaerythritol tetrakis[2-(dodecylthiocarbonothioylthio) 
-2-methylpropionate]. 
 
Pentaerythritol tetrakis[2-(dodecylthiocarbonothioylthio)-2-methylpropionate] (4-arm-
DDMAT) is a chain transfer agent used in reversible addition-fragmentation chain 
transfer polymerisation. It is a yellow crystal. The 4-arm-DDMAT used in this study is 
purchased from Sigma-Aldrich UK (97% HPLC) and used as received. 
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 2,2′-Azobis(2-methylpropionitrile) 
 
Figure 2.4 Structure of 2,2′-Azobis(2-methylpropionitrile). 
 
2,2′-Azobis(2-methylpropionitrile) (AIBN) is one of the most commonly used radical 
initiators in the polymerisation reaction. It is a colourless crystal. The AIBN used in this 
study is purchased from Sigma-Aldrich UK (98%). AIBN was recrystallised in 
methanol and stored at -20°C before use.  
 Primers for qPCR 
Primers for the equine COL3α1 gene were purchased from Sigma-Aldrich UK with the 
following sequences: 
Forward 5’-3’: GGCCATCTGGTGACAAAGGA 
Reverse 5’-3’: CCAGGCAAGCCCTACAAAGA 
Primers for the equine 18s gene were purchased from Thermo Fisher Scientific with the 
following sequences: 
Forward 5’-3’: CCCAGTGAGAATGCCCTCTA 
Reverse 5’-3’: TGGCTGAGCAAGGTGTTATG 
 COL3α1 gene-specific siRNA 
The COL3α1 specific siRNA was designed by and purchased from Sigma-Aldrich UK 
with the following sequences: 
Sense 5’-3’: CAUCACAUAUCACUGCAAA [dT][dT] 
Antisense 5’-3’: UUUGCAGUGAUAUGUGAUG[dT][dT] 
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 General cell culture reagents 
Dulbecco’s modified Eagle medium (DMEM), L-glutamine, penicillin-streptomycin, 
foetal calf serum, trypsin with EDTA, trypan blue and PBS tablets were purchased from 
Fisher Scientific. Human recombinant transforming growth factor-beta 1 (TGF-β1) was 
acquired from PEPROTECH and prepared as the manufacturer instructed. Rabbit anti-
collagen III antibodies were obtained from Abcam UK, goat anti-rabbit antibodies were 
obtained from Sigma Aldrich UK and both diluted in PBS with 0.1% BSA to 
appropriate concentration before use.  
 General cell culture consumables and equipment 
Cell culture flasks, plates and culture dishes were purchased from Fisher Scientific. 
Tips, filtered tips, serological pipettes and pipette controllers were purchased from 
Starlab UK. Mechanical pipettes were obtained from Eppendorf Germany, and 
multichannel pipettes were purchased from Triple Red UK. Corning® 96-well black 
polystyrene clear bottom microplate was purchased from Fisher Scientific.  
2.3. Polymer synthesis 
2.3.1. Introduction of RAFT Polymerisation 
RAFT polymerisation has control over the molecular weight and polydispersity of 
generated polymers. The control is achieved using a chain transfer agent, mostly 
thiocarbonylthio compounds, to mediate the polymerisation via a reversible chain-
transfer process under certain conditions. Different RAFT agents have different 
compatibility with different monomers. The compatibility between the RAFT agent and 
the monomer would have a significant effect on the ultimate polymerisation result. 
When the RAFT agent is selected for incompatible monomers, the RAFT agent would 
show reduced activity in mediating the reversible chain transfer process and would 
result in an uncontrolled free radical polymerisation. 
 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid has good compatibility with 
monomers such as styrene, acrylate and acrylamide but showed no compatibility with 
vinyl esters and vinyl amides. Therefore, it is selected to mediate the RAFT 
polymerisation of PDMAEA monomers. 
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2.3.2. Experimental Conditions of PDMAEA Synthesis 
All manipulations of toxic and flammable chemical reagents were performed in a 
chemical fume hood with appropriate body protection equipment. The syntheses of 
PDMAEA polymers were performed in round bottom flasks with proper volume on a 
MR Hei-Standard Magnetic Stirrer (Heidolph Instruments) equipped with an 
appropriate heating block. The polymers were purified by precipitation into hexane in 
large beakers with stirring on a magnetic stirrer (Fisher Scientific). Polymer precipitants 
were re-dissolved in acetone and the acetone was then removed by using a Buchi 
rotavapor at 40°C. The collected polymers were kept in a desiccator for 24 hours and 
then stored at 4°C.  
2.4. Nuclear Magnetic Resonance Spectroscopy (NMR) 
2.4.1. Introduction of NMR 
Nuclear magnetic resonance (NMR) spectroscopy is an analytical spectroscopic 
technique based on the magnetic properties of the atomic nucleus. Certain nuclei 
resonate at a specific frequency when placed in a strong magnetic field. Variations in the 
resonant frequency can be captured and analysed, which further provide critical 
structural information about molecule in which the atom resides. In many atoms (1H, 
13C, 15N), the spinning of the positively charged nucleus creates a micro-magnetic field. 
The classic model considers the spinning nucleus to have an angular momentum and 
which would attempt to align with the external magnetic field when placed into one. 
The external magnetic field would exert a torque on the spinning nucleus and result in a 
circular motion referred to as precession. The rate of precession is proportional to the 
external magnetic field strength and can be described as follows: 
𝜐0 =
𝛾𝐵0
2𝜋⁄  
Where υ0 is the Larmor frequency in Hertz which represents the precession rate, γ is the 
magnetogyric ratio, being the ratio of magnetic moment to the angular momentum of a 
nucleus, and B0 is the strength of the external magnetic field. The resonant frequency 
can be measured by applying a signal scan to the sample, and varying the frequency 
until an absorbance of energy is detected1. 
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However, the classic model cannot answer all aspects of the NMR phenomenon, and 
therefore the quantum model has been suggested. For certain nuclei, such as 1H or 13C, 
there are two independent spin states which are referred to as α and β spin states. In the 
absence of an external magnetic field, the two spin states have the same energy level, 
hence at thermal equilibrium, the number of nuclei in these two states would be equal.  
 
Figure 2.5 When placed in an external magnetic field, two states with different energy level can be 
detected, namely α state with low energy level and β state with high energy level, respectively. The 
figure is a adapted from Jacobsen et al.1 
 
However, when placed in a strong external magnetic field, the α state, which is in 
alignment with the magnetic field, has a lower energy level than the β state, which is 
opposed to the external magnetic field. This would lead to a change in the thermal 
equilibrium, resulting in a slightly larger number of nuclei being in the α state (low 
energy state) and fewer being in the β state (high energy state). It is possible for a 
nucleus to absorb electromagnetic energy that exactly matches the energy difference 
(ΔE) between the α and β states and “jump” from the lower energy state to the higher 
energy state. The energy difference (ΔE) corresponds to the frequency of the 
electromagnetic radiation: 
∆𝐸 = ℎ𝜐0 =
𝛾𝐵0
2𝜋⁄  
where h is Planck’s constant, 𝜐0  is the resonant frequency is in the radio frequency 
range1. 
2.4.2. Experimental Conditions and Sample Preparation  
All 1H NMR and 13C NMR spectra were recorded on a Burker Advance III 400MHz 
solution state spectrometer at 400MHz in CDCl3. All chemical shifts are recorded in 
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ppm relative to tetramethylsilane (TMS). Bruker Topspin 3.2 software was used to 
analyse the data.  
For 1H NMR spectra, samples were dissolved in CDCl3 to a final concentration of 5 
mg/mL and 400 μL of sample solution was loaded into an NMR tube. For 13C NMR 
spectra, samples were dissolved in CDCl3 to a final concentration of 25 mg/mL and 400 
μL of sample solution was loaded into an NMR tube.  
2.5. Gel Permeation Chromatography (GPC) 
2.5.1. Introduction and the Basic Principle 
Gel permeation chromatography (GPC), also referred to as size exclusion 
chromatography (SEC), is an analytical technique used to separate samples based on 
their molecular size. Different from other separation techniques that are based on the 
physical or chemical interactions between column packing and analytes, the separation 
of GPC is based on the molecule size or hydrodynamic diameter of analytes. When 
analyte dissolved in eluent flows through the porous column packing, chromatographic 
separation will take place. Analytes with smaller hydrodynamic diameters would be 
able to diffuse into the porous matrix while analytes with larger hydrodynamic diameter 
would move around the packing matrix. As a result, analytes with a smaller molar mass 
or hydrodynamic diameter would elute more slowly, while the larger one would elute 
faster.  
GPC is commonly used in the characterisation of polymers and other macromolecules 
such as proteins. Abundant studies have involved the use of GPC as a characterisation 
technique 2-4. It is well established that GPC is an efficient and reliable method to 
characterise polymer molecular weight and polydispersity.  
2.5.2. Experimental Conditions and Sample Preparation 
Gel permeation chromatography was performed on a G7810A Agilent PL-GPC50 
system connected with a refractive index detector. A PLgel 5 μm MiniMIX-C (50*4.6 
mm) guard column was connected to two PLgel 5 μm Mixed-D (300*7.5 mm) columns 
in series and elevated at a temperature of 30°C. A mixture of HPLC grade chloroform 
triethylamine (95/5, v/v) was degassed and used as the eluent. The machine was 
calibrated using Agilent EasiVial GPC calibration polystyrene standards with a 
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molecular weight ranging from 180 Da to 300 kDa. The flow rate was set at 1 mL/min. 
Data were collected and analysed with CIRRUSTM data stream software. Samples were 
dissolved in eluent to a final concentration of 5 mg/mL and filtered with a 0.45 μM 
PTFE membrane before injected into the machine through the injection valve manually. 
The number average molar mass (Mn), weight average molar mass (Mw) and the 
dispersity (ᴆ) were obtained.  
2.6. Potentiometric Titration 
2.6.1. Experimental Conditions and Sample Preparation 
Volumetric burettes (50 mL, A, SLG UK) were used in the titration of PDMAEA 
solutions and the pH was monitored by a Mettler Toledo SevenEasy® pH meter. The pH 
meter was calibrated with pH buffer solution (pH 4.01, pH 7.00, pH 10.01, Thermo 
Fisher).  
The polymer solution was prepared by dissolving 50 mg of each polymer from the stock 
library was dissolved in 150 mM sodium chloride (NaCl) solution and diluted to a final 
volume of 10 mL (final concentration 5 mg/mL). HCl solution (0.1 M) was prepared by 
dilution of 8.4 mL of 37% concentrated HCl in deionised water to 1 L. NaOH solution 
(0.1M) was prepared by dissolving 4.0 g of NaOH in 1 L of deionised water.  
2.7. Dynamic Light Scattering 
2.7.1. Introduction and the Basic Principle 
Dynamic light scattering (DLS) is a technique commonly used to determine the size 
distribution of analytes such as small particles in suspension or polymers in solution5. In 
DLS experiments, the suspended particles diffuse in a random fashion by a process 
known as Brownian motion. This results in the fluctuation in the scattered light signals 
collected at the detector, owing to random fluctuations in the relative positions of the 
particles. Since the intensity measured by the detector is a combination of all the 
scattered signals from the total volume, the intensity would fluctuate randomly over 
time and this forms the basis of DLS experiments6. 
The fluctuation depends on the size of the diffusing particles. Smaller particles in 
solution diffuse faster compared to the larger ones, resulting in a more rapidly 
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fluctuating intensity signal. By using a mathematical method known as autocorrelation, 
the fluctuation intensity data could be used to acquire critical information about the 
particle solution. The autocorrelation function C(τ) represents the correlation between 
the light scattering intensity at two different times, t and (t+τ). At an arbitrary time, the 
intensity is represented by I(t), and I(t+τ) and the correlation function is: 
𝐶(𝜏) = {𝐼(𝑡) ∙ 𝐼(𝑡 + 𝜏)} 
When the sampling interval time becomes very large, it is considered that there is no 
correlation between I(t) and I(t+τ), and therefore the function could be derived into: 
𝐶(𝜏) = {𝐼(𝑡) ∙ 𝐼(𝑡)} = {𝐼(𝑡)}2 
In a DLS instrument, the digital signals are collected by a detector and further processed 
by an autocorrelator using a second-order correlation function normalised with the long-
term correlation data {I(t)}2. The acquired normalised time correlation of the intensity is 
g(2)(τ) can be expressed as: 
𝑔 (2)(τ) =
{𝐼(𝑡) ∙ 𝐼(𝑡 + 𝜏)}
{𝐼(𝑡)}2
 
The relationship of g(2)(τ) and the first-order correlation function can be expressed as 
follows, by the Siefert relationship: 
𝑔 (2)(τ) = 𝛽 + 𝐴|𝑔 (1)(τ)|2 
 
Where β is the baseline acquired by the instrument and A is a parameter based on the 
geometry of the scattering. For particles with Brownian motion diffusion, the 
correlation function is described as: 
𝑔 (1)(τ) = 𝑒(−𝐷𝑞
2𝜏) 
Where D is the translational diffusion coefficient, and q is the magnitude of the 
scattering wave. For particles that are spherical and non-interacting, the hydrodynamic 
radius (Rh) can be deducted by using the Stokes-Einstein equation with translational 
diffusion coefficient D: 
𝑅ℎ = 𝐾𝑏𝑇/6𝜋𝜂𝐷 
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Where Kb is the Boltzmann constant, T is the temperature and η is the viscosity. This 
equation demonstrates that the particle size is inversely proportional to the translational 
diffusion coefficient7. 
2.7.2. Experimental Conditions 
A Malvern Zetasizer Nano ZS (Malvern Instruments, UK) was used to obtain the size 
and zeta-potential of all polymer and polyplex solutions. The measurement of the 
hydrodynamic diameter of all samples was performed at 25°C using 633 nm (4 mW) 
He-Ne laser and the measurement angle was set at 173° backscattered. The size 
distribution by intensity, number and volume were recorded and analysed using Malvern 
Zetasizer software (Ver 7.11). 
Zeta-potential of all sample solutions were determined using a Zetasizer Nano ZS based 
on the electrophoretic light scattering principle. The measurement of all samples was 
performed at 25°C in Folded Capillary Cells DTS1060 (Malvern instruments). Data 
were recorded using the Malvern Zetasizer software (Ver 7.11). Buffering system used 
was 10 mM HEPES buffer solution.  
2.8. Agarose Gel Electrophoresis 
2.8.1. Introduction  
Agarose gel electrophoresis is one of many gel electrophoresis methods that allow for 
the separation of mixed analytes of macromolecules, such as DNA or RNA, in a matrix 
of agarose. Electrophoresis uses an electrical field to separate DNA fragments in an 
agarose gel matrix. When an electrical field is applied, negatively charged DNA would 
move through the matrix towards a positive electrode. The Agarose gel matrix acts as a 
molecular sieve that interferes slightly with the motion of small molecules, but 
drastically slows down the movement of large molecules. Agarose gels are characterised 
by a mean pore size, which is closely related to Agarose concentration in the matrix. 
Molecules smaller than the mean pore size are almost unaffected, while the migration of 
those that are larger than the mean pore size is significantly influenced. Thus, the 
approximate length of a DNA fragment can be determined by running it on an agarose 
gel along with a DNA ladder, which is a set of DNA standards that are used to identify 
the approximate size of a sample molecule run on a gel during electrophoresis. When 
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DNA or RNA fragments are condensed to other materials such as proteins or polymers 
to form strongly bound complexes, the behaviour is determined by the overall parameter 
of the complex. For example, when DNA fragments are condensed to cationic lipids or 
polymers and form a positively charged particle, instead of moving towards the positive 
electrode, it would stay still or move towards the negative electrode, depending on the 
size of the complex. Thus, agarose gel electrophoresis can also be used to determine the 
formation of certain complexes.  
2.8.2. Experimental Conditions and Sample Preparation 
The low molecular weight (¬185 bp) dsDNA molecules extracted from salmon sperm 
was purchased from Sigma Aldrich UK. Agarose gel was prepared with a Sub-Cell GT 
UV-Transparent Mini-Gel Tray and caster (with 8- and 12-well comb). Electrophoresis 
was performed with Mini-Sub® cell GT system (Bio-Rad UK) with PowerPac™ Basic 
Power Supply (Bio-Rad UK). Bands were visualised by using Gel Doc™ XR+ Gel 
Documentation System (trans-UV, 302nm) and figures captured and analysed with 
Image LabTM software (Ver.5.2.1). Another alternative approach for visualising bands 
was using ChemiDoc-It®2 810 imager at trans-UV 302 nm (U.V.P, USA) and data 
collected and analysed using the software provided.  
The TAE buffer (50X) was prepared by dissolving 24.2g of Trizma® Base (Tris-base, 
Sigma Aldrich UK), 5.71 mL acetic acid, 10 mL of 0.5M sodium EDTA in deionised 
water and topped up to 100 mL. The working TAE buffer(1X) is diluted from 50X TAE 
buffer by adding deionised water.  
Two different fluorescent nucleic acid dyes were used in this study. Ethidium bromide, a 
classic, reliable but highly toxic intercalating agent was used at a concentration of 
0.006% (0.6 μg/mL) for post-casting staining of the agarose gel. The working solution 
was prepared by adding 30 μL of EtBr stock solution (10 mg/mL in deionised water) in 
500 mL of 1X TAE buffer. GelRed® (Biotium, USA), which is another sensitive, stable 
and environmentally safe dye, was used as purchased.  
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2.9. General Cell and Tissue Culture 
2.9.1. 3T3 Mouse Fibroblast and Adult Horse Achilles Tenocyte Culture 
All cell culture operations were performed under an aseptic environment in a class II 
microbiology safety cabinet (NUAIRE, Inc. USA). Adult horse Achilles tenocyte, 
kindly donated by Dr D. Guest (Animal Health Trust, UK), were collected at post-
mortem from horses with the approval of the Animal Health Trust Ethical Review 
Committee (AHT_02_2012) and received frozen at passage 7. Mouse NIH3T3 
fibroblast was obtained from the European Collection of Cell Cultures (ECACC, No. 
93061524). 
Cells were cultured as monolayers in Dulbecco’s modified Eagle media supplemented 
with 10% heat-inactivated fetal calf serum (FCS), 1% L-glutamine (final concentration 
2 mM, original stock concentration at 200 mM, Invitrogen) and 1% penicillin-
streptomycin (final concentration 100U/mL, original stock concentration at 10,000 
U/mL, GibcoTM, Thermo Fisher). This media is referred to as complete medium in the 
rest of the thesis.  
Cells were cultured in Thermo Scientific™ Nunc™ T175 (for Horse tenocyte) or T75 
(for 3T3 Fibroblast) cell culture flasks with filter caps under 37°C with 5% CO2 in a 
humidified incubator. A typical cell passage procedure was performed as follows: Cells 
were cultured until 80-90% confluency was reached, the media was removed, and the 
cells were washed once with fresh sterile 1X PBS. Two microlitres of Trypsin/EDTA 
(for T175 flask, 1mL for T75 flask) solution (0.025% trypsin and 0.01% EDTA in 
Phosphate Buffered Saline, Gibco) were added and incubated for five minutes before 
topping up to 10 mL with complete medium to neutralise trypsin. Cells were collected 
by centrifugation at 3000 rpm using a centrifuge (VWR) for five minutes. Cells were re-
dispersed in fresh complete media and transferred to a new culture flask. Cells used in 
all experiments were between passages 9-14 (Horse Tenocyte) and passages 20-24 (3T3 
Fibroblast).  
2.9.2. Cell Count and Optical Microscopy  
Cell counts were performed using Trypan blue exclusion assay and counted using 
haemocytometer. Ten microlitres of cell suspension and trypan blue solution were 
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mixed and placed in a Neubauer improved haemocytometer chamber (with a depth of 
0.1 mm, Marienfeld) and sealed with a glass coverslip. The mixture was viewed under 
an optical microscope (EVOS Cell Imaging Systems, Thermo Fisher) with 10X or 20X 
objectives. Colourless cells were counted as live cells, while the dead cells would lose 
membrane integrity and thus stained by trypan blue.  
The concentration of cells was calculated as the following equation: 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑)(𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)
(𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐ℎ𝑎𝑚𝑏𝑒𝑟𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑)
 
The volume of chambers counted represents the total volume of chambers counted 
which in all experiments are 4*1*1*0.1 mm3 (0.4 μL). 
2.10. CellTiter 96® AQ One Solution Cell Proliferation Assay 
2.10.1. Introduction and the Basic Principle 
The CellTiter 96® AQ One Solution Cell Proliferation Assay (MTS assay) is a 
colourimetric method for determining the number of viable cells in proliferation. The 
CellTiter96® AQ One Solution Cell Proliferation Assay contains a tetrazolium 
compound5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-2-thiazolyl)-2-(4-
sulfophenyl)-2H-tetrazolium inner salt(also known as MTS) and an electron coupling 
reagent (phenazine ethosulfate; PES). PES was used as a stabiliser to be combined with 
MTS to form a stable solution.  
 
Figure 2.6 Chemical structure of MTS reagent. 
 
The MTS assay is based on the bio-reduction of MTS tetrazolium compound into a 
formazan product, which is coloured and soluble in culture media, by viable cells 
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(figure 2.7). The reduction is caused by NADPH or NADH produced by dehydrogenase 
in viable cells. Generated formazan products could be detected by an absorbance at 490 
nm, and the quantity is proportional to the metabolic activity of the living cells in 
culture.  
Figure 2.7 The bio-reduction of MTS tetrazolium compound into a formazan product. 
2.10.2. Experimental Conditions and Sample Preparation 
CellTiter 96® Aqueous One Solution Cell Proliferation Assay was used as purchased 
and will be referred to as MTS assay in the rest of the thesis. 10 μL (per 100 μL of 
media) of MTS reagent was added to the sample solution and incubated at 37°C for one 
hour. The sample plate was measured for absorbance at 490 nm in an Omega FLUOstar 
plate reader (BMG LABTECH).  
2.11. Cell Proliferation Assay (CyQUANT® NF Kit) 
2.11.1. Introduction and the Basic Principle 
The CyQUANT® NF assay is based on cellular DNA staining and the measurement of 
fluorescent dye. Because cellar DNA content is highly proportional to cell number, the 
cell viability can be determined by the measure of cell proliferation extent of treated 
cells compared with the untreated cells 8,9. This assay is designed to be easily 
manipulated in only a few steps: removal of culture media, the addition of DNA binding 
dye, incubation and measurement. This enabled quick and efficient measurement and 
determination of cell viability.  
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2.11.2. Experimental Conditions and Sample Preparation. 
Cells were cultured in Corning® 96 well black polystyrene clear bottom microplate. 
CyQUANT® NF Cell proliferation assay was used as purchased. Upon usage, 1X dye 
binding solution was prepared by adding 22 μL of CyQUANT® NF dye reagent to 11 
mL of 1X HBSS buffer. Growth medium was removed from samples cells and 100 μL 
of 1X dye binding solution was dispensed into each well. The plates were covered and 
incubated at 37°C for 45 minutes, and fluorescence intensities were measured by using 
CLARIOstar® microplate reader with excitation at 485 nm, and emission at 530 nm and 
the instrument was set to detect signal from the bottom of the well. Cells treated with 
saline were employed as -ve control; no +ve control was employed in this assay. 
2.12. Quantitative real-time Polymerase Chain Reaction  
2.12.1. Introduction and the Basic Principle 
Quantitative polymerase chain reaction (qPCR), also referred to as real-time polymerase 
chain reaction (Real-Time PCR), is a technique based on the polymerase chain reaction 
(PCR) to analyse target DNA molecule amplification. Compared with traditional PCR, 
qPCR monitors the amplification of a targeted DNA in real time. Quantitative PCR has 
many applications in molecular biology, for example in diagnosis, detection of 
phytopathogens or quantification of gene expression. In this study, qPCR is mainly used 
to quantify the expression level of a certain target gene (Equine COL3α1) compared to 
the reference gene.  
The basic principle of qPCR is described as follow:  
The key feature of qPCR is to monitor the amplification as the PCR happens. Therefore, 
qPCR is carried out in a thermal cycler with fluorescence detector to detect the 
fluorescence signal emitted by the excited fluorophore. Also, it is essential for the 
thermal cycler to be equipped with an illuminator that can excite samples with a beam 
of light at a specific wavelength. The PCR process generally consists of the following 
three phases: the first phase is the denature phase where the sample is heated to 95°C to 
allow the separation of double-stranded nucleic acid into single strands. The second 
phase is the annealing, where the temperature is reduced to 50-60°C to allow the 
primers to bind with its DNA template. The third phase is the extension phase where the 
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temperature is increased to 70°C where the DNA polymerase would assist the extension 
of DNA chains in forming new double-stranded DNA. The three phases were repeated 
for 25-40 times to amplify enough DNA. The produced DNA would bind to a DNA-
binding dye that only fluorescence after binding to DNA when excited. The sample 
would be excited, and the fluorescence intensity measured as the PCR proceeds.  
One problem is that the template used in PCR must comprise DNA molecules, the 
extracted RNA molecules cannot be applied directly. Therefore, reverse transcription 
polymerase chain reaction is used to convert RNA into complementary DNA (cDNA). 
The complementary DNA is later used as a template is qPCR and amplified. With the 
combination of RNA extraction, reverse transcription PCR and quantitative PCR, it is 
made possible to quantify the expression of the target gene.  
In quantitative real-time polymerase chain reaction, there are two strategies: absolute 
quantification and relative quantification. In absolute quantification, by using the 
standard curve method, the quantity of unknown samples is based on a known quantity. 
The advantages of the absolute quantification include high sensitivity, and also provides 
the absolute quantification of the original sample. However, using absolute 
quantification could be difficult due to drawbacks such as a high demand for sample 
purity and complicated manipulation procedurals 10. Therefore, relative quantification 
was selected. In relative quantification, changes in gene expression are analysed by 
comparison of a given sample to another reference sample, normally referred to as a 
reference gene. The expression of the reference gene should be consistent in different 
tissue, and the expression of the reference gene could be used as an internal reference. 
The role of a reference gene includes: 1) it is essential as it is used to compare with 
target gene 2) it is used to monitor whether the manipulation process has introduced 
errors that would cause changes in sample gene level. Commonly used reference genes 
include GAPDH and β2-actin. In this thesis, the 18s ribosomal RNA gene (18s gene) is 
selected as a reference gene, for it is reported to be widely employed in the analysis of 
equine samples 11,12.  
2.12.2. RNA Extraction 
Growth medium was removed, and cells were lysed directly by using TRI Reagent™ 
Solution. The lysed solution was transferred to a clean centrifuge tube and stored at -
80°C overnight. The lysed solution was defrosted, added with 100 μL of 1-Bromo-3-
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chloropropane (BCP) and mixed before incubating at room temperature for ten minutes. 
Then the mixture solution was centrifuged at 12000g for 30 minutes at 4°C using a 
HERAEUS FRESCO 17 centrifuge (Thermo Scientific). After centrifugation, phase 
separation was observed, and 400 μL of clear phase (upper phase) was transferred to a 
clean centrifuge tube and 500 μL of bioreagent grade isopropanol was added. The 
mixture was vortexed for ten seconds and incubated at room temperature for ten 
minutes before centrifuged at 12000g, 4°C for 20 minutes. A pellet was observed at the 
bottom of the centrifuge tube. The excess liquid was aspired, and 750 μL of 70% 
ethanol solution (made in bioreagent grade water) was added. The pellet was quickly 
vortexed and then centrifuged at 12000g, 4°C for 15 minutes. The clear supernatant was 
removed, and RNA pellet was dissolved in 20 μL of bioreagent grade water.  
2.12.3. Reverse Transcription 
RNA concentration and purity were determined by using the NanoDrop® ND-1000 
Spectrophotometer. An appropriate amount of RNA solution containing 1 μg of total 
RNA was transferred into a clear 0.2 mL centrifuge tube and topped up to 5 μL with 
bioreagent grade water. Five microlitres of High Capacity cDNA Reverse Transcription 
(Applied Biosystems™, Thermo Scientific) reagent master mix, which contains 1.0 μL 
of 10X RT buffer, 0.4 μL of 25X dNTP mix (100mM), 1.0 μL of 10X RT random 
primers, 0.5 μL of MultiScribe™ Reverse Transcriptase, 0.5 μL of RNase inhibitor and 
1.6 μL of bioreagent grade water, was added to RNA solution. The centrifuge tube 
containing RNA-RT reagent mixture was loaded into a PTC-100 thermal cycler (MJ 
research, UK). The thermal cycler was programmed with the following conditions: 
25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes, terminates and remains 
at 4°C.  
2.12.4. Quantitative Polymerase Chain Reaction (qPCR) 
Working primer solution was prepared by mixing 5 μL of the forward primer and 5 μL 
of reverse primer stock solution (100 μM) and topped up to 100 μL with bioreagent 
grade water. 18 μL of the qPCR master mix was prepared by mixing 10 μL of SYBR® 
Green JumpStart™ Taq ReadyMix™, 1 μL of working primer solution and 7 μL of 
bioreagent grade water. Two microlitres of cDNA solution was mixed with 18 μL of 
qPCR master mix and loaded into Non-Skirted PCR Plate (Starlab) or Rotor Gene® 
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PCR strip tubes with caps (Qiagen). The qPCR was performed on Bio-Rad C1000 
Touch thermal cycler (using PCR plates, Bio-Rad) and Rotor-Gene Q PCR cycler (using 
strip-tubes, Qiagen). The PCR cycler was programmed to execute the following cycle 
conditions: Initial denaturation at 94°C for two minutes, followed by cycles of 
denaturation at 94°C for 15 seconds, annealing, extension and fluorescence reading at 
60°C for one minute. Data were collected and analysed with CFX Manager (Bio-Rad) 
or Rotor-gene Q software.  
2.12.5.  Relative Quantification using 2-∆∆Ct Method 
The basic principle of the 2-∆∆Ct method is reported by Livak et al. 13. To describe 
briefly, the 2-∆∆Ct method is based on the following equation: 
𝑋 = 𝑋0 × (1 + 𝐸𝑋)
𝑛   (1) 
Where X represents the quantity of target gene molecule; X0 represents the initial 
quantity of target molecule; Ex represents the amplification efficiency of the target 
molecule; n is the cycle number. 
Assume that X reached a threshold value, equation (1) could be expressed as: 
𝑋𝑡 = 𝑋0 × (1 + 𝐸𝑋)
𝐶𝑡,𝑋   (2) 
Where Xt represents the quantity of target gene molecule reached threshold value, Ct,x 
represents the cycle number of the target gene when it has threshold value.  
The same equation applies to the reference gene as well: 
𝑅𝑡 = 𝑅0 × (1 + 𝐸𝑟)
𝐶𝑡,𝑟   (3) 
Where Rt represents the quantity of target gene molecule that reached threshold value, 
Ct,r represents the cycle number of the target gene when reached threshold value. R0 
represents the initial quantity of reference gene. 
Dividing Xt by Rt, and assuming that the target gene and reference gene have the same 
amplification efficiency E, a new equation is generated as follows: 
𝑋𝑡
𝑅𝑡
=
𝑋0×(1+𝐸)
𝐶𝑡,𝑋
𝑅0×(1+𝐸)
𝐶𝑡,𝑟
 = K  (4) 
Where K is a constant, equation (4) simplifies as follows: 
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𝑋𝑛 = 𝐾 × (1 + 𝐸)
−∆𝐶𝑡   (5) 
Where Xn represents the number of gene molecules in a quantified sample where the 
ratio of X0 and R0 is fixed. ∆Ct represents the difference between Ct,x and Ct,r . 
Eventually, assuming that Xn,s is the quantity of gene in the treated sample, Xn,cb is the 
quantity of gene in the untreated sample, dividing Xn,s by Xn,cb results in: 
Xn,s
Xn,cb
=  (1 + E)−∆∆𝐶𝑡   (6) 
In the equation, -∆∆Ct = -(∆Ct,s - ∆Ct, cb). 
In optimised experimental conditions, the amplification efficiency is controlled at ~1, 
where the fold change between the treated group and the untreated group is 2-∆∆Ct.  
2.13. Fluorescent Cytochemistry 
2.13.1. Introduction and the Basic Principle 
Immunocytochemistry (ICC) is a commonly used technique to visualise the location of 
a specific protein or antigen in cells. The visualisation involves the use of a protein 
specific primary antibody and the use of a fluorescent secondary antibody that can 
specifically bind to the primary antibody. Immunocytochemistry is considered to be a 
powerful tool for researchers to evaluate the protein expression visibly.   
2.13.2. Experimental Conditions 
All cell culture related manipulation is performed as described in section 2.9. Glass 
coverslips (VWR, 14mm) were sterilised by 70% ethanol or by UV light for one hour. 
The coverslips were placed in Nunc 24 well plates and coated with 2% gelatine for 20 
min at room temperature to enhance cell attachment. After cell seeding and treatment, 
cells were fixed using a 3% paraformaldehyde solution. The 3% paraformaldehyde 
solution was prepared by adding 3.6g paraformaldehyde to 120mL and heating up to 
50°C in a fume hood, adding a few drops of NaOH as it is necessary to promote 
dissolution. The solution was cooled down to room temperature, and the pH was 
adjusted to 7.0 - 7.4 by adding 1M HCl. The solution was then supplemented with 10L 
1M CaCl2 and 10 l 1 M MgCl2, and then sterilised by filtering through a 0.22 μm filter. 
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Fixed cells were preserved in 1X PBS and stored at 4°C, ready for further 
permeabilisation, blocking and antibody staining. The details for cell seeding, treatment, 
permeabilisation and staining is further described and discussed in Chapter six.  
The primary antibody, anti-collagen III produced from rabbit, was purchased from 
Abcam and received at a concentration of 1 mg/mL. A working solution was diluted at 
1:100 from the original stock. The secondary antibodies, an anti-rabbit IgG-FITC 
antibody produced in goats was purchased from Sigma Aldrich UK and diluted in 1:100 
as a working solution. The stained samples were mounted with Vectashield® hardest 
mounting media containing DAPI (cat. no. H-1500 vector laboratories) before 
visualising under fluorescent microscope. 
Imaging was performed using a Zeiss Axioplan 2ie microscope with Axiovision 
software equipped with an FITC or DAPI filter. Pictures were taken with a 20x 
magnification PlanApochromat (0.6 NA) objective and a Zeiss AxioCam HRm CCD 
camera. 
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3. Chapter 3 The Synthesis and Characterisation of a Library 
of PDMAEA Polymers 
3.1. Introduction  
Research in the drug delivery presently evaluated the potential and benefits of 
chemically synthesised gene delivery vectors, such as cationic lipids and polymers, for 
gene therapy. With regards to polymers, significant attention is paid to cationic 
polymers which possess positive charge and able to condense with nucleic acids to form 
nanocarriers caller polyplexes. Cationic polymers usually refer to polymers with 
abundant primary, secondary, tertiary or quaternary amine group or other positively 
charged functional groups. Typical example incudes polyethylenimine (PEI), chitosan, 
polyamidoamine (PAMAM), poly (2-dimethylaminoethyl methacrylate) (PDMAEMA) 
and poly (dimethylaminoethyl acrylate) (PDMAEA) 1,2.  
PEI contains a wide range of primary, secondary and tertiary amines groups in its 
structure which can protonate to efficiently bind to DNA to form into condensing 
toroidal and globular nanostructures 3, and can be internalised by cells via clathrin-
mediated endocytosis 4. However, PEI is also associated with severe toxicity, and some 
studies suggested that the mechanism by which PEI induces toxicity is related to its 
ability to disrupt the cell membrane and its integrity, followed by activation of 
mitochondrial-mediated apoptosis program 5,6. These unwanted adverse effects have 
spurred the design and engineering of new polycation-based gene delivery systems with 
different structures and compositions. 
Poly (dimethylaminoethyl methacrylate) (PDMAEMA) has emerged as a potential 
substitute for PEI. This cationic polymer demonstrates relatively lower cytotoxicity in 
cultured cell lines and capability of protonation at natural pH and below 7. A variety of 
PDMAEMA polymers with different structures have been reported in literatures, 
including linear, branched and dendritic, as transfecting agents 7. For example, Georgiou 
et al. have discussed the role of star polymers in gene delivery and their structure-
activity relationship, in which the effect of molecular mass on transfection efficiency 
and cell viability was investigated 8. More recently, studies have suggested that 
branched PDMAEMAs perform better than their linear counterparts as transfecting 
agents, which is attributed to the ability of branched PDMAEMA to densely compact 
DNA, maintain buffering capacity and exhibit lower cytotoxicity 9. Among the branched 
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PDMAEMA polymers, star-shaped polymers are most attractive due to their simple 
structure and ease of synthesis and scale-up. In another study, Yu et al., have reported 
that transfection efficiency of branched PDMAEMA polymers increases with increasing 
degree of branching 10.  
However, the acrylate version and homopolymer of PDMAEMA, Poly 
(dimethylaminoethyl acrylate) (PDMAEA), received little attention, despite its excellent 
loading capacity, low immunogenicity and capability of biodegradation 11. Nevertheless, 
a significant number of studies have been conducted exploring the potential 
development of PDMAEA into a delivery system. The success of developing new pH-
sensitive miktoarm star terpolymer system, which refers to asymmetric branched 
macromolecules with tailored polymer side chains varying from each other,  using 
PDMAEA as the pH-responsive blocks has been reported by Liu et al. 12. Another study 
by Dinari et al. reported crosslinking between gold nanorods and PDMAEA. The gold 
nanorods functionalized with PDMAEA have an increased transfection effect on 
HEK-293T cell line with reduced cytotoxicity13. A more recent study completed by 
Whitfield et al. accomplished the successful synthesis of star-shaped PDMAEA polymer 
via Cu(0)-mediated reversible-deactivation radical polymerization, though this study did 
not further explore other parameters such as binding ability, toxicity or the transfection 
efficacy of such polymer 14. Despite these reports, a systematic study that can determine 
the effect of PDMAEA architecture and molecular weight on binding to polyanionic 
DNA and attempt to ascertain their cytotoxicity in cultured cell lines, in a directly 
comparable condition, is lacking and therefore requires further investigation. 
The aim of the chapter:  
To synthesise and characterise a series of new star-shaped and linear PDMAEA based 
polymers using the RAFT polymerisation technique. Two different molecular weights 
for each polymer structure are designed: 10kDa and 20kDa, representing a lower 
molecular weight level and a higher molecular weight level respectively. The RAFT 
polymerisation technique is employed for the synthesis of each polymer with 
pentaerythritol tetrakis [2-(dodecylthiocarbonothioylthio)-2-methylpropionate] (4-arm 
DDMAT) and 2-(dodecylthiocarbonothioylthio)-2-methyl propionate selected as the 
RAFT agent for the synthesis of star-shaped and linear polymer, respectively. The logic 
for using DDMAT and 4-arm DDMAT, which are chemically similar, was to maintain 
directly comparable synthesis routes and conditions, as well as to control the molecular 
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weight of each structure. Furthermore, the synthesis 10kDa and 20kDa polymers for 
each structure also enabled the possible comparison of DNA-binding efficiency to DNA 
and cytotoxicity between polymers of the same molecular weight but different structure, 
and vice versa. The structure and molecular weights of the synthesized polymers were 
characterised by 1HNMR, GPC and potentiometric titration to provide an insight into 
the PDMAEA polymer parameters. 
The main objectives:  
This chapter described the synthesis and characterisation of a library of PDMAEA 
polymers. The following objectives will be achieved: 
 Synthesise and purify linear and star-shaped PMDAEA polymers of 10kDa and 
20kDa molecular weight. 
 Confirm the polymerisation and determine the polymer structure and molecular 
weight by using 1HNMR and GPC characterisation. 
 Test the PDMAEA polymers by potentiometric titration to confirm the pKa values. 
3.2. Material and Methods 
3.2.1. Materials 
The details of the materials used in this chapter can be found in Chapter Two section 
2.2. 
3.2.2.  Synthesis and Characterisation of 10 kDa Linear PDMAEA (PL10) 
The synthesis process is demonstrated schematically in figure 3.1. AIBN was 
recrystallized before use, and DMAEA monomer was de-inhibited with an aluminium 
oxide column (same for the synthesis other PDMAEA polymers). DDMAT (51.0 mg, 
0.140 mmol), AIBN (4.6 mg, 0.028 mmol) and DMAEA (2.0 g, 0.014 mol) were 
dissolved in 8 mL of 2-butanone in a round-bottom flask. The mixture was degassed by 
purging with nitrogen for 25 minutes in the round-bottom flask with a rubber stopper. 
The mixture was then heated up to 70°C and allowed to react for four hours. The 
reaction was stopped by exposure to air. A sample was taken for NMR analysis to 
confirm the conversion rate. 
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Figure 3.1 Synthesis of 10 kDa linear PDMAEA polymer (PL10). 
 
The polymer was purified by precipitating into 100 mL cold hexane three times. 
Typically, the reaction mixture was added into cold hexane at the rate of 1~2 
drops/second through a dropping funnel. Precipitation of yellow gel was observed 
during the procedure. The hexane-polymer solution was centrifuged at 4000 rpm for 
five minutes, and the yellow polymer precipitant was collected. The precipitant was re-
dissolved in butanone and precipitated two more times before the final product was 
dissolved in acetone. The acetone was evaporated using a rotavapor under vacuum and 
samples were collected. The product thus obtained was a yellow viscous gel weighing 
735 mg (yield 52.5%), which was then stored at 4°C for future use. The purified sample 
was analysed by GPC and NMR to confirm its molecular weight, purity and structure. 
To simplify future referencing, the 10 kDa linear PDMAEA polymer was abbreviated to 
PL10. 
3.2.3.  Synthesis and Characterisation of 20 kDa Linear PDMAEA(PL20) 
The synthesis process is shown schematically in figure 3.2. DDMAT (260.0 mg, 0.070 
mmol), AIBN (2.3 mg, 0.014 mmol) and DMAEA (2.0 g, 0.014 mol) were dissolved in 
8 mL of 2-butanone in a round-bottom flask. The mixture was degassed by purging with 
nitrogen for 25 minutes in the round-bottom flask with a rubber stopper. The mixture 
was then heated and elevated at 70°C for 18 hours. The reaction was terminated by 
exposure to the air. Samples were taken for NMR to confirm the conversion rate.  
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Figure 3.2 Synthesis of 20 kDa linear PDMAEA polymer (PL20). 
 
The polymer was purified by precipitating into 100 mL cold hexane three times. The 
reaction mixture was added into cold hexane at the rate of 1~2 drops/second through a 
dropping funnel. Yellow precipitant was observed during the procedure. The hexane-
polymer solution was centrifuged at 4000 rpm for five minutes, and the yellow 
precipitant was collected. The precipitant was re-dissolved in butanone and precipitated 
two more times before the final product was dissolved in acetone and evaporated a 
rotavapor. The product thus obtained was a yellow viscous gel weighing 808 mg (yield 
49.3%), which was stored at 4°C for future use. The purified sample was analysed by 
GPC and NMR to confirm molecular weight, purity and structure. To simplify future 
referencing, the 20 kDa linear PDMAEA polymer was abbreviated to PL20. 
3.2.4. Synthesis and Characterisation of 10 kDa Star-shaped PDMAEA(PS10) 
The synthesis process is shown schematically in figure 3.3. AIBN (18.0 mg, 0.110 
mmol), 4-arm-DDMAT (0.2g, 0.14 mmol) and DMAEA (2.0 g, 0.014 mol) were 
dissolved in 8 mL of 2-butanone in a round-bottom flask. The mixture was degassed by 
purging with nitrogen for 25 minutes in the round-bottom flask with a rubber stopper. 
The mixture was then heated up to 70 °C and allowed to react for eight hours. The 
reaction was terminated by exposure to air. A sample was taken for NMR analysis to 
confirm the conversion rate. 
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Figure 3.3 Synthesis of 10 kDa star-shaped PDMAEA polymer (PS10). 
 
The polymer was purified by precipitating into 100mL cold hexane three times. The 
reaction mixture was added into cold hexane at the rate of 1~2drops/second through a 
dropping funnel. Formation of yellow precipitant was observed during the procedure. 
The hexane-polymer solution was centrifuged at 4000 rpm for five minutes, and the 
yellow polymer precipitant was collected. The precipitant was re-dissolved in butanone 
and precipitated two more times before the final product was dissolved in acetone and 
evaporated using a rotavapor. The product thus collected was a yellow viscous gel 
weighting 968mg (yield 64.5%), and the product was stored at 4°C for future use. The 
purified sample was analysed by GPC and NMR to confirm its molecular weight, purity 
and structure. To simplify future referencing, the 10kDa star-shaped PDMAEA polymer 
was abbreviated to PS10. 
3.2.5. Synthesis and Characterisation of 20 kDa Star-shaped PDMAEA (PS20) 
The synthesis process is shown schematically in figure 3.4. AIBN (9.0 mg, 0.055 
mmol), 4-arm-DDMAT (0.11 g, 0.070 mmol) and DMAEA (2.0 g, 0.014 mol) were 
dissolved in 8 mL of 2-butanone in a round-bottom flask. The mixture was degassed by 
purging with nitrogen for 25 minutes in the round-bottom flask with a rubber stopper. 
The mixture was then heated up to 70 °C and allowed to react for 20 hours. The reaction 
was stopped by exposure to air. A sample was taken for NMR to confirm the conversion 
rate. 
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Figure 3.4 Synthesis of 20 kDa star-shaped PDMAEA polymer (PS20). 
 
The polymer was purified by precipitating into 100 mL cold hexane three times. The 
reaction mixture was added into cold hexane at the rate of 1~2 drops/second through a 
dropping funnel. Yellow precipitant was observed during the procedure. The hexane-
polymer solution was centrifuged at 4000 rpm for five minutes, and the yellow polymer 
precipitant was collected. The precipitant was re-dissolved in butanone and precipitated 
two more times before the final product was dissolved in acetone and evaporated using 
a rotavapor. The product thus collected was a yellow viscous gel weighing 686 mg 
(yield 40%), and the product was stored at 4°C for future use. The purified sample was 
analysed by GPC and NMR to confirm its molecular weight, purity and structure. To 
simplify future referencing, the 20 kDa star-shaped PDMAEA polymer was abbreviated 
to PS20. 
3.2.6. Determination of Polymer pKa Values by Potentiometric Titration 
Polymer solutions of PL10, PL20, PS10 and PS20 were prepared as described in 
Chapter Two section 2.6.2. All solutions were adjusted to pH 2 by using 0.1 M 
hydrochloride acid (HCl) measured by using a Mettler Toledo SevenEasy pH meter.  
Each solution was titrated stepwise by adding 0.1 M sodium hydroxide (NaOH), and the 
pH was monitored during the respective processes. The pKa values were calculated 
from the titration curve. 
 121 
 
3.3. Results 
3.3.1. Confirmation of Polymer Structure by 1H-NMR 
The 1H NMR spectrum of PL10, PL20, PS10 and PS20 was studied. The structure of the 
polymers was confirmed by comparison with data reported in other literature 13,15. 
Through the analysis of the 1H NMR spectrum of the polymers, the confirmation of 
polymerisation and calculates of the conversion rates could be achieved. 
 The 1H NMR spectrum of PS10 
The 1H NMR spectrum of PS10 is illustrated in figure 3.5. Peaks on the spectrum of 
PS10 were allocated based on previous studies and are shown in the figure 16. To briefly 
describe: 1H NMR (400 MHz, CDCl3, δ in ppm): δ 4.05~4.25 (br s, 2H, CH2), δ 
2.53~2.66 (br s, 2H, CH2), δ2.31~2.45 (br s, H, CH), δ 2.25~2.30 (br s, 6H, N(CH3)2), 
1.60~2.03(2br s, 2H, CH2), δ 1.10~1.29 (2 br s, 6H, 2 CH3), δ 1.05~1.10(t, 3H, CH3). 
 
Figure 3.5 1H NMR spectrum of 10 kDa star-shaped PDMAEA polymers. 
 
 The 1H NMR spectrum of PL10 
The 1H NMR spectrum of PL10 is shown in figure 3.6. To briefly describe: 1H NMR 
(400 MHz, CDCl3, δ in ppm): δ 4.00~4.32 (br s, 2H, CH2), δ 2.53~2.61 (br s, 2H, CH2), 
δ2.29~2.41 (br s, H, CH), δ 2.18~2.29 (br s, 6H, N(CH3)2), 1.63~2.24(2br s, 2H, CH2), δ 
1.18~1.30 (2 br s, 6H, 2 CH3), δ 1.05~1.10(t, 3H, CH3). 
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Figure 3.6 1H NMR spectrum of 10 kDa linear PDMAEA polymers. 
 
 The 1H NMR spectrum of PS20 
The 1H NMR spectrum of PS20 is demonstrated in figure 3.7. To briefly describe: 1H 
NMR (400 MHz, CDCl3, δ in ppm): δ 4.09~4.26 (br s, 2H, CH2), δ 2.51~2.64 (br s, 2H, 
CH2), δ2.30~2.45 (br s, H, CH), δ 2.38~2.34 (br s, 6H, N(CH3)2), 1.60~2.00(2br s, 2H, 
CH2), δ 1.11~1.32 (2 br s, 6H, 2 CH3), δ 1.06~1.10(t, 3H, CH3). 
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Figure 3.7 1H NMR spectrum of 20kDa star-shaped PDMAEA polymers. 
 
 The 1H NMR spectrum of PL20 
The 1H NMR spectrum of PL20 is shown in figure 3.8. Peaks were assigned as follows: 
1H NMR (400 MHz, CDCl3, δ in ppm): δ 4.09~4.26 (br s, 2H, CH2), δ 2.51~2.64 (br s, 
2H, CH2), δ2.30~2.45 (br s, H, CH), δ 2.38~2.34 (br s, 6H, N(CH3)2), 1.60~2.00(2br s, 
2H, CH2), δ 1.11~1.32 (2 br s, 6H, 2 CH3), δ 1.06~1.10(t, 3H, CH3). 
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Figure 3.8 1H NMR spectrum of 20kDa linear PDMAEA polymers. 
3.3.2. Confirmation of Molecular Weight by Gel Permeation Chromatography  
Gel permeation chromatography was applied to confirm the molecular weight of the 
PDMAEA polymers. The molecular weight by number (Mn), molecular weight by 
weight (Mn), conversion rate, the degree of polymerisation (DP) and polydispersity (Đ) 
are displayed in Table 3.1.  
Table 3.1 Experimental conditions and molecular weight characterisation of linear and star-shaped 
polymers. a Abbreviation for linear and star-shaped PDMAEA polymers. b Monomer conversion 
was determined by 1H NMR spectroscopy. c Degree of polymerisation d The number of average 
molecular weight and weight average molecular weight were determined by GPC using Agilent 
EasiVial PS standards in triethylamine-chloroform (5-95,v/v).e Dispersity  
Additionally, the GPC spectrum of retention time versus signal intensity of PL10, PS10, 
PL20 and PS20 are shown in figure 3.9. The overlapped curves indicate the similarity in 
retention time.  
Polymer 
entry 
Abbreviatio
na 
Time(h
) 
Convb (%) DPc Mnd 
(kDa) 
Mw 
(kDa) 
Đ e 
 
10k Linear 
20k Linear 
10k Star 
20k Star 
PL10 
PL20 
PS10 
PS20 
4 
18 
8 
20 
66% 
82% 
75% 
85% 
65 
144 
55 
124 
9618 
20996 
9354 
19283 
11063 
24034 
12674 
24529 
1.15 
1.14 
1.35 
1.38 
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Figure 3.9 Gel permeation chromatography spectra of PS10, PS20, PL10 and PL20. 
3.3.3. Calculated pKa Values of PDMAEA Polymers 
The titration curves of PL10, PS10, PL20 and PS20 are demonstrated in figure 3.10.  
 
Figure 3.10 Potentiometric titration curves of PDMAEA polymers and calculated pKa values. 
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Based on the titration curves of PDMAEA polymers, it is considered that PDMAEA 
polymers are polyprotic with two “classes” of protons, though they have repeated units 
of tertiary amines. The apparent two-step titration behaviour has been suggested to be 
caused by the interactions between neighbouring pairs of charged sites in the polymer 
structure17, which will be further explained and discussed in detail in section 3.4. 
In such cases, the pKa of PDMAEA amines is represented by pKa2 in the above figure. 
According to the Henderson–Hasselbalch equation, the pKa1 for the first dissociation 
could be expressed as: 
  𝑝𝐾𝑎1 = 𝑝𝐻 − log10
[𝐻𝐴−]
[𝐻2𝐴]
      (1) 
Likewise, for the amine dissociation process, according to Henderson–Hasselbalch 
equation, it could be described as: 
𝑝𝐾𝑎2 = 𝑝𝐻 − log10
[𝐻𝐴−]
[𝐴2−]
    (2) 
Therefore, the pKa values can be calculated based on the titration curve as shown in 
figure 3.10. The calculated pKa value for PL10, PL20, PS10 and PS20 were 7.8, 7.8, 7.8 
and 7.5, respectively. These pKa values are highly consistent with other studies which 
have suggested that PDMAEA polymers usually have a pKa value of 7.1~8.518-20.   
3.4. Discussion 
A series of PDMAEA polymers have been successfully synthesized via RAFT 
polymerisation. Linear and star-shaped polymers with molecular weights of 10 kDa and 
20 kDa were abbreviated as PL10, PL20, PS10 and PS20, representing linear 10 kDa, 
20 kDa polymers and star-shaped 10 kDa, 20 kDa polymers respectively. The Linear 
PDMAEA polymers were synthesised with DDMAT employed as the RAFT agent. The 
selection of DDMAT as the RAFT agent is mainly based on its excellent reactivity 
compatibility with acrylate type monomers which in this case is DMAEA. On the other 
hand, the synthesis of star-shaped PDMAEA involves the use of pentaerythritol tetrakis 
[2-(dodecylthiocarbonothioylthio)-2-methylpropionate] (4-arm DDMAT) as the RAFT 
agent. The choice of 4-arm DDMAT is based on several reasons, the major one being its 
excellent reactivity with acrylate monomers such as DMAEA monomers as well. 
Another reason to select this RAFT agent is that such molecule has four trithiocarbonate 
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groups attached to a hydrophobic core structure enabling the propagation of four 
PDMAEA chains, thus creating a star-shaped polymer. 
The rationale behind the use of control/living polymerisation for the synthesis of 
PDMAEA polymers was to provide control over the molecular weight, as well as the 
architecture of synthesized polymers with a relatively low polydispersity, compared to 
the conventional free radical polymerisation.  
1H NMR was applied in the characterisation of PDMAEA polymers, and the structure, 
conversion rate and purity could be determined from the 1H NMR spectrum. By 
comparison with the literature, the structure could be associated with peaks from the 
1HNMR spectrum as shown in figure 3.5~3.8. The conversion rate could be determined 
by analysis of the reaction mixture of PDMAEA polymer and unreacted monomer. An 
example 1H NMR spectrum of the polymer-monomer mixture is presented as below in 
figure 3.11.  
 
Figure 3.11 Chemical shift of methylene proton of unreacted DMAEA monomer and synthesized 
polymer. 
As demonstrated in figure 3.11, the triplet peak with a chemical shift at δ4.25(t, 2H, 
CH2, labelled as a) refers to the signal from the methylene group connected to the ester 
group in the unreacted DMAEA monomer. The generated polymers would have 
changed the chemical shift of these same protons at the same location resulting in a 
broad single peak chemical shift at around δ4.12 (br s, 2H, CH2, labelled as a’), 
representing the signals of methylene group connected to the ester group in the 
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PDMAEA polymers. Through the integration of these peaks, the ratio between 
unreacted monomers and generated polymers could be calculated and then converted 
into conversation rates.  
Furthermore, 1H NMR is applied in the determination of the removal of unreacted 
monomers after the purification process. The DMAEA monomers possess a distinctive 
signal peak of a vinyl group with a chemical shift of around δ5.5~6.5, as demonstrated 
in figure 3.12. Since no such peaks can be observed in figures 3.1~3.4, it is considered 
that no traces of DMAEA were present.  
 
Figure 3.12 1H NMR spectrum of DMAEA monomers. 
 
Polymers of two different molecular weight levels, the molecular weight of 10 kDa 
(representing low molecular weight) and 20 kDa (representing high molecular weight), 
were prepared and analysed. The molecular weight and polydispersity of all PL and PS 
PDMAEA polymers were analysed by gel permeation chromatography (GPC), using an 
available polystyrene standard calibration curve (note that the polystyrene standards 
give a relative molecular weight rather than the actual values). The results of Mn, Mw 
and Đ, are presented in Table 3.1. Compared to the theoretical molecular weight 10 kDa 
and 20 kDa, the representative value of Mn for all the PL and PS polymers show a high 
degree of agreement between the theoretical and GPC (Mn value), indicating that good 
control over the molecular weight was possible using RAFT polymerisation 21,22. It must 
be noted that there is a subtle, yet apparent, difference in the molecular weight evolution 
as a function of time between the PL and PS polymers. The PS polymers take a slightly 
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longer time to achieve a similar molecular weight as the linear ones. This might be due 
to the steric hindrance imposed by branches of the star shape polymer during chain 
propagation 23. Similarly, the Đ (dispersity) value of the PL polymers shows a narrower 
distribution (Đ = 1.15 and 1.14) compared to the PS polymers (Đ = 1.35 and 1.38), the 
latter being a known characteristic of star – and branched-polymers. The broader Đ 
value of PS polymers agrees with published work24. The degree of polymerisation (DP) 
determined by end group analysis based on 1H NMR and the calculated DP for all the 
polymers are listed in table 3.1. The DP of PL10 and PL20 were 65 and 144 
respectively, whereas the DP for the PS10 and PS20 polymers were 55 and 124 
respectively. This end group analysis suggests a relatively higher DP was achieved for 
the linear polymers compared to their star counterparts. 
The potentiometric titrations of PDMAEA polymers exhibited apparent two-step 
titration behaviour, and it has been suggested that the interaction between neighbouring 
pairs of charged sites are responsible 25. For polymers containing amine groups, such as 
LPEI and PDMAEA, the amine groups, whether primary, secondary, or tertiary amine 
groups, may protonate by taking a positively charged proton. Each amine group is 
considered as one charge site, which can be in two states, namely deprotonated state and 
protonated state. If a naive model, which assumes all sites the same affinity for protons 
and are arranged in a line and that only the nearest neighbouring site interact, is applied, 
the protonating behaviours can be demonstrated in figure 3.1326. During the protonation 
process, to avoid the formation of energetically unfavourable site pairs in structures 
with multiple charged site lining up next to each other, the 50% protonation is first 
achieved, that is, when the intermediate plateau in a two-step titration was observed.  
 
Figure 3.13 A schematic demonstration of the states of protonated sites in a polymer chain during 
potentiometric titrations. The black circle represents a protonated site in the structure, while the 
white circle represents unprotonated sites. 
 
The 50% protonation state minimises the free energy by avoiding the nearest 
neighbouring site pair interactions. In the first stage of the titration, the number of the 
unprotonated isolated sites decreases as the pH increases. In the second step in the 
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titration, protons must bind to the unprotonated sites even if the neighbouring site is 
already protonated. Therefore, the titration curve of PDMAEA polymers appears to be a 
two-step titration curve with two “classes” of proton 27. 
The pKa values of PDMAEA polymers were calculated based on the titration curve 
acquired from potentiometric titration. The pKa values for PL10, PL20, PS10 and PS20 
were 7.8, 7.8, 7.8 and 7.5, respectively. However, as Grace et al. reported, DMAEA 
monomers have a pKa value of 8.4, it thus seems that the pKa values of PDMAEA have 
decreased compared to its monomer28. The pKa values of monomers are readily 
measured through potentiometric titrations and are equivalent to the pH value when 
equal amounts of base and acid are present. However, unlike monomers, the protonation 
of polymers is closely related to the protonation of different sites in their structure, and 
can be affected by various factors, including the ionic strength of the solution, the 
distribution of ionisable units and the ionisation state of the neighbouring units 29-31. A 
study conducted by Borukhov et al. reported a difference between methacrylic acid 
(MAA) monomer and its copolymer with ethyl acrylate (P(MAA-EA)) 29. Their work 
suggested that the difference might be caused by the formation of collapsed 
microdomains in the polymer chains due to the competition between the hydrophobic 
attraction and the Coulomb repulsion. Besides, it is also mentioned that the charges on 
the polymer chain may inhibit the dissociation of other charged groups29. The 
electrostatic effects in solution may affect the measured pKa values as well. As Smits 
and his colleagues stated in their work, that the increase of salt concentration caused the 
pKa value of LPEI solution to shift to higher values 31. This is explained by the increase 
of salt concentration which has screened the electrostatic potential of the polymer 
chains, resulting in a weaker repulsion of the protons in the solution from the positively 
charged polymer chains 31. Their findings also supported the assumption that the 
distribution of ionisable units and electrostatic potential of the charged units might have 
an effect on the measured pKa values of polymers. Therefore, the pKa value of 
polymers should be reported with relevant information 32. In addition, the literature has 
reported a wide range of pKa values between 7.1 and 8.5 for PDMAEA polymers in 
different studies, and the determined values in this study fit in the above range 18-20. 
Nevertheless, the determined pKa values of PDMAEA polymer are considered at the 
relatively high level, which indicates that PDMAEA polymers could be tightly bound to 
nucleic acids in a low pH environment. It is also reported by Sprouse et al. that the 
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methyl groups  attached to the tertiary amine may also provide a hydrophobic character 
to the polymer, especially in the situation where the polymer is not protonated33.  
3.5. Conclusion 
Hence, it has been demonstrated that a successful synthesis of a library of PDMAEA 
polymers with different molecular weight and chemical structure was achieved. 1H 
NMR analyses have provided an insight into the polymers’ structure, as well as the 
conversion rate of each polymerisation. The molecular weight and polydispersity were 
revealed by the application of GPC, and it has been demonstrated that the synthesized 
PDMAEA polymers are in the range of the desired range of molecular weight with low 
dispersity. Potentiometric titration has provided vital information regarding pKa values 
of PDMAEA polymers. The work presented in this chapter has also exhibited a simple 
and efficient way of synthesizing PDMAEA polymer via RAFT polymerisation.  
The successful synthesis and characterisation of PDMAEA polymers is the first step in 
establishing a PDMAEA-based siRNA delivery system. In the next chapter, PDMAEA 
is condensed to dsDNA and siRNA to form stable polyplexes, followed by 
characterisation of these polyplexes via multiple means.  
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4. Chapter 4 Characterisation of PDMAEA Polymer 
Solutions and PDMAEA-siRNA Polyplexes 
4.1. Introduction 
Polyplexes refer to a type of nanoparticle formed by electrostatic attraction between 
cationic polymers and anion molecules such as DNA or RNA. It is a type of 
nanoparticle that has been widely applied in the delivery of small molecules 1,2. 
Polyplexes showed great potential as a delivery vector for small molecules and have 
undergone clinical trials 3-5. Synthetic polymers such as polyethylenimine (PEI), poly 
(dimethylaminoethyl methacrylate) (PDMAEMA) and poly (dimethylaminoethyl 
acrylate) (PDMAEA) have been applied in siRNA delivery. PDMAEA polymer has 
abundant amine groups in its structure and would be able to quickly protonate and 
become positively charged under a neutral and acid environment, which makes it able to 
condense to negatively charged ionic molecules such as siRNA. The PDMAEA can 
protect siRNA from nuclease degradation, and as PDMAEA polymer can be uptaken by 
cells via clathrin-mediated endocytosis, it also provides a route for the cellular 
internalisation of siRNA6,7. The intracellular release of cationic polyplex was proposed 
to be achieved via “proton sponge” pathway8. Polyplexes uptaken by endosomal or 
lysosomes, would change the osmolarity of the organelle and eventual cause the rupture 
of the vesicle and release the polyplexes into the cytoplasm 9, where siRNA are bound 
to RISC and trigger the degradation of target mRNA. In general, PDMAEA showed 
great potential as an siRNA delivery vector. To deliver siRNA, PDMAEA-siRNA 
polyplexes are typically prepared and administrated either systematically or locally to 
the patient. The extracellular interaction between cationic polyplexes and negatively 
charged serum proteins, and red blood cells could lead to the formation of precipitants 
and clusters and could provide hindrance for the systematic administration of the 
polyplexes. To avoid this, the PDMAEA-siRNA polyplexes prepared in this study are 
designed to be administrated into lesions (normally in tendon tissue or around tendon 
tissue) via local injection, which should reduce the probability of any undesired 
interaction between positively charged polyplexes with negatively charged serum 
proteins and red blood cells.  
Some important parameters are critical to the evaluation of polyplexes. One of them is 
the N:P ratio, normally used to describe the molar ratio between amino groups from the 
polymer to the phosphate groups in siRNA, and has been reported to have an influence 
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on polyplex properties such as cellular uptake and endosomatic activity 9. It is reported 
that in polyplexes designed for the siRNA delivery, an excessive amount of polymer 
content is critical to the formation of stable polyplex, due to the low ionic charge centre 
provided by small RNA molecules 10,11. However, polyplexes with high N:P ratio or 
high overall net surface charge might induce extracellular and intracellular interaction 
with ionic large molecules such as serum protein or might cause cellular membrane 
disruption which is associated with cytotoxicity 12. Therefore, special attention should 
be paid to the monitoring of the overall surface charge and N:P ratio. The formation of 
PDMAEA-siRNA is based on the charge-mediated interactions between cationic 
polymer materials and nucleic acids, the successful formation could be determined by 
using agarose gel electrophoresis by comparing polyplex sample with free DNA, as 
Truong et al. reported 13.  
It is reported that the size and surface charge of nanoparticles would greatly affect their 
uptake rate by the target cell 17, special attention should be paid to the hydrodynamic 
diameter of the polyplexes. Another important parameter that should be determined is 
the zeta potential. For charged particles dispersed in solutions, zeta potential is the 
electric potential in the interfacial double layer of dispersed particle versus a point in the 
continuous phase away from the interface (figure 4.1)14. It is the potential difference 
between the stern layer, which is is the internal layer of the electric double layer formed 
at the surface of the particle, and the slipping plane, which is the boundary between the 
mobile fluid and fluid that remains attached to the surface14. Zeta potential is a measure 
of surface charge and reflects colloidal stability15. 
 
Figure 4.1 A schematic illustration of the electric double layer of a charged particle in solution. 
Figure adapted from Grumezescu14. 
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The stability of colloids in suspension can be explained by DLVO theory, which is 
developed by Derjaguin, Verwey, Landau, and Overbeek in the 1940s16. The DLVO 
theory suggests that the stability of a dispersion of colloids depends on the total 
interaction potential energy VT: 
V𝑇 = V𝐴 + V𝑅 + V𝑆 
Where VA is the attractive energy from van der Waals force, VR is the repulsive force 
from the electrical double layer of charged particles and VS is the potential energy from 
the solvent. VS contributes little compared to VA and VS for nanometer-scale separation 
of the particles and is negligible. Van der Waals force is a distance-dependent interaction 
between atoms or molecules, and VA is affected only by the distance between particles 
and is insensitive to the ionic strength and pH of the solution. While Pan et al. suggested 
that VR can be expressed as follows 17: 
𝑉𝑅 = 2𝜋𝜀𝑎𝜁
2𝑒−𝜅𝐷 (4.1) 
Where ε is the dielectric constant, π is the solvent permeability, a is the radius of the 
particle, D is the distance between the particles, κ is the ionic strength, and ζ is the zeta 
potential. As both VA and VR are related to the distance between particles, the 
interaction energy variation with the separation between the particles can be described 
as in figure 4.2. When the sum of the repulsion forces overcomes the attraction forces, 
the colloidal system is considered stable 18.  
 
Figure 4.2 The interaction energy in relationship to particles separation distance. Figure adapted 
from Buschow et al.16. 
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Equation 4.1 indicates that the zeta potential contributes to the repulsion force between 
particles, and the larger the zeta potential is, the greater the repulsive force is. Particles 
with high zeta potential are electrically stable while particles with low zeta potentials 
tend to congregate or flocculate15. 
Losso et al. reported that phosphatidylcholine-stabilized emulsions with zeta potential 
values of −41 to −50 mV had good stability 19. Some other studies also suggested that 
various particles with zeta potential from 10 mV to 60 mV achieved good stability 20,21. 
It is suggested that a high positive or negative zeta potential greater than 30 mV may 
lead to good stability, and zeta potential of lower than 5 mV are likely to produce 
aggregation14. To conclude, it is necessary to determine the hydrodynamic diameter and 
surface charge at different pHs and different N:P ratio of PDMAEA polymers and their 
polyplexes. 
The aim of the chapter: 
In this chapter, the formation of PDMAEA polymers with dsDNA and siRNA into 
according polyplexes was described and discussed. Firstly, the dsDNA was used as a 
model molecule to study the formulation of  PDMAEA polyplexes. PDMAEA-dsDNA 
polyplexes were prepared at different N:P ratio, and the successful formation of 
PDMAEA polyplexes was confirmed by using agarose gel electrophoresis comparing to 
free dsDNA. The critical polyplex formation N:P ratios were also determined by 
electrophoresis for each PDMAEA polymers. The hydrodynamic diameter and zeta 
potential of all PDMAEA polymer solutions and its polyplexes with dsDNA were 
obtained by using dynamic light scattering. PS10 is selected as to condense with 
COL3α1 specific siRNA to form PS10-siRNA polyplex at N:P ratio of 10:1. The 
formation was confirmed by agarose gel electrophoresis, and the hydrodynamic 
diameter and zeta potential were determined by DLS. Eventually, the influence of molar 
mass and structure on polymer binding capability is discussed. 
The main objectives: 
The aim of this chapter is to study the formation of PDMAEA polyplexes and prepare 
PS10-siRNA polyplexes for the transfection of equine tenocyte and silencing the 
COL3α1 gene. To achieve this goal, the following objectives were accomplished: 
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 Determine the hydrodynamic diameter and zeta potential of PDMAEA polymer 
solutions. 
 Study the formulation of PDMAEA (PL10, PS10, PL20, PS20) polyplexes using 
dsDNA as a model cargo molecule and confirm polyplexes formation by agarose 
gel electrophoresis. 
 Test the PDMAEA polyplexes for their hydrodynamic diameter and zeta potential. 
 Prepare and characterise PS10-siRNA polyplex for the transfection of equine 
tenocyte and silencing the COL3α1 gene. 
4.2. Materials and Methods 
4.2.1. Materials 
The details of the materials used in this chapter can be found in chapter two section 2.2. 
4.2.2. Characterisation of PDMAEA Polymers by DLS 
Thirty milligrams of polymers (PS10, PS20, PL10 and PL20) were dissolved in 30 mL 
of HEPES Buffer (10 mM, pH 7.4) to a final concentration of 1 mg/mL respectively. 
Each polymer solution was divided into six aliquots in vials with a volume of 4 mL. The 
pH of six aliquots of polymers solution was adjusted to 6.0, 6.5, 7.0, 7.5, 8.0, and 8.5 
using 1M HCl and NaOH, respectively. All the samples were left at 4°C overnight. The 
supernatant of all samples was taken for DLS and zeta potential measurement. The 
samples were analysed with a Malvern Nanosizer with Folded Capillary Cells DTS1060 
(Malvern Instruments), and the data were recorded. All measurements were carried out 
in triplicate.  
The hydrodynamic diameter of the PDMAEA polymers was measured in disposable 
plastic cuvette as a function of pH, and 15 sub runs were performed for each sample. 
The data was analysed using the Malvern analysis software. All the samples were made 
and measured in triplicates. 
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4.2.3. The Preparation of PDMAEA Polyplexes 
The dsDNA stock solution was prepared in 1X Tris-acetate-EDTA (TAE) buffer. Briefly, 
a stock solution of 1 mg/mL solution was prepared by adding 10 mg of dsDNA in 10 
mL of 1X TAE buffer (40 mM Tris-base, 2 mM acetic acid and 1 mM EDTA) and pH 
adjusted to 7.4. PDMAEA stock solutions were prepared by dissolving 10 mg of 
PDMAEA polymers (PS10, PS20, PL10 and PL20) in 10 mL of HEPES buffer (10 mM, 
pH at 7.4) to make a stock solution of polymers at the concentration of 1 mg/mL.  
The calculation of N:P ratios was adapted and modified based on literature 9. Typically, 
for 25 μL of the stock DNA solution (total DNA mass would be 25 μg), the required 
volume and concentration of the polymer solution is shown in table 4.1.  
Table 4.1 Preparation of PDMAEA polyplexes. 
Charge ratio（N:P） 1 3   5   7   9  10  15 
Polymer stock(µL) 10.74  32.22  53.69  75.17  96.65  107.39  161.08  
HEPES solution (10 
mM) 
239.26  217.78  196.31  174.83  153.35  142.62  88.92  
concentration(µg/mL) 42.95 128.86 214.77 300.67 386.58 429.54 644.31 
For the preparation of polyplexes, 25 μL of dsDNA solution was added into 250 µL of 
polymer solution with different concentration based on N:P ratios. The polyplex mixture 
was vortexed for ten seconds before being incubated at room temperature for 30 
minutes.  
PS10 PDMAEA polyplexes were selected as the final candidate to condense with 
COL3α1 gene-specific siRNA considering its good binding ability and low cytotoxicity. 
The formulation of PS10-siRNA polyplexes is described as follows: The siRNA (10 
nmol) were resuspended in 100 µL of 30 mM HEPES buffer to prepare a stock solution 
of 100 pmol/μL. Solution of 1 nmol of siRNA (13.2 μg in 10 μL) was diluted to 100 μL 
in 30 mM HEPES buffer. The siRNA solution was added to 100 μL of calculated PS10 
PDMAEA polymer solution (N:P ratio at 10, concentration 6mg/ml) and topped up to 1 
mL, resulting in a final siRNA concentration of 13.2 μg/mL and a final polymer 
concentration of 0.6 mg/mL. The mixture was vortexed for ten seconds in a 1.5 mL 
microcentrifuge tube and incubated at room temperature for 30 minutes. 
 141 
 
4.2.4. Agarose gel electrophoresis of PDMAEA (PL10, PL20, PS10, PS20)-dsDNA 
polyplexes  
Agarose (0.6 g) was suspended in 60 ml of 1X TEA buffer to reach 1% final 
concentration. The agarose was heated in a microwave oven till molten. Afterwards, 5 
μL of GELRED DNA stain was added and mixed into the molten gel, and then the gel 
was cooled down to 50~60°C before casting. Ten microlitres of the polyplexes were 
loaded into each well, and the electrophoresis was performed at 80 V for 40 minutes. 
The gel was then visualized in GELDOC (BIO-RAD) and the data collected and 
analysed using the software provided. 
4.2.5. Characterisation of PDMEAE (PL10, PL20, PS10, PS20)-dsDNA polyplex 
by dynamic light scattering 
Polyplex solution was adjusted to pH 7.4 using 1 M NaOH or 1 M HCl. All the samples 
were left at 4°C overnight. The supernatant of all samples was taken for DLS and zeta 
potential measurement. The sample zeta potential was measured by using a Malvern 
Zetasizer ZS in a DT1070 zeta cell. Data were recorded and analysed using Zetasizer 
Software. The hydrodynamic diameter of the polyplexes was measured in cuvettes with 
15 sub runs for each sample and the data averaged using the Malvern analysis software. 
All the samples were made and measured in triplicate. 
4.2.6. Characterisation of PS10-siRNA polyplex by DLS and electrophoresis 
PS10-siRNA polyplex was adjusted to pH 5.4, 6.4 and 7.4 using 1 M NaOH or 1 M 
HCl. Samples were left at 4°C overnight before the supernatant was taken for DLS and 
zeta potential measurement. The sample zeta potential was measured by using a 
Malvern Zetasizer ZS in a DT1070 zeta cell. Data were recorded and analysed using 
Zetasizer Software. The hydrodynamic diameter of the polyplexes was measured in 
cuvettes with 15 sub runs for each sample and the data were analysed using the Malvern 
analysis software. All the samples were made and measured in triplicate. 
1.5 g of agarose was suspended in 100ml of 1X TEA buffer to reach a final 
concentration of 1.5% and then heated in a microwave oven till molten. The molten gel 
was cooled down to 50~60°C before casting with the comb placed at the edge of the 
tray and left at room temperature in the dark. Ten microlitres of the polyplexes were 
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loaded into the well, and the electrophoresis was performed at 80 V for 40 minutes. To 
stain the siRNA, the gel was then immersed in 400 mL of 0.006% ethidium bromide for 
one hour before visualizing. The gel was then visualized in a ChemiDoc-It®2 810 
imager (U.V.P, USA) and the data were collected and analysed using the software 
provided. 
4.3. Results 
4.3.1. The Hydrodynamic Diameter of PDMAEA Polymers 
Typically, two different size analysis techniques, namely, cumulants analysis and 
distribution analysis, were used to analyse the correlation function. The cumulants 
analysis normally gives a mean particle size (z-average) and an estimate of the width of 
the distribution (polydispersity index, or PDI) and is ideal only when a single size 
population is present in sample solutions. One disadvantage of cumulants analysis is 
that it only describes the average size value, along with the PDI of a single population, 
and it becomes less descriptive as the sample type moves further away from 
monomodal. In an unknown sample with possible multiple size populations the 
cumulants analysis may become less accurate. The second approach, distribution 
analysis, is a mathematical analysis of the correlation function which can describe the 
size distribution in a sample solution. The distribution analysis becomes useful when the 
number of populations, the relative composition of these populations and the presence 
of a large/small population needs to be determined. The distribution analysis typically 
generates three types of size distribution, that is the size distribution by intensity, 
volume and number. The size distribution by intensity is the primary result generated 
based upon the intensity of light scattered by particles, and it is sensitive to the presence 
of large particles, aggregates, or contaminants (such as dust). The size distribution by 
volume and number are derived from the intensity distribution using Mie theory and are 
used for estimating the relative amounts of material in separate peaks.  
The hydrodynamic diameter of PDMAEA polymers in solution was measured at 
different pHs (from 6.0 to 8.5), and the size distribution (intensity and volume) and the 
correlation curves are shown in figure 4.3 – 4.6. The data collected in this study indicate 
that there are multiple size populations present in the sample solutions, though only one 
size population is predominant. Data also suggest that cumulant analysis is not the most 
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suitable method for the analysis of the obtained data due to the high cumulant fit error. 
Therefore, a combination of intensity size distribution and number distribution is used 
to analyse the collected data.  
Figure 4.3 demonstrates the intensity and volume size distribution of PL10 in solutions 
with a pH from 6.0 to 8.5. The intensity distribution data indicate that there are three 
size populations (≤10 nm, ~100 nm and ≥500 nm) in sample solutions at pH 6.0 - 8.0, 
though only the smallest size population (≤10 nm) is the major one. The intensity and 
volume size distribution data of PL10 in solution at pH 8.5 showed only two size 
groups, one is ~40 nm and the other is ~500 nm, and volume distribution suggests that 
the size group of ~40 nm is predominant. Combining these results, it is indicated that 
the majority of PL10 polymers possibly exist in the form of small particles with sizes of 
below 10 nm in solutions with pH from 6.0 - 8.0, while in a solution with pH 8.5 the 
polymers exist in the form of small particles with sizes of ~40 nm. The mean size based 
on intensity and volume distribution data of PL10 polymers in solutions from pH 6.0 - 
8.5 are summarised in table 4.2. The possible structure of PL10 polymers is explained 
and discussed in section 4.4.  
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Figure 4.3 The correlation curves, intensity distribution and volume distribution of PL10 polymer 
in solutions with pHs from 6.0 to 8.5. 
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Table 4.2 Size distribution of PL10 polymers in solutions with pHs from 6.0 to 8.5. Size reported as 
mean value ± SD(N=3). 
pH PL10 
Intensity Volume 
6 4±1 2±1 
6.5 4±1 3±1 
7 5±1. 4±1 
7.5 5±1 4±1 
8 7±2 4±1 
8.5 48±4 42±5 
 
The correlation curves and size distribution of PS10 in pH 6.0 – 8.5 solutions are shown 
in figure 4.4. The intensity size distribution data indicate that at pH 6.0, 7.0, 8.0 and 8.5, 
three size populations were recorded in PS10 solutions, while only two size groups were 
observed at pH 6.5 and 7.5. The volume size distribution data suggest that through 
multiple size groups were recorded, only one size group at each pH is predominant, and 
it is the size group ≤10 nm for pH 6.0 - 8.0 and ~40 nm size group for pH 8.5. These 
data suggest that PS10 showed a similar behaviour to PL10, possibly existing in the 
form of small particles with sizes of below 10 nm in solutions with pH from 6.0 - 8.0, 
while in a pH 8.5 solution the polymers exist in the form of particles with sizes of ~40 
nm. 
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Figure 4.4 The correlation curves, intensity size distribution and volume distribution of PS10 
polymer in pH 6.0 – 8.5 solutions. 
The mean size base PS10 polymers in solutions from pH 6.0 - 8.5 are summarised in 
table 4.3.  
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Table 4.3 Size distribution of PL10 polymers in solutions from pH 6.0-8.5. Size reported as mean 
value ± SD(N=3). 
 
pH PS10 
Intensity Volume 
6 4±1 3±1 
6.5 5±1 4±0 
7 5±1 4±1 
7.5 5±2 4±1 
8 7±1 5±0 
8.5 20±9 24±6 
The size distribution and correlation curves of PL20 and PS20 in pH 6.0 - 8.5 solutions 
are presented in figure 4.5 and 4.6, respectively. The intensity distribution data suggest 
that in both PL20 and PS20 solutions, multiple size populations were observed in all 
pHs, though volume distribution data confirmed only one size group is predominant. 
For both PL20 and PS20, the majority of the polymers may exist in forms of particles 
with sizes below 10 nm at pH 6.0 – 7.5. However, the size increased dramatically to 
~100 nm at pH 8.0 and 8.5 for both PL20 and PS20. The mean size values are reported 
in table 4.4. 
Table 4.4 Size distribution of PL20 and PS20 polymers in solutions from pH 6.0-8.5. Size reported 
as mean value ± SD(N=3). 
pH PL20 PS20 
Intensity Volume Intensity Volume 
6 5±1 4±1 6±1 4±1 
6.5 5±1 4±1 5±1 5±1 
7 7±1 4±1 6±1 4±1 
7.5 8±0 5±1 8±1 4±1 
8 23±4 83±13 25±7 28±3 
8.5 91±3 78±8 79±22 87±9 
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Figure 4.5 The correlation curves, intensity size distribution and volume distribution of PL20 
polymer in pH 6.0 – 8.5 solutions. 
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Figure 4.6 The correlation curves, intensity size distribution and volume distribution of PS20 
polymer in pH 6.0 – 8.5 solutions. 
 
To compare the difference of hydrodynamic diameter of PDMAEA polymer in solutions 
at different pHs, the mean size by volume distribution of all four polymers are plotted 
against pH and are presented in figure 4.7. Statistical analysis (t-test) has been 
performed between sizes at each pH to determine whether the difference between pHs 
in each polymer sample groups was significant.  
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Figure 4.7 Statistical analysis within the group to determine the variation between sizes at each pH 
(ns:p>0.05, *:0.05>p>0.01, **:0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). The data 
represent the mean values ± SD (N=3). 
 
The results suggest, for PL10 solutions, sizes at pH 8.0 are much smaller than those at 
pH 8.5. Similar results were observed in the PS10 sample solution where sizes at pH 8.5 
are significantly larger than those at pH 8.0. For PL20 solutions, a significant difference 
in size was observed between pH 7.5 and 8.0, while PS20 solutions at pH 7.5, 8.0 and 
8.5 showed significant differences between one another and the size increases as the pH 
goes up.  
To determine whether the effect of pH on particle hydrodynamic diameter is influenced 
by polymer types, paired two-way ANOVA was used to analyse the data and the results 
are presented in figure 4.8. The two-way ANOVA compares the mean differences 
between groups that have been split on two independent variables (pH and polymer 
type). Statistical analysis indicates that there are no significant differences between each 
group. The results indicate that there are no significant variations among four types of 
PDMAEA polymer sample groups at different pHs.  
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Figure 4.8 Statistical analysis between PS10, PS20, PL10 and PL20 polymers(ns:p>0.05, 
*:0.05>p>0.01, **:0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). The data represent mean 
values ± SD (N=3). 
 
To conclude, all four PDMAEA polymers may exist in the form of particles with sizes 
below 10 nm at pH 7.5 and below. However, the analysis indicated that the particles 
sizes increased dramatically at pH 8.5 (for PL10 and PS10) and at pH 8.0 (for PL20 and 
PS20). The results also showed that there are no significant differences between the 
particle sizes of PL10, PS10, PL20 and PS20 polymer solutions at different pHs. The 
possible structure of PDMAEA particles in solution and the cause of the increase in 
their sizes at high pHs will be discussed in detail in section 4.4.  
4.3.2. The Zeta Potential of PDMAEA Polymers 
The zeta potential of PL10, PS10, PL20 and PS20 in solutions with pHs ranging from 
6.0 – 8.5 are reported in figure 4.9. Analysis reveals the relationship between pH and 
zeta potential of polymer samples as follows: as the pH increases from 6.0 to 8.5, the 
zeta potential of all PDMAEA polymer solution decreases from above 40 mV to below 
0 mV. This is possibly due to the reduction in the percentage of protonated amine 
groups as the pH increases, and the further triggering of polymers aggregation. 
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Figure 4.9 Zeta potential of four PDMAEA polymer solutions under different pH conditions. The 
data represent the mean values ± SD (N=3). 
 
Another fact observed was that at pH 7.4, all polymer samples retained a positive charge 
of above 20 mV, which suggests that the polymer solutions are colloidal stable at pH 7.4 
and below.  
4.3.3. Confirmation of PDMAEA (PL10, PL20, PS10, PS20)-dsDNA Polyplexes 
Formation by Electrophoresis. 
Four different PDMAEA-dsDNA polyplexes were prepared with N:P ratios from 1 to 15 
and were characterised with agarose gel electrophoresis and dynamic light scattering, 
and free DNA was used as -ve control to indicate whether the DNA was completely 
condensed to polymers. The dsDNA used in this experiment is low molecular weight 
DNA from salmon sperm (~185 bp). The aim of this experiment is to determine the 
minimal N:P ratio required to completely condense to dsDNA for different PDMAEA 
polymers, and the molecular weight of the dsDNA used in this study is known to be 
~185 bp; therefore no DNA ladder was employed in this experiment. The polyplexes 
were first characterised by electrophoresis to confirm successful polyplex formation. 
Data from agarose gel electrophoresis are presented in figure 4.10. The results indicated 
that for different polymers, the required N:P ratio to form polyplexes are variable. The 
PS10 formed polyplexes at an N:P ratio of 5:1 while PL10 polymer formed polyplexes 
at an N:P ratio of 7:1. A polymer with a larger molecular weight such as PS20 formed 
polyplexes at an N:P ratio of 3:1, while PL20 formed polyplexes at an N:P ratio of 5:1. 
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The missing DNA band at the bottom of the gel was a clear indicator for polyplex 
formation, compared to the bright band from free dsDNA control lane.  
 
Figure 4.10 Agarose gel (1%) electrophoresis analysis of PDMAEA-dsDNA polyplexes. Low 
molecular weight dsDNA (~185 bp) from salmon sperm was used to form polyplexes with PDMAEA 
polymers. Red arrows indicate no DNA band was observed at corresponding N:P ratio. a) PS10kDa 
(star-shaped) b) PL10kDa, c) PS20kDa (star-shaped), and d) PL20kDa. The figure colour was 
reversed to better demonstrate the result. 
 
Another underlying concept demonstrated by this result is that for PDMAEAs of 
different structures and molecular weights, the minimum required N:P ratio to form 
polyplex is different. While comparing linear and star-shaped PDMAEA, it is evident 
that star-shaped polymers require a lower N:P ratio to form polyplexes. For polymers of 
the same structure, the ones with larger molar masses require a low N:P ratio for the 
formation of polyplexes.  
4.3.4. Hydrodynamic Diameter and Zeta Potential of PDMAEA (PL10, PL20, 
PS10, PS20)-dsDNA Polyplexes 
The hydrodynamic diameter and zeta potential of PDMAEA-dsDNA polyplexes at pH 
7.4 were determined by DLS. The correlation curves and size distribution were 
demonstrated in figure 4.11. 
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Figure 4.11 The correlation curves, intensity size distribution and volume distribution of PL10, 
PS10, PL20, PS20 polyplexes with dsDNA pH 7.4.  
 
Intensity distribution data indicate that at pH 7.4, one particle size class was present in 
each sample solution. Combining the volume and intensity distribution data, it is 
suggested that PDMAEA (PL10, PS10, PL20, PS20)-dsDNA polyplexes possibly exist 
in the form of particles with a hydrodynamic diameter of ~150 nm. The mean size value 
±SD of four different PDMAEA-dsDNA polyplexes at pH 7.4 are summarised in table 
4.5. 
Table 4.5 Mean size values ± SD (N=3) by intensity and volume distribution analysis of four 
PDMAEA-dsDNA polyplexes at pH 7.4.  
Polyplex N/P DH (Intensity mean ± SD)/nm DH (Volume mean ± SD)/nm 
dsDNA-PL10 10:1 158 ± 1 122 ± 5 
dsDNA-PS10 10:1 181 ± 13 145 ± 3 
dsDNA-PL20 10:1 172 ± 3 145 ± 1 
dsDNA-PS20 10:1 184 ± 8 145 ± 8 
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The zeta potential of four PDMAEA-dsDNA polyplexes at pH 7.4 was obtained via 
DLS and are reported in table 4.6.  
Table 4.6 Zeta potential of four PDMAEA-dsDNA polyplexes. The data represent the mean values ± 
SD (N=3) recorded at pH 7.4. 
Polyplex N/P Zeta potential (mV) Conductivity (mS cm-1) 
dsDNA-PL10 10:1 36.9 ± 0.5 0.15 
dsDNA-PS10 10:1 37.3 ± 1.3 0.11 
dsDNA-PL20 10:1 40.8 ± 0.7 0.11 
dsDNA-PS20 10:1 45.1 ± 0.4 0.41 
 
The hydrodynamic diameter and zeta potential of four PDMAEA-dsDNA polyplexes 
are shown in figure 4.12. Results revealed that all polyplexes have a hydrodynamic 
diameter of below 200 nm, with a positive charge of above 35 mV at pH 7.4. Research 
done by Shang et al. has suggested that polyplexes with a hydrodynamic diameter of 
below 200 nm are the key to improve the stability and cellular uptake rate of 
nanoparticles 22. 
 
 
Figure 4.12 Mean size distribution by volume percentage and zeta potential of four PDMAEA-
dsDNA polyplexes at pH 7.4. The data represent mean values ± SD (N=3). 
 
Furthermore, Valleau et al. suggested that polyplexes with a high positive charge have 
proven to be more colloidally stable based on the DLVO theory 23. While comparing the 
PDMAEA polyplexes, it is noticeable that the polyplexes with 20kDa molar mass have 
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a higher zeta potential than the 10kDa ones and the polyplexes of the star-shaped 
polymers showed a high zeta potential than linear ones.  
4.3.5. Formation and Characterisation of PS10-siRNA Polyplexes.  
PS10 PDMAEA polymer was selected due to its good binding capability and low 
toxicity to condense with COL3α1 specific siRNA forming PS10-siRNA polyplex for 
the transfection of equine tenocyte. Characterisation on PS10-siRNA polyplex is 
performed by using electrophoresis and dynamic light scattering. The aim is to confirm 
the successful formation of polyplex and confirm its hydrodynamic diameter and zeta 
potential. Another objective was to confirm if there is any variance between the PS10-
siRNA polyplex to PS10-dsDNA polyplex. The electrophoresis result is shown in figure 
4.13; free siRNA was used as a negative control, which is not mixed with any polymer 
but with TAE buffer. PS10-siRNA polyplex samples were prepared at an N:P ration of 
10:1. As shown in the figure, the free siRNA lane showed an obvious light band after 
staining and UV visualization while no bands were observed in PS10-siRNA lane. 
These data suggested that successful formation of PS10-siRNA polyplex was achieved 
and the siRNA had been completely condensed to PS10 polymers under the 
experimental conditions. 
 
Figure 4.13 Agarose gel (1.5%) electrophoresis analysis of PS10-siRNA polyplexes. The figure 
colour was reversed to better demonstrate results. The figure is cropped from the original figure. 
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The hydrodynamic diameter and zeta potential of PS10-siRNA polyplex at pH 5.4, 6.4 
and 7.4 were determined by dynamic light scattering. The correlation curves, volume 
and intensity distributions are shown in figure 4.14. The intensity and volume 
distributions confirmed that a single size population of ~150 nm was present in PS10-
siRNA polyplexes solution from pH 5.4 to pH 7.4.  
 
Figure 4.14 The correlation curves, intensity distribution and volume distribution of PS10-siRNA 
polyplexes at pH 5.4-7.4. 
 
The mean size value ±SD and the zeta potential of PS10-siRNA polyplexes at pH 5.4-
7.4 are summarised in table 4.7 and table 4.8, respectively. 
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Table 4.7 Hydrodynamic diameter of PS10-siRNA polyplexes. The data represent mean values ± SD 
(N=3) recorded at the corresponding pH. 
Polyplex pH N/P DH(Intensity distribution ± SD)/nm 
DH(Volume distribution ± 
SD)/nm 
siRNA-PS10 5.4 10:1 147 ± 4 94 ± 6 
siRNA-PS10 6.4 10:1 134 ± 18 79 ± 21 
siRNA-PS10 7.4 10:1 158 ± 44 74 ± 25 
 
Table 4.8 Zeta potential of PS10-siRNA polyplexes. The data represent mean values ± SD (N=3) 
recorded at the corresponding pH. 
Polyplex pH N/P 
Zeta potential 
(mV) Conductivity (mS cm-1) 
siRNA-PS10 5.4 10:1 41.6 ± 2.2 3.62 
siRNA-PS10 6.4 10:1 38.9 ± 1.6 0.44 
siRNA-PS10 7.4 10:1 29.7 ± 1.1 1.33 
 
The size and zeta potential of PS10-siRNA polyplexes are summarised and plotted as a 
function of pH in figure 4.15. The results suggested that PS10-siRNA polyplex has a 
hydrodynamic diameter of ~150 nm by intensity distribution and zeta potential of above 
25mV at pH 5.4, 6.4 and 7.4.  
 
 
Figure 4.15 Size and zeta potential of PS10-siRNA polyplexes at pH 5.4, 6.4 and 7.4. The data 
represent mean values ± SD (N=3). 
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It is evident that the standard deviation and DH would increase as the pH of the solution 
increases, which is an indication of aggregation trends. Another fact is that the zeta 
potential drops as the pH increases, from 41.6 mV to 29.7 mV, possibly due to the 
deprotonation of amine functional groups in PDMAEA polymers.  
4.4. Discussion 
4.4.1. Hydrodynamic Diameter and Zeta Potential of PDMAEA Polymers and its 
Polyplexes 
In this chapter, the hydrodynamic diameter (DH) and zeta potential of PDMAEA 
polymers and its polyplexes, including PDMAEA-dsDNA polyplexes and PS10-siRNA 
polyplexes, is presented. Firstly, the PDMAEA polymers were dissolved in aqueous 
HEPES buffer solution without the addition of any DNA or RNA. The dissolved 
polymer molecules do not remain fully extended in a stationary state; instead they adopt 
various conformations due to the internal rotations that can occur through simple C-C 
bonds and Brownian motion24. Numerous possible conformations can be formed, and 
although these confirmations do not have the same energy, the differences are negligible 
so that the polymers in solution can change from one conformation to another. Due to 
this, polymers dissolved in solution rarely adopt a linear form, rather they form an 
irregular structure known as the random coil (figure 4.16)24.  
 
Figure 4.16 A schematic demonstration of a possible random coil structure of polymers in solution. 
 
The average shape of the polymers with a random coil structure is typically found to be 
spherical, and the size of the spherical shape is affected by many factors such as the 
solvent, temperature and molecular weight of the polymer. For instance, the selection of 
solvent would affect the polymer-solvent interaction. The greater the interaction 
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between solvent and polymer is, the larger will be the hydrodynamic diameter24. In this 
study, the intensity distribution and volume distribution data collected via DLS suggest 
that the PDMAEA polymers dissolved in HEPES solution have a hydrodynamic 
diameter smaller than 10 nm at pH 7.5 and below. One possible explanation is that the 
PDMAEA polymers dissolved in HEPES solution may have adopted the random coil 
structure and formed spherical particles. 
It is evident that the DH and zeta potential of PDMAEA polymers were affected by pH, 
and zeta potential decreases as the pH changes from low to high. As shown in figure 
4.7, as the pH of the solution is adjusted to 8.0, the zeta potential of PDMAEA polymers 
dropped below 20 mV and reached 0 mV at pH 8.5. Correspondingly, the DH of 
PDMAEA polymers remained at ~10 nm while the pH is below 7.5 but increase as the 
pH was adjusted to 8.0 and higher. One possible explanation is that at low pHs, the 
protonated polymers bearing a positive charge provided a repulsive force to prevent the 
formation of large aggregates (figure 4.17).  
 
Figure 4.17 A schematic demonstration of PDMAEA polymers forming large aggregates at pH 8.0 
and above. 
 
At neutral pH and below, PDMAEA polymers, which have abundant amine groups, 
would quickly protonate and become positively charged. Explained by DLVO theory, in 
ionic dispersions, the colloidal stability is affected by two major forces: The Van der 
Waal forces and the electrostatic repulsive forces 25. The balance between the Van der 
Waal forces is an attractive force that would pull particles in solution together, and the 
electrostatic repulsive forces would keep nanoparticles in solution from aggregating. As 
the Van der Waals force is a distance-dependent force, the repulsive forces play an 
important role for charged particles and molecules such as PDMAEA polymers. At low 
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pH, due to the protonation of the polymer molecule, the repulsive force is strong enough 
to keep the balance, and the solution would remain colloidally stable. Once the pH is 
increased above 7.5, the deprotonation would result in a weakened repulsive force 
between molecules and be further overwhelmed by the Van der Waals forces, eventually 
leading to aggregation. This explanation could also be applied to the polyplexes, in the 
study of PS10-siRNA polyplex DH and zeta potential, as pH increases from 5.4 to 7.4, it 
was noticed that the increase of the DH of polyplexes and samples SD corresponds to 
the decrease of the zeta potential of polyplexes. However, the zeta potential was kept at 
above 25 mV at pH 7.4 and below. Therefore no aggregation was observed.  
4.4.2. Formation of PDMAEA-dsDNA Polyplexes and PS10-siRNA Polyplexes.  
A range of N:P ratio from 1:1 to 15:1 was tested for the formation of polyplexes. The 
purpose of designing multiple ratios is to determine the critical polyplex formation N:P 
ratio and compare different PDMAEA polyplexes. In this experiment, for all samples, a 
fixed amount of dsDNA was used to provide a quantified amount of phosphate in the 
preparation of all polyplexes. By changing the N:P ration, it is essentially changing the 
quantity amount of polymers used in the polyplex formation. In such a case, the N:P 
ratio could represent the amount of polymers needed to completely condense with a 
certain amount of dsDNA and siRNA. The lower N:P ratio needed for forming 
polyplexes, the stronger will be the binding ability of the polymer. As presented above, 
the critical polyplex formation ratio for PL10, PS10, PL20 and PS20 is 7:1, 5:1, 5:1 and 
3:1 respectively. The underlying concept of this result is that there is a pattern for the 
formation of PDMAEA polyplexes. Firstly, comparing polymers with the sample 
structure (PL10-PL20, PS10-PS20), it is revealed that polymers with larger molar mass 
tend to require lower N:P ratio to form polyplexes with nucleic acids. Secondly, 
comparing polymers with the same molar mass, it is noticed that star-shaped polymers 
require a lower charge ratio to form polyplex. One possible explanation for the stronger 
binding ability is proposed by Stiriba et al. that an unusually compact (“collapsed”) 
structure, possibly related to branched amphiphiles structure, is responsible for the 
formation of an internal hydrophilic compartment that is capable of condensing with 
guest molecules (figure 4.18)26.  
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Figure 4.18 Schematic figure of the formation of a possible internal hydrophilic compartment in 
star-shaped polymers compared to linear polymers. 
In general, it is concluded that PS10-siRNA polyplex has a DH of ~150nm and zeta 
potential of above 25mV at neutral pH and below, which is consistent with data 
gathered from PDMAEA-dsDNA and studies completed by other researchers27,28. 
4.4.3. Selection of PS10 as a Delivery Vector for the Delivery of siRNA. 
PS10 was selected to condense with siRNA at an N:P ratio of 10:1. The selection of 
PS10 as the vector for the formation of siRNA polyplex was based on the polymer’s 
binding ability and toxicity (discussed in detail in chapter 5). As discussed, star-shaped 
polymers have a better binding ability than linear ones, and as it is presented in chapter 
5, polymers with larger molar mass have higher toxicities compared to the ones with 
lower molar mass. Considering all above, it was decided to select PS10 as the delivery 
vector to form PS10-siRNA polyplex at an N:P ratio of 10 :1 for the silencing of 
COL3α1 gene. The selection of an N:P ratio at 10:1 is based on the facts reported by 
Ketola et al., that complexes formed at high N:P ratio may provide adequate stability in 
the extracellular space29.  
4.5. Conclusion  
The work presented in this chapter described the solution behaviour, including 
hydrodynamic diameter and zeta potential, of PDMAEA polymers and its polyplex. It is 
demonstrated that PDMAEA polymers have a hydrodynamic diameter of ~10 nm and 
with an average zeta potential of above 20 mV at neutral pH and below. Successful 
formation of PDMAEA-dsDNA polyplexes was confirmed by agarose gel 
electrophoresis. The hydrodynamic diameter and zeta potential of PDMAEA-dsDNA 
polyplexes were characterised by dynamic light scattering. The result indicated that the 
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PDMAEA-dsDNA polyplexes had a hydrodynamic diameter between 150 - 180 nm and 
showed zeta potential of above 25 mV. Moreover, it was established that PDMAEA 
polymers with larger molecular weight showed stronger DNA binding capabilities. 
Meanwhile, data also suggested that star-shaped PDMAEA polymers showed stronger 
binding capability compared to the linear ones. Furthermore, PS10 was selected as a 
delivery vector to condense with siRNA, resulting in successful formation of PS10-
siRNA polyplex and confirmed by electrophoresis. The hydrodynamic diameter and 
zeta potential of PS10-siRNA were determined at different pH conditions from 5.4 to 
7.4 by dynamic light scattering. The results suggested that the PS10-siRNA polyplex 
has a hydrodynamic diameter of ~150 nm or smaller diameter and a positive charge of 
29 mV and higher at neutral pH and below. With the successful preparation and 
characterisation of PDMAEA polyplexes, the cytotoxicity profile of PDMAEA and 
PDMAEA polyplexes will be investigated in the next chapter.  
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5. Chapter 5 Cytotoxicity of PDMAEA Polymers and 
PDMAEA Polyplexes 
5.1. Introduction 
RNA interference provides an efficient pathway to silence the expression of a specific 
gene by using small RNA molecules such as siRNA and miRNA, which makes it an 
attractive tool for gene therapy and genetic research. In mammalian cells, the use of 
siRNA is typically accompanied with delivery vectors to overcome biological barriers 
that provide hindrance for siRNA silencing. Although the delivery of siRNA shared 
many of the same intracellular steps as the delivery of DNA, siRNA activity is confined 
within the P-body in the cytoplasm, which does not require the entry into the nucleus. 
However, the delivery of siRNA has proven to be highly challenging, especially in vivo 
1. Thus, it is important to better understand siRNA delivery and develop better delivery 
systems. It is suggested that an effective siRNA delivery system should have properties 
including efficient binding to the cell surface, the capability of being uptaken via 
endocytosis, an endosomal escape mechanism, and the ability to release the siRNA 
cargo into the cytoplasm 2. Also, it is fundamental that the delivery vector should be 
able to condense efficiently with siRNA molecules and should be non-toxic. 
The applications of cationic polymers as drug-delivery agents has been widely studied. 
The use of cationic polymer-DNA/RNA polyplexes in gene therapy are based on the 
hypothesis that the complexes adsorb more effectively to the anionic plasma membrane 
of mammalian cells through electrostatic interactions 3. Studies have also demonstrated 
that cationic delivery systems can be internalised via clathrin-mediated endocytosis and 
can escape from the endosomes via a “proton sponge” pathway 4,5. For gene delivery 
vectors, especially in vivo delivery vectors, toxicity is a critical factor to consider when 
evaluating the potential of a polymer delivery system. As these polyplexes are 
intentionally designed to interact with cells, it is necessary to ensure that these polymer 
vectors are not causing any adverse effects. If a delivery system produces unacceptable 
cytotoxicity, the delivery system will be rendered useless regardless of how efficient the 
system is 6,7,8. Traditional cationic polymer-based systems such as PEI are highly valued 
owing to their high efficiency9,10. Other advantages such as being simple, inexpensive 
and chemically manipulatable are also favoured in a gene delivery system 11. Many 
studies have been done using PEI as a delivery vector. Jiang et al. reported the use of 
DNA-PEI polyplexes encoding green fluorescent protein (GFP) to deliver into tumour 
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cells in six-week-old female C57/BL6 mice and achieved higher levels of GFP 
expression 12. Another study by Peng et al. reported plasmid DNA encoding VEGF165 
gene delivered to epidermal stem cells using PEI-pDNA polyplexes for the treatment of 
wound healing 13. Many more studies on the use of PEI as a gene delivery vector for a 
variety of diseases have been summarised by Di Gioia et al. and others14,15. With the 
development in the field of chemistry and polymer synthesis, several novel cationic 
polymer-based delivery systems have been synthesised and applied in siRNA delivery.  
In recent years, many novel cationic polymer-based delivery systems with lower 
toxicity levels have been widely studied. Some have focused on the modification of PEI 
into blocker polymers, Merkel et al. reporting that PEG−PEI polyplexes with low 
toxicity were used in siRNA Delivery to the lung in vivo 16. Other studies reported the 
use of novel cationic polymers, such as PDMAEA, in the delivery of siRNA. 
Convertine et al. suggested that PDMAEMA-PAA-BMA di-block copolymer is an 
effective and low cytotoxicity nanocarrier in the siRNA knockdown in HeLa cell 17. 
Another study by Benoit showed a PDMAEMA-butyl methacrylate (pDbB) copolymer 
with low toxicity was applied in the siRNA knockdown of polo-like kinase 1 (plk1) 
gene18.  
PDMAEA polymers have received significant attention for their potential in gene 
delivery in recent years. The success of developing new pH-sensitive star-shaped 
polymer systems using PDMAEA as the pH-responsive blocks has been reported by Liu 
et al. 19. Furthermore, the cytotoxicity profile of a series of PDMAEA polyplexes with 
N:P ratio ranging from 10 to 200 was determined on HeLa cells by Truong et al. It is 
reported that at low N:P ratio such as 10:1, PDMAEA polyplexes showed no toxicity 20. 
However, there is a lack of detailed reports regarding the cytotoxicity of PDMAEA and 
its polyplexes in equine tenocytes. 
In addition, the influence of structure and molecular weight on polymer chemical and 
physical behaviour has been reported 21,22. Research by Fischer et al. and Monnery et al. 
suggested that the molecular weights of polymers have a direct influence on the 
cytotoxicity level of polymers 23,24. On the other hand, another research study by Fischer 
et al. indicated that polymer structure has a vital role in the determination of polymer 
cytotoxicity25. However, there is a lack of detailed reports on the influence that 
molecular weight and structure might have on PDMAEA toxicity. Therefore, the 
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cytotoxicity of PDMAEA polymers with different structures and the molecular weights 
was determined and compared in this Chapter.  
In this study, the cytotoxicity profile of PDMAEA polymers and their polyplexes were 
determined. The 3T3 mouse fibroblast was selected as a model cell line for its easy 
manipulation and stable growth rate and 3T3 mouse fibroblast has been widely applied 
in the studies of polymer cytotoxicity as a model cell line 26-28. The cytotoxicity of 
PDAMEA polymers was first tested on 3T3 mouse fibroblasts to provide a preliminary 
report of PDMAEA behaviour. Also, the 3T3 mouse fibroblast contributed to the 
establishment and optimization of experimental conditions. Based on the results 
gathered from cytotoxicity experiments on 3T3 mouse fibroblast, the cytotoxicity of 
PDMAEA polymers was evaluated on equine tenocyte by using an MTS assay.  
Due to the limited availability of COL3α1 gene-specific siRNA, a dsDNA with a short 
base pair similar to siRNA was employed as a model molecule for the study and 
optimization of PDMAEA polyplex formulation. PDMAEA-dsDNA polyplexes were 
first tested for their cytotoxicity to provide a preliminary view of polyplex cytotoxicity. 
Considering the balance of binding capability and cytotoxicity, as well as the limited 
availability of COL3α1 gene-specific siRNA, PS10 was selected as the candidate vector 
polymer to condense with siRNA and was further used in the transfection of equine 
tenocyte. Considering that MTS assay is a metabolic assay based on the metabolizing of 
MTS to formazan compounds, it directly measures the metabolic activity of sample 
cells, rather than cell apoptosis. The same argument was raised by Moghimi et al., who 
suggested that the use of metabolic assay such as MTS are not indicative of apoptosis 29. 
This leads to a possibility that the reduction in viability might not be a result of the 
toxicity of PDMAEA polymers, but a result of suppressed in cell metabolic activity. 
Therefore, the Cyquant Cell Proliferation assay, which is based on live cell nucleus 
staining fluorescence, was introduced to address this issue.  
PEI was selected as a reference for its reputation as an efficient delivery vector, and it’s 
been widely used as a delivery system in other studies. However, literature reported that 
although PEI showed excellent transfection efficiency, its severe toxicity has created 
barriers in its application9,15,30-32. By using PEI as a reference treatment group, the aim 
was to compare the toxicity of PDMAEA and PEI directly.  
Aim of the chapter: 
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The aim of this chapter is to determine the cytotoxicity of PDMAEA and its polyplexes 
on equine tenocytes. The cytotoxicity of PDMAEA polymers and its polyplexes were 
determined by the use of MTS assay and Cyquant Cell Proliferation Assay. The 
influence of polymer concentration and incubation time on cell viability after treatment 
was also determined, as well as the influence of polymer molecular weight and structure 
on polymer cytotoxicity. 
The main objectives: 
 Study the cytotoxicity profile of PDMAEA polymers under a series of 
concentrations and incubation times using 3T3 mouse fibroblast as model cell line 
and MTS assay. 
 Study the cytotoxicity profile of PDMAEA polymers on equine tenocytes over 
different polymer concentrations and incubation time using MTS assay. 
 Determine the cytotoxicity of PDMAEA (PL10, PL20, PS10, PS20)-dsDNA 
polyplexes and PS10-siRNA polyplexes on equine tenocytes using MTS assay and 
cell proliferation assay.  
 Analyse how the polymer structure, polymer molecular weight, polymer 
concentration and incubation time affect the cell viability post-treatment. 
 
5.2. Materials and Methods 
5.2.1. Materials 
The details of the materials used in this chapter are reported in chapter two section 2.2. 
5.2.2. Cytotoxicity of PDMAEA Polymers on Mouse Fibroblast and Equine 
Tenocytes by MTS Assay 
The cytotoxicity of PDMAEA polymer on mouse 3T3 fibroblasts (passage 14) and 
equine tenocytes (Passage 7) were determined by using the MTS assay. The basic 
principle and experimental conditions of general tissue culture and the use of MTS 
assay are reported in detail in chapter two. In each well of a 96-well plate, 10,000 cells 
(for both mouse fibroblast and equine tenocytes) were seeded in 100 μL of medium and 
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incubated for three hours before treatment for cell attachment. The treatment solution 
was made of PDMAEA polymers at different concentrations (2.5, 5, 10, 15, 20, 25, 30 
and 50 μΜ). Three time-points were designed at 24, 48 and 72 hours to determine the 
effect over time. At every time-point, 10 μL of MTS was added into each well and 
incubated for one hour before reading at a wavelength of 490 nm with an Omega Plate 
reader. All the data were normalised to cells treated only with medium and analysed 
with BMG data software. 
5.2.3. Cytotoxicity of PDMAEA Polyplexes on Equine Tenocytes Determined by 
MTS Assay 
The cytotoxicity of PDMAEA polyplexes on equine tenocytes was determined by using 
the MTS assay. PDMAEA-dsDNA polyplexes and PS10-siRNA polyplexes were 
prepared at an N:P ratio of 10:1 as described in chapter four. Considering the balance 
between binding capability and cytotoxicity, PS10 was selected to condense with 
COL3α1 gene-specific siRNA to form PS10-siRNA polyplex. The principle of MTS 
assay and experimental conditions are described in detail in chapter two. In each well of 
a 96-well plate, 10,000 cells (for both mouse fibroblast and equine tenocytes) were 
seeded in 100 μL of medium and incubated for three hours before treatment for cell 
attachment. The treatment solution was PDMAEA-dsDNA polyplex or PS10-siRNA 
polyplex solution at different concentration (2.5, 5, 10, 15, 20, 25, 30 and 50 μΜ 
calculated based on polymer content). Three time-points were designed at 24, 48 and 72 
hours to determine the effect over time. At every time-point, 10 μL of MTS was added 
into each well and incubated for one hour before reading at a wavelength of 490nm with 
an Omega Plate reader. All the data were normalised to cells treated with medium and 
analysed with BMG data software provided before being presented.  
5.2.4. Cytotoxicity of PS10-siRNA Polyplexes on Equine Tenocytes Determined 
using Cyquant NF Cell Proliferation Assay 
PS10-siRNA polyplexes were prepared as described in chapter four at an N:P ratio of 
10:1. The basic principle of Cyquant NF cell proliferation assay and experimental 
conditions were described in detail in chapter two. A calibration curve was first made to 
obtain the optimal seeding density. In each well of a Corning® 96 Well Black 
polystyrene microplate, 2,500 cells were seeded in 100 μL of medium and incubated for 
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three hours to allow cell attachment. The treatment solution was PS10-siRNA 
polyplexes solution at different concentrations (2.5, 5, 10, 15, 20, 25, 30 and 50 μΜ 
calculated based on polymer content). Three time-points were designed at 24, 48 and 72 
hours to determine the effect over time. At every time-point, growth medium was 
removed, and 100 μL of 1X dye binding solution was dispensed into each microplate 
well. The plate was then incubated in the dark for 45 minutes before measuring the 
fluorescence intensity of each sample using a fluorescence microplate reader. All the 
data were normalised to cells treated with medium only and analysed with BMG data 
software provided before being presented. 
5.3. Results 
5.3.1. Cytotoxicity of PDMAEA Polymers on 3T3 Mouse Fibroblast Cells 
Determined by MTS assay 
The cytotoxicity of PDMAEA polymer was evaluated on 3T3 mouse fibroblasts by 
using MTS assay. The metabolic activity at 24-hour post-treatment are demonstrated in 
figure 5.1. The metabolic activity of all samples were normalised to cells treated with 
medium. As shown in figure 5.1 (A), polymers of 10kDa molecular weight (PL10 and 
PS10) showed high metabolic activity (of above 95%) across different concentrations, 
whereas polymers of 20kDa molecular weight (PL20 and PS20) showed decreased 
metabolic activity, especially PS20. For cells treated with PL20, with concentrations of 
15 μM and above, samples started to show consecutive decreases in metabolic activity 
over increased concentration at 24 hours post-treatment. The same trend was observed 
in PS20 as well but with a much more significant decrease in metabolic activity. Cells 
treated with PEI showed a much more severe reduction in viability, with an average of 
43.5% across all concentrations. Variation between PEI and PDMAEA polymers were 
analysed with two-way ANOVA and are shown in figure 5.1 (B). It is demonstrated that 
all PDMAEA treated sample groups showed significantly higher viability compared to 
PEI treated samples. As shown in figure 5.1 (C), it is also demonstrated by the 
comparison of viability between each polymer at 24 hours post-treatment. The data 
indicate that there is no significant difference between PS10-PL10 (when comparing the 
structural effect) and PL10-PL20 (when comparing the molecular weight’s effect). 
However, when comparing the PS20 group to PL20 (structural effect) and PS10 
(molecular weight’s effect), the results showed significant differences. The results from 
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24 hours post-treatment can be considered as an indicator of PDMAEA polymer’s acute 
cytotoxicity. However, it is reported that for certain polymers, delayed cytotoxicity 
following treatment is commonly observed 23,33. Also, in some cases, the transfection 
process may be followed by a long period of incubation. Thus, the cytotoxicity effect of 
PDMAEA polymer was further monitored at 48- and 72-hours post-treatment.  
 
Figure 5.1 Mouse 3T3 fibroblast metabolic activities at 24 hours post-treatment. Samples were 
treated with PDMAEA polymer solutions at different concentrations, and metabolic activities were 
determined using MTS assay. All the results were normalised against cells treated with complete 
medium. The data represent mean values ± SD, N=3 (technical replicates). A) Metabolic activity-
concentration relationship of sample cells treated with PDMAEA polymers solutions at the 24-hour 
time point. B) Statistical analysis between PDMAEA polymers and PEI. 3) Statistical analysis 
among four PDMAEA polymers groups (two-way ANOVA, ns: p>0.05, *: 0.05>p>0.01, **: 
0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). 
 
Figure 5.2 demonstrated the metabolic activity at 48 hours post-treatment. The results 
indicated that cells treated with PL10 and PS10 showed high viability, which is 
consistent with data collected at 24 hours post-treatment. Interestingly, cells treated with 
PL20 and PS20 showed a significant decrease in metabolic activity at 48 hours 
compared with the results from the 24 hours group. For PS20 and PL20 treated samples, 
metabolic activity dropped to 70% and below, even at 2.5μM (being the lowest designed 
concentration). While comparing all polymers groups to PEI treated group, all samples 
showed significantly higher metabolic activity than PEI treated group. Comparison 
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between the metabolic activity of samples treated with PL10 and PS10 indicated that 
between PL10 and PS10 there is no significant difference. While comparing samples 
treated with PS10 and PS20, or PL10 and PL20, it was found that groups with high 
molar mass tend to have lower metabolic activity. Besides, the variance between PL20 
and PS20 had decreased in the 48-hour group, probably due to the reduction of viability 
in PL20 treated samples. 
 
Figure 5.2 Mouse 3T3 fibroblast metabolic activities at 48 hours post-treatment. Samples were 
treated with PDMAEA polymer solutions at different concentrations, and metabolic activities were 
determined using MTS assay. All the results were normalised against cells treated with complete 
medium. The data represent mean values ± SD, N=3 (technical replicates). A) Metabolic activity-
concentration relationship of sample cells treated with PDMAEA polymers solutions at the 48-hour 
time point. B) Statistical analysis between PDMAEA polymers and PEI. 3) Statistical analysis 
among four PDMAEA polymers groups (two-way ANOVA, ns: p>0.05, *: 0.05>p>0.01, **: 
0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). 
 
Data collected from samples at 72 hours post-treatment group are shown in figure 5.3. 
Results suggested that the major trend is consistent with results from 24- and 48-hour 
timeframes. Cells treated with PL10 and PS10 remained at high metabolic activity while 
cells treated with PS20 and PL20 showed comparatively lower viability. Comparing all 
polymer groups to the PEI-treated group, all PDMAEA-treated groups showed higher 
metabolic activity. Comparing between PDMAEA polymer treated groups, the PS20 
treated group showed much lower viability compared to other groups.  
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Figure 5.3 Mouse 3T3 fibroblast metabolic activities at 72 hours post-treatment. Samples were 
treated with PDMAEA polymer solutions at different concentrations, and metabolic activities were 
determined using MTS assay. All the results were normalised against cells treated with complete 
medium. The data represent mean values ± SD, N=3 (technical replicates). A) Metabolic activity-
concentration relationship of sample cells treated with PDMAEA polymers solutions at the 72-hour 
time point. B) Statistical analysis between PDMAEA polymers and PEI. 3) Statistical analysis 
among four PDMAEA polymers groups (two-way ANOVA, ns: p>0.05, *: 0.05>p>0.01, **: 
0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). 
 
The morphology of most cells treated with PDMAEA solutions showed typical healthy 
morphologies, with except those cells treated with PEI across all concentrations and 
cells treated with high concentration solutions of PS20 and PL20. In these groups, most 
of the cells changed their morphologies, cells becoming rounded, and lysed cells being 
visible, along with squibs and cell debris. 
5.3.2. Cytotoxicity of PDMAEA Polymers on Equine Tenocytes by using MTS 
Assay 
The cytotoxicity of PDMAEA polymers on equine tenocytes was determined by using 
the MTS assay. Cultured equine tenocytes were treated with PDMAEA polymer 
solution of different concentrations over 24, 48 and 72 hours. PEI solution was 
employed as positive control. Results at 24 hours post-treatment are illustrated in figure 
5.4. It is shown that all PDMAEA polymer treated sample showed high metabolic 
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activity except for PL20 at a concentration of 50μM, while PEI treated samples showed 
comparatively lower viability as demonstrated in figure 5.4 (A). Statistical analysis on 
the metabolic activity further suggested that all PDMAEA treated samples showed a 
higher level of viability compared to PEI treated the group as presented in figure 5.4 
(B). Figure 5.4 (C) exhibited the comparison between PS10 and PL10, or PL10 and 
PL20, and the results suggested that there are no significant differences between 
polymers of the same molecular weight with a different structure. However, the 
comparison between PS20 and PS10, or PS20 and PL20, indicated a variance of 
different degree, possibly due to the high viability of PS20 group. The morphology of 
all equine tenocyte cells treated with PDMAEA solutions showed typical healthy 
morphologies at 24 hours, with except those cells treated with PEI solutions. 
 
Figure 5.4 Equine tenocyte metabolic activities at 24 hours post-treatment. Samples were treated 
with PDMAEA polymer solutions at different concentrations, and metabolic activities were 
determined using MTS assay. All the results were normalised against cells treated with complete 
medium. The data represent mean values ± SD, N=3 (technical replicates). A) Metabolic activity-
concentration relationship of sample cells treated with PDMAEA polymers solutions at the 24-hour 
time point. B) Statistical analysis between PDMAEA polymers and PEI. 3) Statistical analysis 
among four PDMAEA polymers groups (Two-way ANOVA, ns: p>0.05, *: 0.05>p>0.01, **: 
0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). 
 
At 48 hours post-treatment, samples showed reduced levels of metabolic activities, 
especially at high concentrations (30-50 μM). A similar reduction was observed on 3T3 
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fibroblast cells at 48 hours as well. As in the previous timeframe, all PDMAEA treated 
samples showed a significant difference in viability compared to PEI treated samples. In 
addition, statistical analysis of the data from PS10 treated group and PL10 treated group 
indicated that there is no significant difference between the viability. However, the 
comparison between PS10 - PS20, PL10 - PL20 and PS20 – PL20 showed differences 
by statistical analysis. The morphology of all equine tenocyte cells treated with 
PDMAEA solutions showed typical healthy morphologies. 
 
Figure 5.5 Equine tenocyte metabolic activities at 48 hours post-treatment. Samples were treated 
with PDMAEA polymer solutions at different concentrations, and metabolic activities were 
determined using MTS assay. All the results were normalised against cells treated with complete 
medium. The data represent mean values ± SD, N=3 (technical replicates). A) Metabolic activity-
concentration relationship of sample cells treated with PDMAEA polymers solutions at the 48-hour 
time point. B) Statistical analysis between PDMAEA polymers and PEI. 3) Statistical analysis 
among four PDMAEA polymers groups (Two-way ANOVA, ns: p>0.05, *: 0.05>p>0.01, **: 
0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). 
 
At 72 hours post-treatment, an uprise in metabolic activity levels across all PDMAEA 
samples at all concentrations were observed. In most of the concentrations, the 
metabolic activity is of the same level as cells treated with medium, while in some 
concentrations, such as 2.5, 5, and 10 μM in PS10 and PL10 treated groups, the sample 
viability was at ~130% or even higher (figure 5.6 (A)). Samples treated with PEI still 
showed the comparatively low level of viability, consistent with previous timeframes. A 
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significant difference in viability between PEI and PDMAEA treated samples was also 
observed (figure 5.6 (B)). Comparing PDMAEA samples, the difference in viability is 
significant between PS20 and PS10, and also between PL20 and PL10 (figure 5.6 C). 
The morphology of equine tenocyte cells treated with PEI solutions became rounded, 
and lysed cells being visible, along with squibs and cell debris. 
 
Figure 5.6 Equine tenocyte metabolic activities at 72 hours post-treatment. Samples were treated 
with PDMAEA polymer solutions at different concentrations, and metabolic activities were 
determined using MTS assay. All the results were normalised against cells treated with complete 
medium. The data represent mean values ± SD, N=3 (technical replicates). A) Metabolic activity-
concentration relationship of sample cells treated with PDMAEA polymers solutions at the 72-hour 
time point. B) Statistical analysis between PDMAEA polymers and PEI. 3) Statistical analysis 
among four PDMAEA polymers groups (Two-way ANOVA, ns: p>0.05, *: 0.05>p>0.01, **: 
0.01>p>0.005, ***: 0.005>p>0.001, ****: 0.001>p). 
 
 
5.3.3. Cytotoxicity of PDMAEA-dsDNA Polyplexes on Equine Tenocyte using 
MTS Assay 
Cytotoxicity of PDMAEA-dsDNA polyplexes on equine tenocytes was determined by 
using the MTS assay. Figure 5.7 demonstrates the viability of tenocytes treated with 
PDMAEA polymers at 24 hours post-treatment. The results indicate that cells treated 
with PS10 and PL10 PDMAEA-DNA polyplexes showed high metabolic activity in all 
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concentrations, while cells treated with PS20 and PL20 PDMAEA-dsDNA polyplexes 
showed high viability only in low concentrations (2.5-20 μM). As the concentration 
increased to 50 μM, viability dropped rapidly. Furthermore, polyplexes with high 
molecular weights showed higher toxicity at higher concentration. For instance, PS20-
dsDNA polyplex treated group showed the viability of below 30% at 25, 30 and 50 μM, 
while PL20 polymers treated groups showed the viability of below 30% at 50 μM. 
 
Figure 5.7 Equine tenocyte metabolic activities at 24 hours post-treatment. Samples were treated 
with PDMAEA-DNA polyplex solutions at different concentrations (based on polymer content), and 
metabolic activity was determined using MTS assay. All the results were normalised against cells 
treated with complete medium. The data represent mean values ± SD, N=3 (technical replicates). 
Left: the metabolic activity of cells treated with PS10 and PL10 PDMAEA. Right: the metabolic 
activity of cells treated with PS20 and PL20 PDMAEA. 
 
At 48 post-treatment, cells treated with PS10-DNA polyplexes and PL10-DNA 
polyplexes exhibited high levels of metabolic activity (figure 5.8 left). However, cells 
treated with PS20 and PL20 polyplexes showed relatively lower viability. Both PS20 
and PL20 polyplexes treated group showed viability levels of below 50% at 50 μM.   
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Figure 5.8 Equine tenocyte metabolic activities at 48 hours post-treatment. Samples were treated 
with PDMAEA-DNA polyplex solutions at different concentrations (based on polymer content), and 
metabolic activity was determined using MTS assay. All the results were normalised against cells 
treated with complete medium. The data represent mean values ± SD, N=3 (technical replicates). 
Left: the metabolic activity of cells treated with PS10 and PL10 PDMAEA. Right: the metabolic 
activity of cells treated with PS20 and PL20 PDMAEA. 
 
At 72 hours post-treatment, samples treated with PS10 and PL10 polyplexes showed a 
viability level similar to cells treated with medium for most of the concentrations, 
except for 20, 25 and 50 μM, which had a slightly lower viability level.  
 
Figure 5.9 Equine tenocyte metabolic activity at 72 hours post-treatment. Samples were treated 
with PDMAEA-DNA polyplex solutions at different concentrations (based on polymer content), and 
metabolic activity was determined using MTS assay. All the results were normalised against cells 
treated with complete medium. The data represent mean values ± SD, N=3 (technical replicates). 
Left: the metabolic activity of cells treated with PS10 and PL10 PDMAEA. Right: the metabolic 
activity of cells treated with PS20 and PL20 PDMAEA. 
5.3.4. Cytotoxicity of PS10-siRNA Polyplexes on Equine Tenocyte Cells 
PS10 was selected as a vector to condense with therapeutic siRNA to form polyplex 
used to transfect equine tenocyte, hence it is essential to determine the toxicity of PS10-
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siRNA polyplexes. It is well established that the MTS assay measures the metabolic 
activity, and it is possible that the viability change is not caused by actual cell death but 
suppressed metabolic activity. To address this problem, the Cyquant Cell Proliferation 
assay, which is based on cell nucleus staining, was selected as a supplementary method. 
PS10-siRNA polyplex was prepared and characterised as described in chapter four. 
Cells were treated with PS10-siRNA polyplex solution of various concentration from 
2.5-50 μM and their metabolic activity was monitored and recorded at three different 
timeframes.  
Firstly, the cytotoxicity of PS10-siRNA on equine tenocyte cells was determined using 
the MTS assay and results are shown in figure 5.10. At 24 hours post-treatment, all 
experimental samples showed high levels of metabolic activity (of above 90%) (figure 
5.10 (A)). At 48 hours post-treatment, samples at specific concentrations, such as 2.5 
and 10 μM, showed a short-lived reduction in viability (figure 5.10 (B)). Nevertheless, 
at 72 hours post-treatment, viability in all samples increased to a normal level and were 
maintained at a metabolic activity of above 90% (figure 5.10 (C)).  
 
Figure 5.10 Equine tenocyte metabolic activities post-treatment. Samples were treated with PS10-
siRNA polyplex solutions at different concentrations (based on polymer content), and metabolic 
activity was determined using MTS assay. All the results were normalised against cells treated with 
complete medium. The data represent mean values ± SD, N=3 (technical replicates). A) viability at 
24 hours post-treatment B) viability at 48 hours post-treatment C) viability at 72 hours post-
treatment.  
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Secondly, the cytotoxicity of PS10-siRNA on equine tenocyte was determined using the 
Cyquant Cell Proliferation assay, and the results are shown in figure 5.11. The data 
suggest that at 24 hours post-treatment, all sample groups showed moderate viability of 
about 50% compared to cells treated with medium except for samples at 2.5 μM which 
showed higher viability around 90%. Furthermore, it is observed that viability decreases 
as PS10-siRNA concentration increases. However, at 48 hours, an increase of viability 
across all concentrations was observed, with samples treated with 5 μM PS10-siRNA 
polyplexes reaching 150%. Viability data at 72 hours post-treatment shared a similarity 
with data from 48 hours.  
 
 
Figure 5.11 Equine tenocyte metabolic activity post-treatment. Samples were treated with PS10-
siRNA polyplex solutions at different concentrations (based on polymer content), and metabolic 
activity was determined using Cyquant Cell Proliferation assay. All the results were normalised 
against cells treated with complete medium. The data represent mean values ± SD, N=3 (technical 
replicates). A) viability at 24 hours post-treatment B) viability at 48 hours post-treatment C) 
viability at 72 hours post-treatment. 
5.4. Discussion 
5.4.1. PDMAEA Cytotoxicity on 3T3 Mouse Fibroblast and Equine Tenocyte 
The results presented in figure 5.1 – 5.6 indicated that PL10 and PS10 showed 
extremely low cytotoxicity in both cultured 3T3 mouse fibroblast and equine tenocyte 
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samples. It is demonstrated that cells treated with PS10 and PL10 showed a similar level 
of viability compared to cells treated with medium across all timeframes and 
concentrations. However, for PL20 and PS20, the situation is more complicated. As 
shown in figure 5.1, 3T3 mouse fibroblast samples treated with PL20 showed similar or 
slightly lower metabolic activity levels compared with cells treated with medium, 
whereas the viability of PS20 treated group decreases dramatically as the concentration 
of PS20 solution exceeds 20 μM. At 48- and 72-hour post-treatment, as shown in figure 
5.2 and 5.3, all 3T3 mouse fibroblast samples treated with PL20 and PS20 solutions 
showed a reduction in viability compared with 24-hour group.  
In addition, the cell morphology of most cells treated with PDMAEA solutions showed 
typical healthy morphologies, being long spindle-like shapes, with exceptions of those 
cells treated with PEI across all concentrations and timeframes and 3T3 mouse 
fibroblast cells treated with high concentration solutions of PL20 and PS20. In these 
groups, most of the cells changed their morphologies, cells becoming rounded, and 
lysed cells being visible, along with squibs and cell debris. This might suggest that in 
PEI treated groups and samples treated with high concentration PL20 and PS20 
solutions, metabolic activity suppression and cell death might have occurred at the same 
time. 
Summarising the finding, it is evident that PS10 and PL10 polymers showed extremely 
low or no cytotoxicity across all concentrations at different time points whereas the 
cytotoxicity of PL20 and PS20 is concentration and time-dependent.  
5.4.2. The Influence of Molecular Weight and Structure on PDMAEA 
Cytotoxicity 
One of the objectives in this study is to determine whether polymer structure and 
molecular weight can affect its cytotoxicity. Therefore, PDMAEA polymers of different 
structures and molecular weights were designed and synthesised. While comparing 
polymer with the same molecular weight but with different structures across different 
timeframes on various cell lines, it is demonstrated that for polymers with low 
molecular weight level (10kDa), there is no significant variation between linear and 
star-shaped PDMAEA, as statistics indicate in figure 5.1~5.6. However, star-shape 
PDMAEA polymers with a higher molecular weight (20kDa) showed slightly higher 
toxicity than linear ones in studies conducted with 3T3 mouse fibroblast. Though this 
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difference between linear and star-shaped at the high molecular weight was not 
observed in studies conducted in equine tenocyte samples at any timeframe. The 
underlying explanation of such difference could be related to the difference in biological 
properties between 3T3 mouse fibroblast and equine tenocyte cells, but the detailed 
mechanism remains unclear. One possible explanation is that the difference in metabolic 
activity level between mouse 3T3 fibroblast and equine tenocytes are responsible. 
Though no study on the direct comparison of the metabolic activity between mouse 3T3 
fibroblasts and equine tenocytes has been conducted, it is reported by Zhang and his 
colleagues that fibroblasts have a higher activity level compared to tenocytes under the 
same culturing conditions 34. The difference between the suppressive effect of PL20 and 
PS20 cells may be subtle in cell lines with a low metabolic activity, yet the difference 
could be amplified in cell lines with a higher metabolic activity. Therefore, the observed 
variance between tenocytes treated with PL20 and PS20 are less obvious compared to 
the results from mouse 3T3 fibroblasts.  
The influence of molecular weight on the toxicity of PDMAEA could be determined by 
comparing the viability data of polymers with the same structure but different molecular 
weight. Combining all the information gathered from figure 5.1~5.6, it is shown that 
molecular weight has a more direct effect on PDMAEA polymers. Polymers with larger 
molecular weights are found to have a higher level of cytotoxicity. As demonstrated in 
figure 5.1~5.6, PS20 treated group have significantly lower viability compared to PS10 
treated groups across all timeframes on two different cell lines. Similarly, although 
PL20 treated groups showed the same level of viability at 24 hours timeframes 
compared to PL10 treated groups, data collected at 48- and 72-hours timeframes 
indicated the difference in viability between PL20 and PL10. Therefore, it is concluded 
that for PDMAEA polymer, the cytotoxicity is proportional to its molecular weight. 
Similar results were reported by Cai et al., as they observed a cytotoxicity increase with 
the chain length in PDMAEMA polymers 35. Another work conducted by Monnery and 
his co-workers reported the relationship of toxicity and molar mass in detail also 
mentioned molecular weights of a polymer could influence the cytotoxicity 23,24. It is 
suggested that the cytotoxicity of cationic polymers is the result of a combination of the 
disruptive effect to the cellular membrane and damages to cellular organelles including 
mitochondria and endosomes35,21. The relationship between increasing cytotoxicity and 
high molecular weight can be explained by the fact that polymers with longer chains can 
interact with negatively charged proteins and membranes more effectively in the 
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intracellular space than short ones, due to a relatively less entropic loss from the pure 
thermodynamic point of view35. That is to say, the influence of molecular weight on the 
membrane-damaging potential and, subsequently, on the metabolic activity of cells are 
possibly the result of a more efficient interaction capability of cationic molecules with 
plasma membranes, and increases with increasing molecular weight, due to multiple 
attachments to cell surfaces36. 
To summarise, it is determined by data collected from this study for PDMAEA polymer, 
that the cytotoxicity is proportional to its molecular weight, whereas linear PDMAEA 
polymer showed lower cytotoxicity at higher molecular weight levels compared to star-
shaped ones. However, only two different levels of molecular weight and two different 
structures were selected to contribute to this study, and such a small sample size would 
only support the phenomenon observed between linear and star-shaped PDMAEA. 
Further investigation with a much larger sample size including a broader range of 
different molecular weight, structure and cationic polymers types are required to fully 
determine the relationship of how molar mass and structure would affect polymer 
cytotoxicity. 
5.4.3. Cytotoxicity of PDMAEA Polyplexes in Equine Tenocytes by MTS Assay 
As described in chapter four, PDMAEA-DNA polyplexes were prepared using 
PDMAEA polymers and dsDNA. The PDMAEA-dsDNA polyplexes were reported to 
have a particle size of ~150nm and a surface charge of 40 mV. It is well established that 
the toxicity of polyplexes largely depends on the toxicity of polymer materials, yet some 
recent studies announced that properties of polyplexes such as charge ration, particle 
size and zeta-potential would affect the toxicity of polyplexes as well37,38. Chapter four 
presented the formulation and properties of PDMAEA-dsDNA polyplexes. In this 
chapter, cytotoxicity of PDMAEA polyplexes on equine tenocyte cells was determined 
by MTS assay.  
All PDMAEA-dsDNA polyplexes were prepared at N:P ratios of 10:1 with desired 
concentrations based on their polymer content. Comparing data from all three 
timeframes, it is concluded that at all timeframes, PS10 and PL10 polyplexes showed no 
or minimum level of cytotoxicity. It is noticeable that at high concentration (25-50 μM), 
cells treated with PS20 and PL20 polyplexes showed reduced metabolic activity, 
especially PS20-dsDNA treated group (viability below 25%). It is suggested that the 
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particle size and zeta potential would influence polyplex toxicity, for they may affect 
polyplex stability. Low zeta potential may lead to aggregation of polyplexes due to the 
lack of repulsive forces against attraction forces and results in the formation of 
aggregated large particles and precipitant. The precipitant and large aggregates may 
interact and attach to the cell surface to form a blockage that prevents the effective 
delivery of nutrients and oxygen to cells, which thus leads to suppressed cellular 
activity and cell death39. It is also reported that polyplexes bearing high positive charges 
can either directly or by the detachment of readily adsorbed polymers cause membrane 
damage40. Furthermore, Shao et al. have shown in their publication that nanoparticles 
with high positive zeta potentials caused significantly higher cytotoxic effects than 
those with lower positive or negative zeta potentials 41. The underlying concept might 
be that though high positive zeta potential can provide a polyplex solution with good 
stability, it might also be responsible for high cytotoxicity due to the membrane 
disruption effect.  
To summarise, results indicated that PDMAEA-dsDNA polyplexes showed low 
cytotoxicity at low concentration (below 20 μM based on polymer content). This may 
provide vital information for the selection of optimal polyplex concentration for 
transfection studies. In fact, the siRNA concentration in transfection study is designed at 
50 nM, and the working polyplex concentration in transfection is approximately 0.3 μM 
(with PS10 polymers at a charge ratio of 10:1), which is lower than the lowest 
concentration (2.5 μM) presented in this chapter and should not cause any toxicity 
effect. 
5.4.4. Cytotoxicity of PS10-siRNA polyplex in Equine Tenocytes by using MTS 
and Cyquant Assays 
Work presented in this chapter has employed MTS assay as the primary approach for 
the determination of cellular viability. MTS assay is a metabolic assay based on the 
metabolizing of MTS to formazan compounds. In other words, the MTS assay directly 
measures the metabolic activity of sample cells, rather than cell apoptosis. The same 
argument was raised by Moghimi et al., who suggested that the use of metabolic assay 
such as MTS are not indicative of apoptosis29. This leads to a possibility that the 
reduction in viability might not be a result of toxicity of PDMAEA polymers, but a 
result of suppressed in cell metabolic activity. That could be one reason why in some 
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cases, the observed viability level is above 100% as indicated in figure 5.1~ 5.6. It is 
observed that in some polymer treated samples, metabolic activity would increase as the 
polymer concentration increases to a certain point. Beyond this point, viability would 
start to decrease as the concentration increases. For example, PEI treated samples 
showed a low level of viability at 2.5 μM but increases as polymer concentration 
increased, peaking at 15 μM. Beyond this concentration, sample viability reduced as 
concentration further increases. Furthermore, equine tenocytes treated with 10 μM PL10 
and PS10 solutions also showed higher metabolic activity compared to samples treated 
with 5 μM PL10 and PS10 solutions, and in some cases, for example, equine tenocytes 
treated with PL20-dsDNA polyplexes at 24 hours post-treatment showed activity values 
in excess of 100% (normalised to cells treated with medium). This could possibly be 
explained by the higher exposure concentrations provoking greater mitochondrial 
activity, which has been suggested to be involved in the reduction of MTT and MTS 
compounds into formazan products42. However, increased polymer concentration 
provoking the mitochondrial activity cannot explain the low metabolic activity in 
samples treated with low concentrations of PEI, as shown in figure 5.1 – 5.6, for studies 
conducted by other researchers reported that at low concentrations PEI of different 
molecular weight and structure showed low toxicity in various cell lines 33,43. The low 
metabolic activity in samples treated with low concentration PEI solution might be due 
to a technical error in the preparation of PEI sample solutions that resulted in a higher 
final concentration than the designed value.  
To address the issue that MTS assay measures the metabolic activity rather than cell 
death, the Cyquant Cell Proliferation assay, which is based on live cell nucleus staining 
fluorescence, was introduced. Due to the biological changes in apoptosis cell including 
blebbing and apoptotic DNA fragmentation, the DNA content in apoptosis cells was 
removed by washes before staining. Such an assay would reflect the number of living 
cells samples have at selected timeframe. Studies done by Jones et al. demonstrated that 
Cyquant Cell Proliferation assay is a sensitive method to determine cell number 44. 
The viability of PS10-siRNA polyplex treated equine tenocytes were determined using 
MTS assay, and results are presented in figure 5.10 and 5.11, respectively. As exhibited 
in figure 5.10, PS10-siRNA polyplex treated cell showed similar viability compared to 
the cells treated with medium at all timeframes. However, the cell viability detected by 
using Cyquant Cell Proliferation assay suggests a much lower value compared to MTS 
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assay at 24 hours post-treatment, as illustrated in figure 5.11 (A). Data collected at 24 
hours suggested that at polyplex concentration of 2.5 μM, cells showed viability close to 
100%. However, as the polyplex concentration increases, the viability gradually 
decreases. At the highest polyplex concentration, the viability level is around 50%. 
Nevertheless, with further incubation at 48 and 72 hours, an increase in cell viability 
was observed. The increase of viability level could be explained by the self-proliferation 
of tenocytes which survived the acute toxicity phrase 45,46. Though at high 
concentration, PS10-siRNA polyplex showed acute toxicity effect on the cells, this 
occurs only at a concentration above 10μM, which provided critical information in 
polyplex dosage selection.   
5.5. Conclusion 
To conclude, data from this study indicated that PDMAEA showed lower toxicity within 
the tested range than PEI. It is also found that in PDMAEA with a molar mass of 10kDa 
showed much lower toxicity than the 20kDa one. Though PS20 and PL20 PDMAEA 
polymers showed high toxicity at high dosage, their toxicity at low concentration was 
found to be acceptable. Another outcome was that within the test range of the 
experiment, it was found that star-shaped PDMAEA polymers showed higher toxicity 
level that linear ones at high molar mass in mouse 3T3 fibroblast cells. Although the 
data on how the structure of polymers would affect its toxicity was performed using a 
small sampling size, it has provided preliminary insight into the relationship between 
structure and PDMAEA polymer toxicity. The cytotoxicity studies of PS10-siRNA on 
equine tenocytes using two different assays suggested the use of PS10-siRNA polyplex 
at a concentration of below 5μM is an ideal dosage for the transfection and silencing in 
the future. In general, it is concluded that PDAMEA is considered as a vector with low 
toxicity and suitable for further testing of its transfection efficiency. In the next chapter, 
PS10-siRNA polyplexes were applied on TGF-β1 stimulated equine tenocytes, and the 
transfection and silencing effect on COL3α1 gene was evaluated by means of qPCR and 
immunocytochemistry. 
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6. Chapter 6 Transfection Efficiency of PDMEAE-siRNA 
Polyplexes Based on qPCR and Immunocytochemistry 
6.1. Introduction 
Tendon injuries are one of the most common types of soft tissue injury affecting 
millions worldwide, and currently, there is a lack of effective treatment in a clinical 
situation 1. Nowadays, the most common applied clinical therapeutic approach is the use 
of Non-steroidal anti-inflammatory drugs (NSAIDs) for pain control and surgical 
operation, which requires a long recovery period and has a risk of re-injury 2,3. 
Therefore, there is an urgent need for novel effective therapeutic strategies for tendon 
injury. 
In recent years, gene therapy has attracted enormous attention as a novel therapeutic 
strategy for tendon injury and numerous studies have been conducted. Earlier in 2001, 
Luo et al. reported the use of adenovirus to transfer the BMP-12 gene into chicken 
tenocytes in vitro to increase collagen type I synthesis 4. Another study by Suwalski et 
al. suggested that the delivery of pDNA encoding PDGF gene successfully improved 
the healing of injured tendons in a rat model and achieved a lasting expression of two 
weeks 5. The use of the liposome-based system to transfect the fibromodulin gene was 
reported by Delalande et al. The delivery of fibromodulin gene has achieved fast wound 
closure speed and a pronounced migration of tenocytes in vivo and in vitro 6. A more 
recent study by Abbah et al. showed the use of pDNAs encoding decorin and 
interleukin-10 to co-transfect human tenocytes via polyplexes to suppress the 
expression of TGF-β and demonstrated positive results in vitro 7. The literature 
mentioned above and many more indicated that the gene therapy has a prominent 
potential in the future therapy of tendon injury.  
However, one of the issues the researchers confront is that the repaired tendon has a 
weakened mechanical property compared with the native tendon. This is believed to be 
caused by the formation of scar tissue during the healing process 1,8. In native tendon 
tissue, collagen type I accounts for 95% of the extracellular matrix, which is highly 
organised, compact, aligned and responsible for the mechanical strength of tendon 
tissue 9. In contrast, collagen type III has a relatively low abundance but has an 
important role in the healing process. The upregulation of collagen type III, during the 
healing process and in degenerative conditions, may cause weakening of the mechanical 
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strength of the tissue, since type III fibres are thinner, smaller, disorganised and more 
extensible than type I due to less crosslinking sites present in type III collagen 3. 
Moreover, upregulation of type III collagen could form adhesion sites and reduce 
lubrication between the tendon and surrounding tissues causing friction, pain or even 
scar tissue formation 10. It appears that collagen type III and its regulator gene could be 
a potential target for gene therapy in tendon injury. 
In order to gain a deeper understanding of collagen type III upregulation, Eriksen et al, 
compared the amount of collagen type I and III at the rupture and two other sites of the 
same tendon tissue and showed collagen type content was significantly higher at the 
rupture site, whereas no changes were observed for the two healthier sites 11. Attempts 
to diminish the adhesion by targeting related genes has been reported by Chen et al. It is 
reported that RelA/p65 inhibition may be a promising therapeutic approach to prevent 
tendon adhesion 12. A similar study by Freeberg et al. targeted Serpine1 gene, which is 
related to the suppression of protease activity such as MMP, aiming to enhance the 
activity of MMPs and further reduce the formation of adhesion in tendon tissues13. 
Moreover, the studies by Chen et al. and Freeberg at al. both employed siRNA as a 
means to suppress the expression of their target gene. 
Several studies have involved the application of small interfering RNA (siRNA) as a 
therapeutic molecule to alter collagen synthesis in tendon repair. siRNA has gained 
popularity from its ability to knock down a specific selected gene, thereby leading to 
down-regulation of target proteins. For instance, Ruan et al. reported targeting 
extracellular signal-regulated kinase (ERK 2), which is involved in the regulation of 
collagen expression and proliferation of fibroblast cells, as well as joint adhesion. In the 
study, an intra-articular administration of siRNA was achieved through the use of 
lentivirus and resulted in a reduction of joint adhesion 14. In addition, another study by 
Lu et al. showed the efficacy of siRNA in regulating the isoform of collagen type V. 
Collagen type V was reported to be significantly elevated in tendon healing and play an 
important role in fibrillogenesis. Lu et al. reported the selective silencing of the collagen 
V α2 chain in cultured tenocytes resulted in similar fibre morphology as normal 
tenocytes. On the other hand, treating the tenocytes with collagen Vα1 chain siRNA 
resulted in smaller and abnormal fibre morphology, which indicated that the influence 
of α1 chain is more apparent than the α2 chain on the formation of fibrils 15. To 
summarise, these studies demonstrated great potential for siRNA application and local 
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delivery of siRNA to control collagen expression during the healing process. 
Nonetheless, there is a lack of research studies on the application of siRNA targeting 
collagen type III in the treatment of tendon injuries. However, one of the challenges in 
gene delivery, including siRNA, is the need for a safe and efficient delivery system.  
The work presented in previous chapters has described the synthesis of a new synthetic 
polymer-based gene delivery system from four-armed Poly[2-(Dimethylamino) ethyl 
acrylate) (PDMAEA). It is also demonstrated that such cationic polymer-based delivery 
systems have good condensation ability with low toxicity. Considering the balance 
between nucleic acid binding ability and toxicity, PDMAEA polymer PS10 was selected 
to condense with siRNA, forming PS10-siRNA polyplex as described in chapter four.  
Aim of the chapter: 
The aim of this chapter is to provide an insight into the effects that PS10-siRNA has on 
the expression of COL3α1 gene and related protein production. In this chapter, the 
transfection efficiency of PS10-siRNA polyplex was evaluated on TGF-β1 stimulated 
equine tenocytes. The stimulation effect of different dosages and times of TGF-
β1stimulation on COL3α1 gene were determined by qPCR. The expression of COL3α1 
gene in equine tenocytes was first up-regulated by the addition of TGF- β1. Afterwards, 
the expression level of the COL3α1 gene was knocked down by using PS10-siRNA 
polyplexes containing COL3α1 gene-specific siRNA. The post-transfection expression 
level of COL3α1 gene in all samples was analysed by qPCR, and the collagen type III 
protein expression in samples was investigated by immunocytochemistry.  
The main objectives: 
 Study the TGF-β1 stimulation on COL3α1 gene at different concentrations and 
stimulus times.  
 Determine the COL3α1 gene expression level in TGF-β1 stimulated equine 
tenocytes transfected with PS10-siRNA by qPCR over different timeframes. 
 Examine the collagen type III production level of TGF-β1 stimulated equine 
tenocytes transfected with PS10-siRNA by immunocytochemistry. 
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6.2. Material & Methods 
6.2.1. Materials 
The details of the materials used in this chapter can be found in chapter two section 2.2. 
6.2.2. Effect of TGF-β1 Stimulation on COL3α1 Gene by qPCR and 
Determination of Optimal Dosage 
Ten micrograms of Recombinant Human Transforming Growth Factor-β1 (TGF-β1) 
was reconstituted in 100 μL of 10 mM citric acid (pH 3.0) and further diluted to 10 
ng/μL by adding PBS buffer with 0.1% BSA as suggested in manufacturer’s protocol. 
Adult equine tendon cells were cultured in six-well plates at a density of 600,000 
cells/well in 2 mL of complete DMEM medium and incubated for 24 hours before 
treatment. To determine the desired stimulation dose of TGF-β1, the culture medium 
was replaced with complete DMEM medium supplemented with TGF-β1 at different 
final concentrations (0.5, 1, 10, 25 and 50 ng/mL). Cells were then incubated for 24 
hours prior to harvest. To determine the effect of TGF-β1 on the upregulation of the 
COL3α1 gene, cells were cultured under the same conditions as described previously 
but replacing medium supplemented with TGF-β1 at a concentration of 10 ng/mL. Cells 
were then harvested after 24, 48 and 72 hours. The harvested cells were lysed, RNA 
extracted, and reverse transcribed to cDNA and finally analysed by qPCR, as described 
in chapter two.  
6.2.3. Transfection of Equine Tenocyte using PS10-siRNA Polyplex 
PS10-siRNA polyplex was prepared as described in the previous chapter. The final 
siRNA concentration used for transfection was 50 nM. The siRNA buffer was prepared 
according to the manufacturer’s protocol. To briefly describe, 0.303 g of Tris-base and 
0.29 g of sodium chloride was dissolved in 50 mL of bio-reagent grade water before 
pressed through a 0.22 μm pore size membrane filter to make 50 mL of the buffer with 
100 mM NaCl and 50 mM Tris-base. The siRNA was received as a dried powder. Tubes 
were quickly spun down before reconstituting by adding siRNA buffer solution. 
Appropriate bio-reagent grade water was added to reach a concentration of 100 μM. 
Then the siRNA solution was aliquoted into 10*10 μL 100 μM (1000 pmol/aliquot) 
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aliquots and kept at -80°C. Cultured adult equine tendon cells were seeded onto 6-well 
plates at a density of 600,000 cells/well. Cells were incubated for 24 hours to allow 
attachment, and then the media was supplemented with TGF-β1 at 10 ng/mL.  
Twenty-four hours after TGF-β1 stimulation, the cells were treated with samples 
including siRNA solution, PS10 solution, PS10-random-siRNA polyplex, PS10-siRNA 
polyplex and PEI-siRNA polyplex. The cells were incubated for 24, 48 and 72 hours 
before harvesting, followed by RNA extraction and reverse transcription. COL3α1 and 
endogenous control 18S gene mRNA levels were analysed by qPCR. Unstimulated cells 
with no TGF-β1 and cells treated with PS10-random-siRNA were used as negative 
control, whereas PEI-siRNA was used as positive control. The data are presented as 
relative expression (fold change) normalised using the 18s reference gene. All the 
transfection experiments were performed in duplicates. 
6.2.4. Immunocytochemistry on Equine Tenocyte Cells 
Cells were seeded at a density of 15,000 cells/well in a total volume of 500 μL of 
complete DMEM onto a 24-well plate and left at 37°C for 24 hours. Culture medium 
was replaced with 500 μL of complete DMEM supplemented with TGF-β1 at a 
concentration of 1 ng/mL (due to the change of cell density) and incubated for 24 hours. 
Cells were then treated with samples including siRNA solution, PS10 solution, PS10-
random-siRNA polyplex, PS10-siRNA polyplex and PEI-siRNA polyplex at a final 
siRNA concentration of 50 nM (25pmol/ well). After treatment, cells were incubated for 
72 hours before the medium was removed and washed three times with PBS. 500 μL of 
3%PFA was added to each well and incubated at room temperature for 20 minutes. 
Subsequently, PFA was removed, and the cells were washed three times with ice-cold 
PBS and kept in fresh PBS before permeabilization. PBS was removed before adding 
0.5 mL/well 0.1% Triton-X-100 PBS solution and incubated for one hour at room 
temperature. Cells were washed three times with cold sterile PBS and then incubated 
with blocking buffer (2.5% horse serum in PBS) at room temperature for 20 minutes. 
Blocking buffer was removed and the cells were then incubated with the rabbit anti-
collagen III primary antibody diluted to the appropriate concentration (1:100 dilution to 
10μg/ml) in PBS in a humid box overnight at 4°C. After overnight incubation, samples 
were washed three times and incubated with goat anti-rabbit secondary antibody at an 
appropriate concentration (1:100 dilution) in PBS for three hours at room temperature. 
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Samples were then washed three times with PBS and rinsed with milliQ water, and then 
mounted with Vectashield® hard mounting media containing DAPI (cat. no. H-1500 
vector laboratories). Imaging was performed using a Zeiss Axioplan 2ie microscope 
using Axiovision software with FITC or DAPI filter. Pictures were taken with a 20x 
magnification PlanApochromat (0.6 NA) objective and a Zeiss AxioCam HRm CCD 
camera. 
6.3. Results 
6.3.1. TGF-β1 Stimulation on COL3α1 Gene Expression 
TGF-β1 was used to increase the synthesis of type III collagen in cultured equine 
tenocytes. Cultured tenocytes were supplemented with different concentrations of TGF-
β1 (0.5, 1, 10, 25 and 50 ng/mL) and incubated for 24 hours. The results in figure 6.1 
showed the relative expression of the COL3α1 gene normalized to the 18s reference 
gene, both measured by qPCR. Due to the lack of sufficient replicates, it wasn’t able to 
perform any statistical analysis to determine the variation between groups. Nevertheless, 
some indications can be observed in these data. The data suggested that the relative 
gene expression of COL3α1 (up-regulation fold change) increased in a dose-dependent 
manner after TGF-β1 stimulation, and the expression reached three-fold when 
stimulated with TGF-β1 at a concentration of 10 ng/mL. However, the relative 
expression gradually decreased to two-fold and one and a half fold as the TGF-β1 
concentration increased to 25 and 50 ng/mL. Based on the results, it is considered that 
10 ng/mL is the optimal stimulus concentration and was applied in the forthcoming 
experiments.  
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Figure 6.1 Effect of TGF-β1 treatment on cultured equine tenocytes treated with different 
concentrations of TGF-β1 for 24 hours. The COL3α1 relative expression was normalised to 18s 
reference gene. The relative expression at different concentrations were normalised to the untreated 
group. The data represent individual values and mean values, N=2 (technical replicated).  
 
In addition, to study the stimulus effect of TGF-β1 on COL3α1 gene expression over 
time, cultured tenocytes were treated with TGF-β1 at a concentration of 10ng/mL and 
incubated for 24, 48 and 72 hours. The results are presented in figure 6.2, showing that 
the fold change of COL3α1 gene was higher in TGF-β1 stimulated samples compared to 
unstimulated samples at all timeframes. Furthermore, the COL3α1 gene expression 
level, in the presence of TGF-β1, was slightly higher at 48 hours, with a mean up-
regulation fold change of three compared to an ~ two-fold change at 24 and 72 hours. 
However, due to the lack of sufficient replicates, it wasn’t able to perform any statistical 
analysis to determine the variation between the expression levels at different 
timeframes. 
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Figure 6.2 TGF-β1 stimulation effect on the expression of COL3α1 gene in equine tenocytes over 
time. Cultured equine tenocytes were treated with 10 ng/mL of TGF-β1 and incubated for 24, 48 
and 72 hours. The COL3α1 gene relative expression was normalised to 18s reference gene. The 
relative expression was normalised to the untreated group. The dotted line indicates the COL3α1 
gene expression level of untreated groups. The data represent individual values and mean values, 
N=2 (technical replicates). 
6.3.2. Silencing Effect of siRNA Interference using PS10 as a Delivery Vector on 
TGF-β1 Stimulated Cells 
The silencing effect of PS10-siRNA polyplex on COL3α1 gene in the TGF-β1 
stimulated equine tenocytes cultured cells was investigated. Tenocytes were treated with 
PS10-siRNA polyplexes, as well as other controls. The results are shown in figure 6.3, 
the mRNA levels being presented as a up-regulated fold change in all samples, 
determined by qPCR at three different timeframes.  
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Figure 6.3 PS10-siRNA mediated silencing of COL3α1in cultured equine tenocytes. The relative 
expression of COL3α1 was monitored and presented. Relative gene expression of cultured tenocytes 
stimulated with TGF-β1 at 10 ng/ml concentration was calculated and presented at (A) 24 hours, 
(B) 48 hours and (C) 72 hours. The COL3α1 relative expression was normalised to 18s reference 
gene. The data represent individual values (scattered dots) and mean values, N=2(technical 
replicates). 
 
To describe, at 24 hours post-treatment (figure 6.3 A), an up-regulated expression of 
COL3α1 gene was observed in all treated samples (about 1.5-fold to 2-fold change), 
while PS10-siRNA polyplexes treated sample had a slightly higher fold change of about 
3.5-fold, compared to untreated samples. Furthermore, the results at 48 hours post-
treatment (figure 6.3 B) revealed that the expression level of the COL3α1 gene 
increased dramatically. When normalized with unstimulated cells, the expression of 
TGF-β1 solely treated group showed the same level as at 24 hours, while other treated 
samples showed significant increases. Samples treated solely with PS10, PS10-siRNA 
polyplex, PS10-random-siRNA polyplex and PEI-siRNA polyplex showed a fold 
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change of about 8-fold or higher when normalized with the unstimulated sample. At 72 
hours post-treatment, the expression level of COL3α1 reduced to the two-fold level in 
all samples. However, due to the lack of enough replicates, it wasn’t able to perform 
statistical analysis to determine the variation between different groups. Nevertheless, 
some trend and indications can be observed in these data. Interestingly, the PS10-siRNA 
polyplex treated group displayed a lower expression level (about 20% lower) of 
COL3α1 gene at 48 hours, compared to non-therapeutic PS10-random-siRNA treated 
group, indicating a possible PS-siRNA mediated-silencing (knockdown) effect. In 
contrast, the PEI-siRNA complex treated group showed no significant reduction 
compared to the non-therapeutic PS10- random -siRNA treated group. Statistical 
analysis indicated that the difference between PS10-random-siRNA polyplexes treated 
group and PS10-siRNA polyplexes treated samples are significant. Contrarily, and as 
shown in figure 6.3, at 72 hours post-transfection, the PS10-siRNA treated group 
showed no significant silencing effect compared to non-therapeutic PS10-random-
siRNA treated ones, while PEI-siRNA polyplex showed a reduction of 0.5-fold 
compared to the non-therapeutic PS10-random-siRNA treated samples. Nonetheless, the 
overall fold change of COL3α1 was lower at 72 hours post-treatment, compared to the 
48 hours post-treatment.  
6.3.3. Immunocytochemistry 
Previously stimulated tenocytes with TGF-β1 were subsequently treated with PS10-
siRNA polyplex and other controls and incubated for 72 hours before samples were 
fixed for immunocytochemical staining. As shown in figure 6.4, the nuclei in all 
samples were stained with DAPI (blue), and collagen type III was labelled with a 
fluorescent secondary antibody and coloured in green. Images captured indicated both 
production and distribution of collagen type III within the cellular cytoplasm and in the 
extracellular space of the cells. Note that due to the possible toxicity and manipulation 
during the immunocytochemistry process, the cell density is significantly lower than 
other samples.  
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Figure 6.4 Immunocytochemistry of TGF-β1 stimulated tenocytes treated with PS10-siRNA 
polyplex as well as other controls. The scale bar represents 30 μm. Exposure time was fixed at 650 
ms. Nuclei were stained with DAPI (blue) and Collagen III was coloured in green. Merged images 
were created with Image J software.  
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After fixation of the exposure time while capturing the images, fluorescent intensity 
analysis was carried in order to quantify the amount of collagen type III within the 
sample. Three random fields on the sample slip were selected, exposed and analysed. 
The overall fluorescent intensity of the selected field was determined and normalized by 
the total number of cells within the field. The data are presented in table 6.1. 
Table 6.1 Normalised fluorescent intensity of TGF-β1 stimulated tenocytes treated with PS10-
siRNA polyplex as well as other controls. The data were presented as the mean value of three 
random fields with SD. 
  Unstimulated Solely 
TGFβ1 
Solely 
siRNA 
Solely 
PS10 
PS10-random- 
siRNA polyplex 
PS10-siRNA 
polyplex 
PEI-
siRNA 
polyplex 
Mean 
intensity 
0.067 0.084 0.073 0.150 0.373 0.385 N/A 
SD 0.002 0.004 0.009 0.009 0.130 0.035 N/A 
Based on the data, all TGFβ1 treated samples showed higher fluorescent intensity 
levels, compared to the unstimulated group. Moreover, both the PS10-siRNA polyplex 
treated group and the PS-10-random-siRNA treated group showed much higher 
fluorescent intensity, compared to the other groups. Specifically, it was about five times 
higher than the unstimulated group, solely TGF-β1 treated and solely siRNA treated 
group. Note that the cell number in PEI-siRNA polyplexes sample groups are 
significantly lower than other groups, and the intensity signal is not enough for analysis. 
Therefore, the mean intensity of samples treated with PEI-siRNA polyplexes has not 
been reported. 
6.4. Discussion 
 TGF-β1 stimulation on COL3α1 gene in cultured tenocytes 
TGF-β1 was used to stimulate the COL3α1 gene expression in cultured equine 
tenocytes in order to mimic the pathological process in injured tendon tissue. Though it 
would be ideal to use equine tenocytes isolated from injury sites of an adult horse, 
rather than cells isolated from healthy tendon tissue, due to the complexity of isolating 
the cells from freshly wounded horse tendon, lack of fresh biomaterials and considering 
that the up-regulation of COL3α1 gene expression in an injured tendon is a result of 
multiple factors involving inflammatory cells and cytokines, an alternative approach of 
using TGF-β1 to stimulate cells from a healthy tendon was adopted. A similar approach 
has also been reported by Freeberg et al. 13. The effect of the concentration and 
incubation time of TGF-β1 stimulation in cultured equine tenocytes was investigated by 
qPCR to determine the relative expression of COL3α1 gene. The results revealed that 
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the optimal TGF-β1 stimulation dosage for COL3α1 gene is 10 ng/mL. Moreover, the 
stimulation effect is maximized at 48 hours post-stimulation. 
 Silencing of COL3α1 gene by PS10-siRNA polyplex delivery 
The potential of the PS10-siRNA polyplex in specifically silencing the COL3α1 gene 
expression in TGF-β1 stimulated tenocytes was studied. Apart from the therapeutic 
PS10-siRNA polyplex, a variety of controls were also introduced to TGF-β1 stimulated 
tenocytes. A randomly sequenced siRNA, considered to be non-COL3α1 specific, was 
purchased and used to form PS-random-siRNA polyplex which was employed as the 
negative control. PEI-siRNA polyplex was prepared by using 10kDa branched PEI and 
COL3α1 specific siRNA and employed as the positive control. The PEI-siRNA polyplex 
was designed to carry the same amount of siRNA as the PS10-siRNA polyplexes and 
was prepared with same N:P ratio. Other control groups including PS10 group (only 
PS10) and siRNA group (only siRNA) were also prepared to study the potential effect 
they might have on the expression level of COL3α1 gene. TGF-β1 treated group (only 
TGF-β1), and unstimulated groups were designed to provide a base-line in both 
stimulated and non-stimulated situations, respectively. Three different timeframes of 24-
, 48- and 72-hours post-treatment were designed to investigate the influence of 
incubation time on the COL3α1 gene expression. The mRNA level of COL3α1 gene was 
analysed in all samples and normalized with 18s gene mRNA level. The choice of 18s 
gene as a reference gene is based on previous studies conducted in equine cell lines 16,17.  
At 24 hours post-transfection, all samples showed an increase of about 2-fold in the 
expression level of COL3α1 gene. At 48 hours post-transfection, the up-regulation of 
COL3α1 gene expression peaked in samples treated with PS10-siRNA polyplex, PS10-
random-siRNApolyplex and PEI-siRNA polyplex, with ~8-fold change in their 
expression level. This is most probably because the highest TGF-β1 stimulation of 
COL3α1 synthesis was achieved at 48 hours. At 72 hours post-transfection, the level of 
expression COL3α1 gene reduced to about 2-fold compared to the unstimulated group. 
It seems that all polyplexes (PS10-siRNA polyplex, PS10-random-siRNA polyplex and 
PEI-siRNA polyplex) treated samples showed either similar (at 24- and 72-hours post-
transfection) or higher (at 48 hours post-transfection) levels of COL3α1 expression, 
compared to the unstimulated group and to the solely TGF-β1 treated group. Though no 
studies have reported the stimulus effect of PDMAEA polymer on the up-regulation of 
COL3α1 gene, it was suggested by De Rosa et al. that the cationic charges on polymer 
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surface increased the synthesis of collagen I and III 18. One explanation is that the 
polycations coupling to plasma membrane lipid bilayers can induce a redistribution of 
oppositely charged lipids into regions known as domains 19. The formation of domains 
can influence cellular membrane functioning, such as altering the local transmembrane 
permeability or act as sequester enzyme substrates and thereby controlling enzymatic 
activity and/or cell signalling processes 18. 
Though it seems that polyplexes treated groups have triggered an unexpected up-
regulation of COL3α1 gene at 48 hours, by comparison between the polyplexes treated 
groups, the data suggested that the siRNA induced silencing effect might be successful. 
As demonstrated in figure 6.3, the PS10-siRNA polyplex treated group showed about 
20% lower expression level compared to the PS10-random-siRNA treated group, which 
is the negative control, at 48 hours post-transfection. This is possibly due to the 
COL3α1 gene-specific siRNA mediated RNAi under the delivery of PS10 polymer. 
However, due to the unexpected increase in COL3α1 gene expression in the polyplexes 
treated samples, it might not accurately reflect the silencing effect, and further study is 
required.  
 Immunocytochemistry on PS10-siRNA transfected tenocytes 
The immunocytochemistry of TGF-β1 stimulated tenocytes transfected with PS10-
siRNA polyplexes at 72 hours post-transfection was demonstrated in figure 6.4, as well 
as other control groups. The newly synthesised type III collagen are typically secreted 
into ECM, therefore most of the type III collagen is expected to be found outside of the 
cells. However, in this study, to examine the total type III collagen produced, cells were 
permeabilised to allow staining of collagen both inside and outside of the cells. Since 
the tenocytes were permeabilized before conjugation with primary antibody, the 
fluorescent signal indicated the localisation of intracellular collagen type III as well as 
on the cell surface. The exposure time during the imaging is fixed at 650 ms, and 
intensity analysis could be performed to quantify the amount of collagen type III 
protein. As shown in table 6.1, the samples treated with PS10-siRNA polyplex and 
PS10-random-siRNA show much higher intensities compared to other control groups, 
indicating that a larger amount of collagen type III protein was produced. The data 
properly correlate with qPCR data at 48 hours post-treatment, connecting the high 
mRNA level to the high protein production. Unfortunately, possibly due to the toxicity 
of PEI, the cell density in the PEI-siRNA polyplexes treated group is significantly lower 
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than other groups, and might not correctly reflect the collagen type III production, hence 
it was not possible to perform intensity analysis on those samples.  
6.5. Conclusion 
In this chapter, the transfection efficiency of PS-siRNA polyplex has been evaluated on 
TGF-β1 stimulated equine tenocytes. Firstly, the COL3α1 expression level in cultured 
tenocytes was successfully stimulated by adding exogenous TGF-β1. Cells treated with 
an optimal dose of TGF-β1 were incubated with PS-10 siRNA, over 24, 48 and 72 
hours, as well as other controls. The results of qPCR analysis suggested that cells 
incubated with PS-siRNA polyplex showed about a 20% lower expression level in 
COL3α1 gene compared with non-specific siRNA-PS10 polyplex treated cells at 48 
hours timeframe, at which the expression of COL3α1 gene is maximised. However, data 
analysis also indicated that all cells treated with TGF-β1 and PS10 polyplexes showed a 
high expression level of COL3α1 gene compared to cells treated solely with TGF-β1. 
The mechanism behind this phenomenon remains unclear and possible explanation has 
been discussed, further studies might be required to provide a detail and more reliable 
explanation on this observation. The immunocytochemistry at 72 hours confirmed the 
production of collagen type III protein in all stimulated samples, while PS containing 
polyplex treated samples exhibited a higher fluorescent intensity, which is consistent 
with data acquired from qPCR. To summarise, results from this chapter might have 
suggested a successful transfection of tenocytes using PS10-siRNA polyplex, though the 
suppression effect of COL3α1 gene is unsatisfactory due to an unexpected stimulation 
of COL3α1 gene in all PS10 treated samples. Further study into the cause of the PS10 
trigger COL3α1 gene up-regulation is required.  
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7. Chapter 7 Conclusions and Future Work 
7.1. General Conclusions and Discussions  
The main aim of this study was to investigate the potential of PDMAEA polymers as a 
siRNA delivery vector. Firstly, four different PDMAEA polymers, including 10kDa 
linear PDMAEA (PL10), 10kDa star-shaped PDMAEA (PS10), 20kDa linear PDMAEA 
(PL20) and 20kDa star-shaped PDMAEA (PS20), have been successfully synthesised 
via RAFT polymerisation, as reported in chapter three. Analysis of polymer samples 
confirmed that the produced polymers have designed molecular weights, unique 
structures of linear and star-shaped and low polydispersity values. Though the use of 
RAFT polymerisation technique in the synthesis of linear PDMAEA polymers and 
copolymers has been widely reported, and Whitfield et al. have achieved successful 
production of star-PDMAEA polymers using Cu-mediated ATRP, the synthesis of star-
shaped PDMAEA polymers via core-first RAFT polymerisation approach are rarely 
mentioned 1-4. The results from this work have provided a simple and efficient one-step 
synthesis of star-shaped PDMAEA polymers with controlled molecular weight and low 
dispersity via RAFT polymerisation. The PDMAEA polymers also have pKa values of ~ 
7.8, which suggested that the amine groups could become protonated and the positive 
charges may maintain the solubility of the polymers in aqueous solution and may 
provide an advantage in condensation with nucleic acids. It has also been observed that 
there is a difference between the pKa values of the DMAEA monomers (pKa ~8.4)5 and 
PDMAEA polymers, possibly due to the protonation of polymers having been affected 
by various factors, including solution ionic strength, distribution of ionisable units and 
ionisation state of the neighbouring units 6-8. 
Secondly, as presented in chapter four, this study explored the zeta potential, 
hydrodynamic diameter in solution and DNA binding ability of the PDMAEA polymers, 
as well as the formation of polyplexes between PDMAEA polymers and dsDNA/siRNA 
molecules. The results suggested that PDMAEA polymers have small hydrodynamic 
diameters (of ≤10 nm) in solutions with pH value, and the measured hydrodynamic 
diameter increased.as the pH increases. Furthermore, it was also observed that the zeta 
potential of PDMAEA polymers in solution decreased as the pH increases. It is possible 
that the PDMAEA polymers dissolved in aqueous solution, rather than remaining fully 
extended in a stationary state, they adopted irregular random coil structures which are 
typically found to be spherical 9. In lower pH environments, the amines groups within 
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the PDMAEA polymers’ structure would protonate and become positively charged, 
which may have provided repulsive forces between polymer particles sufficiently 
adequate to keep the system colloidal stable, and further enabled PDMAEA polymers to 
stay in forms of small particles. As the pH increases, amine groups in the polymer 
structure deprotonated and the polymer particles begin to aggregate to form large 
particles. These findings indicated that the PDMAEA polymers have high positive 
charges and relatively small hydrodynamic diameter in aqueous solution with low pH, 
which may be advantageous for the formation of polyplexes with negatively charged 
nucleic acid molecules. In addition, the DNA/RNA condensation ability of the 
PDMAEA polymers were determined by mixing polymers with a quantitative amount of 
dsDNA molecules based on different N:P ratios. The results showed that polymers with 
larger molecular weights would require a lower N:P ratio to completely condense to the 
dsDNA molecules, and star-shaped polymers require a lower N:P ratio to form 
polyplexes compared to their linear counterparts. This could be possibly explained by a 
“collapsed” structure formed by the star-shaped polymers, perhaps due to branched 
amphiphiles side chains, which can condense with guest molecules more efficiently. 
Taken together, it is concluded that polymers with larger molecular weights and a higher 
level of branching are provided with an advantage in the process of condensation. 
Moreover, polyplexes of four PDMAEA polymers with dsDNA and PS10 with siRNA 
were analysed. All the polyplexes have moderate hydrodynamic diameters of (less than 
200 nm), which suggested that the polyplexes could be efficiently taken up by cells via 
clathrin-mediated endocytosis 10,11. The determined hydrodynamic diameter of these 
PDMAEA-dsDNA/siRNA polyplexes are similar to the values reported in other 
studies12-14. When compared to other nanoparticles, including silver nanoparticles, poly 
(ethylene glycol)-containing liposomes and PEI-PEG polyplexes, the PDMAEA-
DNA/RNA polyplexes have similar hydrodynamic diameters 15-17. The zeta potential of 
PDMAEA polyplexes were also measured under relevant pH values and results showed 
that the polyplexes have high positive charges, indicating moderate colloidal stabilities 
of these PDMAEA polyplex solutions 18.  
Chapter five explored the cytotoxicity of the PDMAEA polymers on different cell lines. 
The synthesised PDMAEA polymers were tested on mouse 3T3 fibroblast and equine 
tenocyte samples and have provided several insights into the toxicity of PDMAEA 
polymers. PDMAEA polymers showed low cytotoxicity at low concentrations. When 
compared to PEI, PDMAEA polymers showed lower cytotoxicity at medium and high 
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concentrations at all timeframes on both mouse 3T3 fibroblasts and equine tenocytes. 
Besides, the data revealed that for polymers with molecular weights of 10kDa, both 
linear and star-shaped (PL10 and PS10) showed low toxicity across all concentrations 
and timeframes on both cell lines, while polymers with molecular weights of 20kDa 
(PL20 and PS20) showed significantly higher toxicity at high concentrations. Therefore, 
it is concluded that PDMAEA toxicity is proportional to molecular weight and sample 
concentration. It has been suggested that the cytotoxicity of cationic polymers is caused 
by the disruptive effect on the cellular membrane and resulting in damages to cellular 
organelles including mitochondria and endosomes 19. It has been reported that the 
membrane disruptive ability of the polymers may be related to the quantity of cationic 
functional groups in the structure, in the case of PDMAEA polymers, these are the 
amine groups 20. The increase in amine content in polymer structure and in polymer 
solution may explain the increased toxicity in polymers with larger molecular weights 
and in polymer solutions at higher concentration. It is also suggested that polymers with 
larger molecular weight and longer chains can interact with negatively charged proteins 
and membranes more effectively in the intracellular space than short ones 19, which 
might also explain the increased toxicity in polymers with larger molecular weights. 
However, the relationship between polymer architecture and cytotoxic remained 
unclear. Although in experiments conducted on mouse 3T3 fibroblasts, the toxicity of 
PS20 is slightly higher than PL20, this difference was not seen in cell samples treated 
with PL10 and PS10. Moreover, in experiments conducted on equine tenocytes there is 
no significant difference in cytotoxicity between linear polymers and star-shaped 
polymers. There is a lack of evidence to support any conclusion relating PDMAEA 
polymer architecture to its cytotoxicity in this study. Yet, cases of high branching results 
in high toxicity in PEI were observed and reported by Kafil et al. 21. This indicates that 
further enquiry into an architecture-toxicity relationship is required. To summarise, it is 
suggested that PDMAEA polymers showed lower cytotoxicity than PEI and are capable 
of protonation under neutral environment conditions, plus the ability to enhance 
condensation with nucleic acids. Among the four PDMAEA polymers, PL20 and PS20 
have shown better binding ability at the cost of higher toxicity, while PL10 and PS10 
have slightly compromised binding ability but displayed good biocompatibility. It is 
also evident that the toxicity of PDMAE polymers is time and concentration dependent. 
Thus, proper treatment concentration and incubation time should be considered. The 
cytotoxicity profile of PDMAEA polyplexes was determined by incubation with 3T3 
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fibroblast cells and horse tenocytes then analysed with MTS assay. The data indicated 
that the PDMAEA-dsDNA and PS10-siRNA polyplexes are well tolerated by the 
tenocyte and 3T3 fibroblast cells at low polyplex concentrations. In addition, when 
compared to other studies using unmodified PEI delivery systems (25kDa, linear), the 
PDMAEA polymers showed much lower cytotoxicity, while the PEI delivery systems 
showed stronger DNA binding capability, as PEI-dsDNA/siRNA polyplexes were 
prepared at lower N:P ratios of 2:121,22. 
Concluding the findings in chapter four and five, the PDMAEA-dsDNA polyplexes and 
PS10-siRNA polyplex have appropriate hydrodynamic diameters with high zeta-
potential, which indicated potential good cellular uptake and moderate colloidal 
stability. Toxicity studies of these polyplexes revealed good biocompatibility with 
different cell lines. The results suggested that PDMAEA polyplexes can be used as safe 
gene delivery vectors.  
Finally, in chapter six, the transfection ability of PDMAEA polymer were explored. One 
PDMAEA polymer (PS10) was condensed to therapeutic siRNA to form COL3α1 gene 
specific polyplexes and introduced into equine tenocytes. Cell samples were first 
stimulated with TGF-β1, with the intention of mimicking the behaviour of tenocytes in 
injured tissue, to up-regulate the expression of the COL3α1 gene. Then, these stimulated 
samples were treated with therapeutic polyplexes. However, at 48 hours post-
transfection, an unexpected increase in the expression of the COL3α1 gene in samples 
treated with PS10 was observed compared with unstimulated ones. 
Immunocytochemistry at 72 hours post silencing confirmed the production of the 
increased amount of collagen type III. The reason for this dramatic increase remains 
unclear, however. Although no studies have reported the stimulus effect of PDMAEA 
polymer on the up-regulation of the COL3α1 gene, it was suggested by De Rosa et al. 
that the presence of cationic charges on cell adhesion-resistant polymer surface 
increased the synthesis of collagen I and III, the release of their metabolites, and the 
expression of their mRNA in fibroblasts 23. This could be explained by polyelectrolyte 
coupling to plasma membrane lipid bilayers which can induce a redistribution of 
oppositely charged lipids into regions known as domains 24,25. The formation of domains 
can influence cellular membrane functioning, for example, by altering the local 
transmembrane permeability, or by acting as sequester enzyme substrates or 
activator/inhibitors, thereby signalling processes 23. Furthermore, though cells treated 
 213 
 
with PS10-siRNA polyplexes showed lower levels of COL3α1 expression when 
compared to PS10-random-siRNA treated group at 48 hours, but due to the stimulation 
effect of PDMAEA polymer on the expression of COL3α1 gene, there isn’t enough 
evidence and it is difficult to draw the conclusion that the specific silencing was 
successful. Further studies are required to determine the transfection efficiency of 
PDMAEA polymers.  
To summarise, a PDMAEA cationic polymer siRNA delivery system has been 
successfully developed and proven to be biocompatible with good nucleic binding 
efficiency. Such a system may have good potential in the application siRNA delivery or 
improving tendon healing and the treatment of tendon injury. However, PDMAEA 
polymers would trigger an up-regulation of COL3α1 gene expression and the 
transfection efficiency cannot be clearly demonstrated with current data. Further 
enquiries into the transfection efficiency of PDAMEA polymers and the cause of the 
increase are required.  
7.2. Future Work 
 Determination of PDMAEA polymer transfection efficiency 
In this study, the original intention was to use PS10-siRNA polyplexes, which contains a 
COL3α1 gene-specific siRNA sequence, to determine the transfection efficiency of 
PDMAEA polymers by the analysis of the COL3α1 gene expression level before and 
after transgene. However, PDMAEA polymer triggered an unexpected up-regulation 
effect on the expression of the COL3α1 gene, thus the transgene efficiency of PDMAEA 
polymers cannot be accurately determined. Future studies could focus on the use of 
other methods, for example, delivering plasmid DNA (pDNA) expressing either 
luciferase or green fluorescent protein in equine tenocytes. The PDMAEA polymers 
could be condensed to pDNA to form polyplexes and introduced to equine tenocytes. 
After transfection, the quantity of luciferase could be determined by using relative 
assays 26. This may provide a more efficient approach to determine the transgene ability 
of PDMAEA polymers without the influence of other factors such as TGF-β1 and 
siRNA specificity. 
 PDMAEA modification 
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One advantage of the synthetic polymer-based delivery system is that various 
modifications are available. PDMAEA polymers synthesised in this thesis study have 
the potential to be developed into other copolymers with PDMAEA blocks. The 
combination of PDMAEA polymer with other polymer blocks would provide infinite 
possibilities to form multifunction polymers or stimulus responsive polymers. Another 
possible route is with PDMAEA synthesised via RAFT polymerisation, resulting in 
polymers with the thiol-containing functional group at one end of the polymer. In some 
cases, polymers containing thiocarbonylthio groups were prepared via RAFT 
polymerisation, which could react with nucleophiles and ionic reducing agents to 
generate thiols (figure 7.1)27. The thiol group may provide potential applications in 
radical-mediated thiol-ene click reactions or a potential crosslinking site for thiol cross-
linking 28,29. 
 
Figure 7.1 Processes for thiocarbonylthio removal to generate thiols. 
 Would the suppression of collagen type III production reduce the formation of scar 
tissue? 
The research work presented in this thesis describes the attempt to suppress the 
expression of collagen type III in an in vitro situation. Though the delivery system has 
been proven to be capable of transfection, due to the up-regulation effect of PDMAEA 
polymers, the suppression of the COL3α1 gene was less satisfactory. Besides, this study 
is mainly conducted in vitro, thus how PDMAEA polymer or collagen type III could 
affect tendon tissue cannot be observed directly. Hopefully, in the future, the improved 
PDMAEA delivery system could be employed to suppress collagen type III on an injury 
animal model in vivo. It would be interesting to find out if suppression of collagen type 
III production could reduce the formation of scar tissue. 
 Controlled release system 
Compared to the viral delivery system or pDNA transfection, one trait of siRNA 
silencing is that the effective period is limited. Generally, siRNA mediated gene 
silencing can be observed as early as 24 hours post-transfection and the effect would 
last up to seven days, though the duration and level of knockdown are dependent on cell 
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type and concentration of siRNA. In some cases, prolonged siRNA interference is 
required; to achieve prolonged siRNA silencing with single dosage siRNA transfection 
could increase the cost and could be inconvenient. Therefore, a controlled release 
siRNA delivery system would be ideal for situations which needs a prolonged siRNA 
silencing. PDMAEA polymer has the potential of being modified and developed into a 
hydrogel-based controlled release system which could be interesting. Functional groups 
such as thiol groups could be generated with proper cleavage. Thiol groups could be 
applied in the bioconjugation with multiple crosslinking reagents. One interesting 
thought would be to use cleaved PDAMEA polymers with thiol end groups to crosslink 
with PEG-maleimide polymers to generate a hydrogel-network which potentially has 
the ability to entrap siRNA molecules and slowly release as the PEG-rich network 
degrades.  
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